BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965. [PMID: 11583749 DOI: 10.1016/s0140-6736(01)06102-5] [Cited by in Crossref: 4721] [Cited by in F6Publishing: 5012] [Article Influence: 214.6] [Reference Citation Analysis]
Number Citing Articles
1 Hawsawi NM, Saber T, Salama HM, Fouad WS, Hagag HM, Alhuthali HM, Eed EM, Saber T, Ismail KA, Al Qurashi HH, Altowairqi S, Samaha M, El-hossary D. Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital. TropicalMed 2023;8:92. [DOI: 10.3390/tropicalmed8020092] [Reference Citation Analysis]
2 Zhang K, Chen L, Zhu C, Zhang M, Liang C. Current Knowledge of Th22 Cell and IL-22 Functions in Infectious Diseases. Pathogens 2023;12:176. [DOI: 10.3390/pathogens12020176] [Reference Citation Analysis]
3 Brzdęk M, Dobrowolska K, Flisiak R, Zarębska-Michaluk D. Genotype 4 hepatitis C virus-a review of a diverse genotype. Adv Med Sci 2023;68:54-9. [PMID: 36640687 DOI: 10.1016/j.advms.2022.12.003] [Reference Citation Analysis]
4 Hafeez Khan A. Liver Function Tests in Hepatitis C Patients of Local Population of Lahore. PBMJ 2022. [DOI: 10.54393/pbmj.v5i12.831] [Reference Citation Analysis]
5 Derayea SM, Hamad AE, Mohammed BS. Mathematical Processing of Absorption as Green Smart Spectrophotometric Methods for Concurrent Assay of Hepatitis C Antiviral Drugs, Sofosbuvir and Simeprevir: Application to Combined Pharmaceutical Dosage Forms and evaluation of the method greenness.. [DOI: 10.21203/rs.3.rs-2355622/v1] [Reference Citation Analysis]
6 Hsiao C, Meng J, Hong J, Ly X, Lin M, Chang C, Nguyen MT, Cheng T, Lin W, Burnouf P, Al-qaisi TS, Liu E, Su Y. Engineering a High-Affinity Anti-Methoxy Poly(ethylene glycol) (mPEG) Antibody for Sensitive Immunosensing of mPEGylated Therapeutics and mPEG Molecules. Bioconjugate Chem 2022. [DOI: 10.1021/acs.bioconjchem.2c00416] [Reference Citation Analysis]
7 Ahn Y, Lee H, Han JE, Cho HJ, Cheong JY, Park B, Kim SS. Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment. J Liver Cancer 2022;22:125-135. [DOI: 10.17998/jlc.2022.05.24] [Reference Citation Analysis]
8 Panigrahi M, Palmer MA, Wilson JA. MicroRNA-122 Regulation of HCV Infections: Insights from Studies of miR-122-Independent Replication. Pathogens 2022;11:1005. [PMID: 36145436 DOI: 10.3390/pathogens11091005] [Reference Citation Analysis]
9 Kiattanaphon A, Vipsoongnern Y, Kunthalert D, Sistayanarain A. Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a. Mol Biol Rep 2022. [PMID: 36002650 DOI: 10.1007/s11033-022-07803-5] [Reference Citation Analysis]
10 Nguyen MT, Shih YC, Lin MH, Roffler SR, Hsiao CY, Cheng TL, Lin WW, Lin EC, Jong YJ, Chang CY, Su YC. Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group. Commun Chem 2022;5:88. [PMID: 36697876 DOI: 10.1038/s42004-022-00709-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kuwano A, Yada M, Nagasawa S, Tanaka K, Morita Y, Masumoto A, Motomura K. Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib. J Viral Hepat 2022;29:543-50. [PMID: 35499194 DOI: 10.1111/jvh.13681] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sharma A, Virmani T, Sharma A, Chhabra V, Kumar G, Pathak K, Alhalmi A. Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance. Diabetes Metab Syndr Obes 2022;15:1845-64. [PMID: 35733643 DOI: 10.2147/DMSO.S369712] [Reference Citation Analysis]
13 Gutiérrez-rojas L, de la Gándara Martín JJ, García Buey L, Uriz Otano JI, Mena Á, Roncero C. Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review. Gastroenterología y Hepatología 2022. [DOI: 10.1016/j.gastrohep.2022.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Khan A, Nawaz M, Ullah S, Rehman IU, Khan A, Saleem S, Zaman N, Shinwari ZK, Ali M, Wei DQ. Core amino acid substitutions in HCV-3a isolates from Pakistan and opportunities for multi-epitopic vaccines. J Biomol Struct Dyn 2022;40:3753-68. [PMID: 33246391 DOI: 10.1080/07391102.2020.1850353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Սարգսյան Ս. ՔՐՈՆԻԿ ՎԻՐՈՒՍԱՅԻՆ C ՀԵՊԱՏԻՏ. ՀԱԿԱՎԻՐՈՒՍԱՅԻՆ ԲՈՒԺՄԱՆ ՓՈՒԼԵՐԸ (ՎԵՐԼՈՒԾՈՒԹՅՈՒՆ). MSEJ 2022. [DOI: 10.56936/18291775-2022.33-22] [Reference Citation Analysis]
16 Khan M, Rauf W, Habib F, Rahman M, Iqbal S, Shehzad A, Iqbal M. Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease. BMC Complement Med Ther 2022;22. [DOI: 10.1186/s12906-022-03578-1] [Reference Citation Analysis]
17 Oe N, Takeda H, Eso Y, Takai A, Marusawa H. Clinical and Molecular Basis of Hepatocellular Carcinoma after Hepatitis C Virus Eradication. Pathogens 2022;11:430. [DOI: 10.3390/pathogens11040430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Nakajima T, Karino Y, Hige S, Suii H, Tatsumi R, Yamaguchi M, Arakawa T, Kuwata Y, Toyota J. Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection. Ann Hepatol 2022;27:100566. [PMID: 34688887 DOI: 10.1016/j.aohep.2021.100566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Kim IJ, Yoo SH, Kim S, Cho YY, Yoo KY, Kim HJ, Lee HW. Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia. J Clin Med 2022;11:1451. [PMID: 35268541 DOI: 10.3390/jcm11051451] [Reference Citation Analysis]
20 Guan J, Ren Y, Wang J, Zhu H. The Knowledge on HCV: From the Discovery to the Elimination. Infectious Microbes and Diseases 2022;4:1-6. [DOI: 10.1097/im9.0000000000000085] [Reference Citation Analysis]
21 Patil VS, Harish DR, Vetrivel U, Roy S, Deshpande SH, Hegde HV. Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from Terminalia chebula: A Structural Perspective. Molecules 2022;27:1076. [DOI: 10.3390/molecules27031076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Cornberg M, Manns MP. The curing regimens of HCV: A SWOT analysis. Antivir Ther 2022;27:13596535211072672. [PMID: 35491553 DOI: 10.1177/13596535211072672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
24 Manrai M, Dawra S, Kapoor R, Srivastava S, Singh A. Anemia in cirrhosis: An underestimated entity. World J Clin Cases 2022; 10(3): 777-789 [DOI: 10.12998/wjcc.v10.i3.777] [Reference Citation Analysis]
25 Hozáková L, Vokatá B, Ruml T, Ulbrich P. Targeting the Virus Capsid as a Tool to Fight RNA Viruses. Viruses 2022;14:174. [DOI: 10.3390/v14020174] [Reference Citation Analysis]
26 Pabjan P, Brzdęk M, Chrapek M, Dziedzic K, Dobrowolska K, Paluch K, Garbat A, Błoniarczyk P, Reczko K, Stępień P, Zarębska-Michaluk D. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals? Viruses 2022;14:96. [PMID: 35062302 DOI: 10.3390/v14010096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 Kuwano A, Yada M, Nagasawa S, Tanaka K, Morita Y, Masumoto A, Motomura K. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment. J Viral Hepat 2022;29:35-42. [PMID: 34661320 DOI: 10.1111/jvh.13625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Villamil FG, Massenzio NE, Baré PC, Cocco PA, Cairo FM, Picchio GR. Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: The O'Brien Project. Ann Hepatol 2022;27 Suppl 1:100577. [PMID: 34740846 DOI: 10.1016/j.aohep.2021.100577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Lee WJ, Foster GR. Hepatitis C. Reference Module in Life Sciences 2022. [DOI: 10.1016/b978-0-12-821618-7.00268-6] [Reference Citation Analysis]
30 Kim W. Chronic Liver Disease. Sex/Gender-Specific Medicine in the Gastrointestinal Diseases 2022. [DOI: 10.1007/978-981-19-0120-1_14] [Reference Citation Analysis]
31 Elfiky AA, Mahran HA, Ibrahim IM, Ibrahim MN, Elshemey WM. Molecular dynamics simulations and MM-GBSA reveal novel guanosine derivatives against SARS-CoV-2 RNA dependent RNA polymerase. RSC Adv 2022;12:2741-50. [DOI: 10.1039/d1ra07447d] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
32 Manns MP, Maasoumy B. Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol 2022;19:533-50. [PMID: 35595834 DOI: 10.1038/s41575-022-00608-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
33 González Grande R, Santaella Leiva I, López Ortega S, Jiménez Pérez M. Present and future management of viral hepatitis. World J Gastroenterol 2021; 27(47): 8081-8102 [DOI: 10.3748/wjg.v27.i47.8081] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Tahata Y, Sakamori R, Takehara T. Treatment progress and expansion in Japan: From interferon to direct-acting antiviral. Glob Health Med 2021;3:321-34. [PMID: 34782876 DOI: 10.35772/ghm.2021.01083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Yadav CH, Babu AM. Development and Validation of Head-space Gas Chromatographic Method in Tandem with Flame ionized detection for the determination of Residual solvents in Simeprevir API Synthesis. RJPT 2021. [DOI: 10.52711/0974-360x.2021.00900] [Reference Citation Analysis]
36 Huang P, Wang Y, Yue M, Ge Z, Xia X, Jeyarajan AJ, Holmes JA, Yu R, Zhu C, Yang S, Lin W, Chung RT. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. Liver Int 2021;41:2341-57. [PMID: 34051040 DOI: 10.1111/liv.14976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World J Hepatol 2021; 13(9): 1069-1078 [PMID: 34630875 DOI: 10.4254/wjh.v13.i9.1069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Aisyah DN, Story A, Kremyda-vlachou M, Kozlakidis Z, Shalcross L, Hayward A. Assessing hepatitis C virus distribution among vulnerable populations in London using whole genome sequencing: results from the TB-REACH study. Wellcome Open Res 2021;6:229. [DOI: 10.12688/wellcomeopenres.16907.1] [Reference Citation Analysis]
39 Kumar N, Prabhu SS, Monga I, Banerjee I. Influence of IL28B gene polymorphisms on PegINF-RBV-mediated HCV clearance in HIV-HCV co-infected patients: A meta-analysis. Meta Gene 2021;29:100909. [DOI: 10.1016/j.mgene.2021.100909] [Reference Citation Analysis]
40 Jhaveri R, Yee LM, Antala S, Murphy M, Grobman WA, Shah SK. Responsible Inclusion of Pregnant Individuals in Eradicating HCV. Hepatology 2021;74:1645-51. [PMID: 33743550 DOI: 10.1002/hep.31825] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
41 Xu Y, Jiang X, Zhou Y, Ma M, Wang M, Ying B. Systematic Evolution of Ligands by Exponential Enrichment Technologies and Aptamer-Based Applications: Recent Progress and Challenges in Precision Medicine of Infectious Diseases. Front Bioeng Biotechnol 2021;9:704077. [PMID: 34447741 DOI: 10.3389/fbioe.2021.704077] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
42 Nurtjahyani SD, Taufiq Probojati R, Muhammad Ansori AN, Amin M, Handajani R. Haplotype Network Analysis and Phylogenetic Tree Construction of Hepatitis C Virus (HCV) Isolated from Tuban, Indonesia. RJPT 2021. [DOI: 10.52711/0974-360x.2021.00734] [Reference Citation Analysis]
43 Uricoli B, Birnbaum LA, Do P, Kelvin JM, Jain J, Costanza E, Chyong A, Porter CC, Rafiq S, Dreaden EC. Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy. Adv Healthc Mater 2021;10:e2002214. [PMID: 33690997 DOI: 10.1002/adhm.202002214] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
44 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
45 Lin HH, Hsu SJ, Lu SN, Chuang WL, Hsu CW, Chien RN, Yang SS, Su WW, Wu JC, Lee TH, Peng CY, Tseng KC, Qin A, Huang YW, Chen PJ. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. JGH Open 2021;5:929-40. [PMID: 34386602 DOI: 10.1002/jgh3.12613] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
46 Ehsan N, Sweed D, Elsabaawy M. Evaluation of HCV-related liver fibrosis post-successful DAA therapy. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00129-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
47 Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021; 27(23): 3249-3261 [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
48 Saraceni C, Birk J. A Review of Hepatitis B Virus and Hepatitis C Virus Immunopathogenesis. J Clin Transl Hepatol 2021;9:409-18. [PMID: 34221927 DOI: 10.14218/JCTH.2020.00095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
49 Strohbehn IA, Seethapathy R, Lee M, Sise ME. Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease. Kidney360 2021;2:1316-25. [PMID: 35369667 DOI: 10.34067/KID.0001812021] [Reference Citation Analysis]
50 Ahn YH, Lee H, Kim DY, Lee HW, Yu SJ, Cho YY, Jang JW, Jang BK, Kim CW, Kim HY, Park H, Cho HJ, Park B, Kim SS, Cheong JY. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C. Gut Liver 2021;15:410-9. [PMID: 32893194 DOI: 10.5009/gnl20151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
51 Tani J, Senoh T, Moriya A, Ogawa C, Deguchi A, Sakamoto T, Takuma K, Nakahara M, Oura K, Tadokoro T, Mimura S, Fujita K, Yoneyama H, Kobara H, Morishita A, Himoto T, Tsutsui A, Nagano T, Takaguchi K, Masaki T. Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers (Basel) 2021;13:2257. [PMID: 34066708 DOI: 10.3390/cancers13092257] [Reference Citation Analysis]
52 Fagan O, Armstrong P, Merwe KVD, Crosnoi D, Steele C, Sopena-Falco J, Parihar V. Viral hepatitis: A brief introduction, review of management, advances and challenges. World J Meta-Anal 2021; 9(2): 139-152 [DOI: 10.13105/wjma.v9.i2.139] [Reference Citation Analysis]
53 Teng W, Liu YC, Jeng WJ, Su CW. Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers (Basel) 2021;13:1729. [PMID: 33917345 DOI: 10.3390/cancers13071729] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
54 Falade-Nwulia O, Sulkowski MS. Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. J Infect Dis 2020;222:S745-57. [PMID: 33245350 DOI: 10.1093/infdis/jiaa534] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
55 Wu CM, Su FH, Muo CH, Huang JC, Wu MM, Yeh CC. Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin. Viruses 2021;13:475. [PMID: 33799370 DOI: 10.3390/v13030475] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Lee DH, Ryu SH, Myung HJ, Shin YJ, Lee SH, Park TY, Moon JS. Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals. Korean J Gastroenterol 2021;77:88-91. [PMID: 33633000 DOI: 10.4166/kjg.2020.145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Nakajima T, Karino Y, Hige S, Suii H, Tatsumi R, Yamaguchi M, Arakawa T, Kuwata Y, Hasegawa T, Toyota J. Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic hepatitis C virus-infected patients. J Gastroenterol Hepatol 2021;36:367-75. [PMID: 32991760 DOI: 10.1111/jgh.15280] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
58 Gomes C, Ginzberg D, Wong RJ. Delays and Gaps in Progressing Through the Hepatitis C Virus Cascade of Care: An Underserved Safety-net Hospital Experience. J Transl Int Med 2020;8:261-7. [PMID: 33511053 DOI: 10.2478/jtim-2020-0039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Stevens ER, Nucifora KA, Hagan H, Jordan AE, Uyei J, Khan B, Dombrowski K, des Jarlais D, Braithwaite RS. Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population. Clin Infect Dis 2020;70:2652-62. [PMID: 31400755 DOI: 10.1093/cid/ciz726] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
60 Singh A, Gupta V. SARS-CoV-2 therapeutics: how far do we stand from a remedy? Pharmacol Rep 2021;73:750-68. [PMID: 33389724 DOI: 10.1007/s43440-020-00204-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
61 Mangia A, Piazzolla V. Current Management of Patients with HCV Genotype 2. Hepatitis C: Care and Treatment 2021. [DOI: 10.1007/978-3-030-67762-6_6] [Reference Citation Analysis]
62 Moshfegh F, Ezzati A, Ezzati A, Bahraini M, Boluki E, Fazeli A. Therapeutic and Diagnostic Approaches for SARS-CoV-2. VP 2021;07:63-79. [DOI: 10.4236/vp.2021.72006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Andrade LJDO, França LS, França LS, Sousa ALOFD, Bittencourt AMV. Hepatite C e doenças autoimunes da tireoide. Hepatite C e tireoide 2021. [DOI: 10.7476/9786586213737.0006] [Reference Citation Analysis]
64 Puchades L, Berenguer M. Emerging Management of Hepatitis C in Transplant. Emerging Transplant Infections 2021. [DOI: 10.1007/978-3-030-25869-6_38] [Reference Citation Analysis]
65 Andrade LJDO, França LS, França LS, Cruz T, Bittencourt AMV, Paraná R. Interferon-alfa: um interferente endócrino. Hepatite C e tireoide 2021. [DOI: 10.7476/9786586213737.0005] [Reference Citation Analysis]
66 Abdullah, Niaz K, Khan F. Hepatitis C. Influence of Nutrients, Bioactive Compounds, and Plant Extracts in Liver Diseases 2021. [DOI: 10.1016/b978-0-12-816488-4.00014-0] [Reference Citation Analysis]
67 Kato N. Hepatitis C virus (HCV) : Development of anti-HCV agents and anti-HCV therapy. Okayama I Z 2020;132:131-143. [DOI: 10.4044/joma.132.131] [Reference Citation Analysis]
68 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical Practice Guidelines Panel: Chair:, EASL Governing Board representative:, Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series(☆). J Hepatol 2020;73:1170-218. [PMID: 32956768 DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 381] [Cited by in F6Publishing: 371] [Article Influence: 127.0] [Reference Citation Analysis]
69 Eijsink JFH, Al Khayat MNMT, Boersma C, Ter Horst PGJ, Wilschut JC, Postma MJ. Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands. Eur J Health Econ 2021;22:75-88. [PMID: 33064259 DOI: 10.1007/s10198-020-01236-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
70 Ran L, Zhao W, Wang H, Zhao Y, Bu H. Vitamin C as a Supplementary Therapy in Relieving Symptoms of the Common Cold: A Meta-Analysis of 10 Randomized Controlled Trials. Biomed Res Int 2020;2020:8573742. [PMID: 33102597 DOI: 10.1155/2020/8573742] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
71 Manso CF, Bibby DF, Lythgow K, Mohamed H, Myers R, Williams D, Piorkowska R, Chan YT, Bowden R, Ansari MA, Ip CLC, Barnes E, Bradshaw D, Mbisa JL. Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway. Front Microbiol 2020;11:576572. [PMID: 33162957 DOI: 10.3389/fmicb.2020.576572] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
72 Nguyen HA, Cooke GS, Day JN, Flower B, Phuong LT, Hung TM, Dung NT, Khoa DB, Hung LM, Kestelyn E, Thwaites GE, Chau NVV, Turner HC; SEARCH Investigators. The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam. Wellcome Open Res 2019;4:129. [PMID: 32734002 DOI: 10.12688/wellcomeopenres.15408.2] [Reference Citation Analysis]
73 Nguyen HA, Cooke GS, Day JN, Flower B, Phuong LT, Hung TM, Dung NT, Khoa DB, Hung LM, Kestelyn E, Thwaites GE, Chau NVV, Turner HC; SEARCH Investigators. The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam. Wellcome Open Res 2019;4:129. [PMID: 32734002 DOI: 10.12688/wellcomeopenres.15408.2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Mushtaq S, Akhter TS, Khan A, Sohail A, Khan A, Manzoor S. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan. Front Pharmacol 2020;11:550205. [PMID: 32982753 DOI: 10.3389/fphar.2020.550205] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
75 Harada K, Nakashima D, Nagao Y, Hidaka I, Sakaida I, Mishima K. Treatment of refractory oral lichen planus using direct antiviral agents in a patient with chronic hepatitis C: A case report. Oral Science International 2020;17:213-217. [DOI: 10.1002/osi2.1070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
76 Dent M, Hamorsky K, Vausselin T, Dubuisson J, Miyata Y, Morikawa Y, Matoba N. Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model. Cell Mol Gastroenterol Hepatol 2021;11:185-98. [PMID: 32861832 DOI: 10.1016/j.jcmgh.2020.08.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
77 Aleman S, Söderholm J, Büsch K, Kövamees J, Duberg AS. Frequent loss to follow-up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus. Liver Int 2020;40:1832-40. [PMID: 32294288 DOI: 10.1111/liv.14469] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
78 Yuan J, Yu J, Huang Y, He Z, Luo J, Wu Y, Zheng Y, Wu J, Zhu X, Wang H, Li M. Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus. BMC Med 2020;18:204. [PMID: 32731873 DOI: 10.1186/s12916-020-01663-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
79 Ibrahim MM, Maria DN, Wang X, Simpson RN, Hollingsworth TJ, Jablonski MM. Enhanced Corneal Penetration of a Poorly Permeable Drug Using Bioadhesive Multiple Microemulsion Technology. Pharmaceutics 2020;12:E704. [PMID: 32722550 DOI: 10.3390/pharmaceutics12080704] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
80 Luo Y, Zhang Y, Wang D, Shen D, Che YQ. Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection - A Real-World Cohort Study. Cancer Manag Res 2020;12:5323-30. [PMID: 32753950 DOI: 10.2147/CMAR.S254580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
81 Serumondo J, Penkunas MJ, Niyikora J, Ngwije A, Kiromera A, Musabeyezu E, Umutesi J, Umuraza S, Musengimana G, Nsanzimana S. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators. BMC Public Health 2020;20:946. [PMID: 32546216 DOI: 10.1186/s12889-020-09000-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
82 Laursen TL, Sandahl TD, Kazankov K, George J, Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. World J Gastroenterol 2020; 26(22): 2931-2947 [PMID: 32587440 DOI: 10.3748/wjg.v26.i22.2931] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
83 Liu D, Ndongwe TP, Puray-Chavez M, Casey MC, Izumi T, Pathak VK, Tedbury PR, Sarafianos SG. Effect of P-body component Mov10 on HCV virus production and infectivity. FASEB J 2020;34:9433-49. [PMID: 32496609 DOI: 10.1096/fj.201800641R] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
84 Mohammed BS, Hamad AE, Derayea SM. Stress stability study of simeprevir, a hepatitis C virus inhibitor, using feasible TLC-spectro-densitometry: application to pharmaceutical dosage form and human plasma. RSC Adv 2020;10:21100-7. [PMID: 35518774 DOI: 10.1039/d0ra01172j] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
85 Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. Semin Immunol 2019;43:101300. [PMID: 31771760 DOI: 10.1016/j.smim.2019.101300] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 28.0] [Reference Citation Analysis]
86 Dent M, Hamorsky K, Vausselin T, Dubuisson J, Miyata Y, Morikawa Y, Matoba N. Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model.. [DOI: 10.1101/2020.04.22.056754] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
87 Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J Med Virol 2020;92:740-6. [PMID: 32227493 DOI: 10.1002/jmv.25798] [Cited by in Crossref: 180] [Cited by in F6Publishing: 199] [Article Influence: 60.0] [Reference Citation Analysis]
88 Njiomegnie GF, Read SA, Fewings N, George J, McKay F, Ahlenstiel G. Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection. J Clin Med. 2020;9. [PMID: 32268490 DOI: 10.3390/jcm9041030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
89 Plemper RK. Measles Resurgence and Drug Development. Curr Opin Virol 2020;41:8-17. [PMID: 32247280 DOI: 10.1016/j.coviro.2020.02.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
90 Harding BN, Whitney BM, Nance RM, Ruderman SA, Crane HM, Burkholder G, Moore RD, Mathews WC, Eron JJ, Hunt PW, Volberding P, Rodriguez B, Mayer KH, Saag MS, Kitahata MM, Heckbert SR, Delaney JAC. Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study. BMC Infect Dis 2020;20:238. [PMID: 32197585 DOI: 10.1186/s12879-020-04958-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
91 Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci. 2020;17:892-902. [PMID: 32308542 DOI: 10.7150/ijms.43079] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
92 El Kassas M, Alboraie M, Naguib M, Omar H, Tahan AE, Moaz I, Abdellah M, Ezzat S, Wifi MN, Sherief AF, Eltabbakh M, Abdelsalam L, Eissa AH, Omran D. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. Turk J Gastroenterol 2019;30:708-13. [PMID: 31418415 DOI: 10.5152/tjg.2019.18514] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
93 Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020;92:479-490. [PMID: 32052466 DOI: 10.1002/jmv.25707] [Cited by in Crossref: 674] [Cited by in F6Publishing: 724] [Article Influence: 224.7] [Reference Citation Analysis]
94 Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, Müllhaupt B, Wedemeyer H, Lacombe K, Matthews GV, Schultz M, Klein M, Hezode C, Mercade GE, Kho D, Petoumenos K, Marks P, Tatsch F, Dos Santos AGP, Gane E; SMART-C Study Group. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J Hepatol 2020;72:431-40. [PMID: 31655134 DOI: 10.1016/j.jhep.2019.10.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
95 Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477. [PMID: 32119961 DOI: 10.1016/j.lfs.2020.117477] [Cited by in Crossref: 410] [Cited by in F6Publishing: 460] [Article Influence: 136.7] [Reference Citation Analysis]
96 Ahn YH, Park H, Lee MJ, Kim DH, Cho SB, Cho E, Jun CH, Choi SK. Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea. Gut Liver 2019;13:549-56. [PMID: 30970433 DOI: 10.5009/gnl18432] [Reference Citation Analysis]
97 Tani J, Morishita A, Sakamoto T, Takuma K, Nakahara M, Fujita K, Oura K, Tadokoro T, Mimura S, Nomura T, Yoneyama H, Kobara H, Himoto T, Tsutsui A, Senoh T, Nagano T, Ogawa C, Moriya A, Deguchi A, Takaguchi K, Masaki T. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. Oncol Lett. 2020;19:2205-2212. [PMID: 32194718 DOI: 10.3892/ol.2020.11341] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
98 Lee CC, Su YC, Ko TP, Lin LL, Yang CY, Chang SS, Roffler SR, Wang AH. Structural basis of polyethylene glycol recognition by antibody. J Biomed Sci 2020;27:12. [PMID: 31907057 DOI: 10.1186/s12929-019-0589-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
99 Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Chen KY, Ko YM, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML. Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir. J Gastroenterol Hepatol 2020;35:151-6. [PMID: 31373037 DOI: 10.1111/jgh.14815] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
100 Shirazi F, Wang J, Wong RJ. Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965. J Clin Exp Hepatol 2020;10:30-6. [PMID: 32025164 DOI: 10.1016/j.jceh.2019.06.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
101 Kienskaya K, Belova I, Sardushkin M, Butorova I, Kuskov A, Ulybina O, Guznova N. Antimicrobial Composition based on Highly Dispersed Zinc oxide and Ribavirin. Biiotehnologiâ (Mosk ) 2020;36:94-98. [DOI: 10.21519/0234-2758-2020-36-4-94-98] [Reference Citation Analysis]
102 Puchades L, Berenguer M. Emerging Management of Hepatitis C in Transplant. Emerging Transplant Infections 2020. [DOI: 10.1007/978-3-030-01751-4_38-1] [Reference Citation Analysis]
103 Buchanan R, Cooper K, Grellier L, Khakoo SI, Parkes J. The testing of people with any risk factor for hepatitis C in community pharmacies is cost-effective. J Viral Hepat 2020;27:36-44. [PMID: 31520434 DOI: 10.1111/jvh.13207] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
104 Rosa-Hezode I, Chousterman M, Costes L, Labourdette C, Elghozi B, Krastinova E, Roudot-Thoraval F. Cascade of care for migrants tested Hepatitis C antibodies positive in France through a systematic screening programme: The PRECAVIR study. J Viral Hepat 2019;26:1496-9. [PMID: 31433886 DOI: 10.1111/jvh.13192] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
105 Kamp WM, Sellers CM, Stein S, Lim JK, Kim HS. Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma. Sci Rep 2019;9:17081. [PMID: 31745132 DOI: 10.1038/s41598-019-53051-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
106 Abdurakhmanov DT, Rozina TP, Nikulkina EN, Burnevich EZ, Tanashuk EL, Severov MV, Filatova AL, Milovanova SY, Karpov VV, Moiseev SV. [Antiviral therapy of chronic hepatitis C: 30 years success story]. Ter Arkh 2019;91:110-5. [PMID: 32598621 DOI: 10.26442/00403660.2019.11.000470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
107 Colussi G, Donnini D, Brizzi RF, Maier S, Valenti L, Catena C, Cavarape A, Sechi LA, Soardo G. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. World J Gastroenterol 2019; 25(40): 6094-6106 [PMID: 31686765 DOI: 10.3748/wjg.v25.i40.6094] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
108 Khatun M, Ray RB. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells 2019;8:E1249. [PMID: 31615075 DOI: 10.3390/cells8101249] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 18.5] [Reference Citation Analysis]
109 Danilenko NG, Siniauskaya MG, Lukashyk SP, Karpov IA, Davydenko OG. “Double Punch”: Hepatitis C in Patients with Genetic Defects of Iron Metabolism. Cytol Genet 2019;53:407-17. [DOI: 10.3103/s0095452719050062] [Reference Citation Analysis]
110 Sadeghimehr M, Bertisch B, Schaetti C, Wandeler G, Richard J, Scheidegger C, Keiser O, Estill J. Modelling the impact of different testing strategies for HCV infection in Switzerland. Journal of Virus Eradication 2019;5:191-203. [DOI: 10.1016/s2055-6640(20)30036-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
111 Lazear HM, Schoggins JW, Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity 2019;50:907-23. [PMID: 30995506 DOI: 10.1016/j.immuni.2019.03.025] [Cited by in Crossref: 456] [Cited by in F6Publishing: 472] [Article Influence: 114.0] [Reference Citation Analysis]
112 Vecchio F, Messina G, Giovenzana A, Petrelli A. New Evidence of Exocrine Pancreatopathy in Pre-symptomatic and Symptomatic Type 1 Diabetes. Curr Diab Rep 2019;19:92. [PMID: 31471779 DOI: 10.1007/s11892-019-1223-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
113 Auker-Howlett D, Wilde M. Reinforced reasoning in medicine. J Eval Clin Pract 2020;26:458-64. [PMID: 31435979 DOI: 10.1111/jep.13269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
114 Wei L, Shang J, Ma Y, Xu X, Huang Y, Guan Y, Duan Z, Zhang W, Gao Z, Zhang M, Li J, Jia J, Yang Y, Wen X, Wang M, Jia Z, Ning B, Chen Y, Qi Y, Du J, Jiang J, Tong L, Xie Y, Wu JJ. Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C. J Clin Transl Hepatol 2019;7:221-5. [PMID: 31608213 DOI: 10.14218/JCTH.2019.00018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
115 d'Avigdor WMH, Budzinska MA, Lee M, Lam R, Kench J, Stapelberg M, McLennan SV, Farrell G, George J, McCaughan GW, Tu T, Shackel NA. Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver. Sci Rep 2019;9:10596. [PMID: 31332246 DOI: 10.1038/s41598-019-46664-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
116 Lioznov DA, Dunaeva NV, Chung NH, Gorchakova OV, Antonova TV. Chronic hepatitis C: modern condition of the problem. Nefrologiâ (St -Peterbg ) 2019;23:36-46. [DOI: 10.24884/1561-6274-2019-23-4-36-46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
117 Sakamaki A, Kamimura K, Fukui N, Watanabe H, Sakai N, Tominaga K, Mizuno K, Takamura M, Kawai H, Sugai T, Yamagiwa S, Someya T, Terai S. A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety. BMC Gastroenterol 2019;19:85. [PMID: 31195993 DOI: 10.1186/s12876-019-1013-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
118 McGlynn EA, Adams JL, Kramer J, Sahota AK, Silverberg MJ, Shenkman E, Nelson DR. Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C. JAMA Netw Open 2019;2:e194765. [PMID: 31173117 DOI: 10.1001/jamanetworkopen.2019.4765] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
119 Nakagomi R, Tateishi R, Masuzaki R, Soroida Y, Iwai T, Kondo M, Fujiwara N, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Tanaka Y, Otsuka M, Kato N, Moriya K, Ikeda H, Koike K. Liver stiffness measurements in chronic hepatitis C: Treatment evaluation and risk assessment. J Gastroenterol Hepatol 2019;34:921-8. [PMID: 30393960 DOI: 10.1111/jgh.14530] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
120 Rich HE, McCourt CC, Zheng WQ, McHugh KJ, Robinson KM, Wang J, Alcorn JF. Interferon Lambda Inhibits Bacterial Uptake during Influenza Superinfection. Infect Immun 2019;87:e00114-19. [PMID: 30804099 DOI: 10.1128/IAI.00114-19] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
121 Panyala BR, Mukherjee RM, Devarakonda H, Tadivaka S, Padaki NR, Sharma M, Duvvuru NR. Genotype distribution in relation to viral load in a large cohort of Indian patients with chronic hepatitis C virus infection: A retrospective analysis. Indian J Gastroenterol 2019;38:110-6. [PMID: 30903612 DOI: 10.1007/s12664-019-00934-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
122 Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet 2019;393:1319-29. [PMID: 30704789 DOI: 10.1016/S0140-6736(18)32277-3] [Cited by in Crossref: 171] [Cited by in F6Publishing: 170] [Article Influence: 42.8] [Reference Citation Analysis]
123 Kamp WM, Sellers CM, Stein SM, Lim JK, Kim HS. Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma.. [DOI: 10.1101/575670] [Reference Citation Analysis]
124 Luna JM, Saeed M, Rice CM. Taming a beast: lessons from the domestication of hepatitis C virus. Curr Opin Virol 2019;35:27-34. [PMID: 30875640 DOI: 10.1016/j.coviro.2019.02.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
125 Lv DD, Wang ML, Chen EQ, Wu DB, Tao YC, Zhang DM, Tang H. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection. Eur J Gastroenterol Hepatol 2019;31:382-8. [PMID: 30383554 DOI: 10.1097/MEG.0000000000001299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
126 Tolentino B, Singh RR, Misra S, Dieterich DT, Sarpel D. An update on the management of hepatitis C virus and human immunodeficiency virus co-infection. Future Virology 2019;14:185-195. [DOI: 10.2217/fvl-2018-0116] [Reference Citation Analysis]
127 Chou JW, Silverstein AR, Goldman DP. Short-term budget affordability of hepatitis C treatments for state Medicaid programs. BMC Health Serv Res 2019;19:140. [PMID: 30819153 DOI: 10.1186/s12913-019-3956-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
128 Duerr M, Schrezenmeier EV, Lehner LJ, Bergfeld L, Glander P, Marticorena Garcia SR, Althoff CE, Sack I, Brakemeier S, Eckardt KU, Budde K, Halleck F. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients. BMC Nephrol 2019;20:36. [PMID: 30717681 DOI: 10.1186/s12882-019-1218-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
129 Norton BL, Akiyama MJ, Zamor PJ, Litwin AH. Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice. Infect Dis Clin North Am 2018;32:347-70. [PMID: 29778260 DOI: 10.1016/j.idc.2018.02.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
130 Alazard-Dany N, Denolly S, Boson B, Cosset FL. Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets. Viruses. 2019;11. [PMID: 30621318 DOI: 10.3390/v11010030] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
131 Altintas E, Yalin S, Sezgin O, Ucbilek E, Tombak A, Kanik A. Erythrocyte Membrane Protein Band 3 Predicts Interferon Ribavirin-Induced Anemia. OJRM 2019;08:5-16. [DOI: 10.4236/ojrm.2019.82002] [Reference Citation Analysis]
132 Dash S, Aydin Y, Stephens CM. Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase Inhibitor. Viral Polymerases 2019. [DOI: 10.1016/b978-0-12-815422-9.00008-5] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
133 Dinda B. Pharmacology of Iridoids. Pharmacology and Applications of Naturally Occurring Iridoids 2019. [DOI: 10.1007/978-3-030-05575-2_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
134 Mcdaniel KF, Ku Y, Sun Y, Chen H, Shanley J, Middleton T, Or YS, Kempf D. The Discovery and Development of HCV NS3 Protease Inhibitor Paritaprevir. Topics in Medicinal Chemistry 2019. [DOI: 10.1007/7355_2018_42] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
135 Venkatraman S. Discovery of Boceprevir, a Ketoamide-Derived HCV NS3 Protease Inhibitor, for Treatment of Genotype 1 Infections. Topics in Medicinal Chemistry 2019. [DOI: 10.1007/7355_2018_40] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
136 Alqahtani SA, Sulkowski MS. The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infection. Topics in Medicinal Chemistry 2019. [DOI: 10.1007/7355_2018_59] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
137 Diaz VF, Olson M, Jacobson IM. The Evolution of Clinical Trials for Hepatitis C. Topics in Medicinal Chemistry 2019. [DOI: 10.1007/7355_2019_64] [Reference Citation Analysis]
138 Li DK, Chung RT. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. Methods in Molecular Biology 2019. [DOI: 10.1007/978-1-4939-8976-8_1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 14.5] [Reference Citation Analysis]
139 Chen F, Freyer C, Gong L, Zekry A. Hepatitis B Virus, Hepatitis C Virus, the Microbiome, and Hepatocellular Carcinoma. Gastrointestinal Diseases and their Associated Infections 2019. [DOI: 10.1016/b978-0-323-54843-4.00004-0] [Reference Citation Analysis]
140 Thurmond S, Wang B, Song J, Hai R. Suppression of Type I Interferon Signaling by Flavivirus NS5. Viruses 2018;10:E712. [PMID: 30558110 DOI: 10.3390/v10120712] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
141 Rentiya ZS, Wells M, Bae J, Chen KJ, Chao AN, Turgeon N, Shah SM, Hanout M. Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations. Graefes Arch Clin Exp Ophthalmol 2019;257:447-52. [PMID: 30547319 DOI: 10.1007/s00417-018-04209-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
142 Kumar R, Hsiang JC, Tan J, Thurairajah PH. Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report. Clin Mol Hepatol 2019;25:326-30. [PMID: 30509013 DOI: 10.3350/cmh.2018.0063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
143 Sugiura A, Joshita S, Umemura T, Yamazaki T, Fujimori N, Kimura T, Matsumoto A, Igarashi K, Usami Y, Wada S, Mori H, Shibata S, Yoshizawa K, Morita S, Furuta K, Kamijo A, Iijima A, Kako S, Maruyama A, Kobayashi M, Komatsu M, Matsumura M, Miyabayashi C, Ichijo T, Takeuchi A, Koike Y, Gibo Y, Tsukadaira T, Inada H, Kiyosawa K, Tanaka E. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. J Viral Hepat 2018;25:1462-71. [PMID: 30044517 DOI: 10.1111/jvh.12973] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
144 Buettner N, Thimme R. Sexual dimorphism in hepatitis B and C and hepatocellular carcinoma. Semin Immunopathol 2019;41:203-11. [PMID: 30498927 DOI: 10.1007/s00281-018-0727-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
145 Wang XX, Luo BF, Jiang HJ, Cong X, Jin Q, Ma DL, Wei L, Feng B. Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir. World J Gastroenterol 2018; 24(40): 4554-4564 [PMID: 30386105 DOI: 10.3748/wjg.v24.i40.4554] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
146 Jovanovic-cupic S, Bozovic A, Krajnovic M, Petrovic N. Hepatitis C: Host and Viral Factors Associated with Response to Therapy and Progression of Liver Fibrosis. Hepatitis C - From Infection to Cure 2018. [DOI: 10.5772/intechopen.76417] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
147 Pradat P, Virlogeux V, Trépo E. Epidemiology and Elimination of HCV-Related Liver Disease. Viruses 2018;10:E545. [PMID: 30301201 DOI: 10.3390/v10100545] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
148 Jacobson IM. Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis? Gastroenterology 2018;155:969-71. [PMID: 30201359 DOI: 10.1053/j.gastro.2018.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
149 Yoo SH, Kwon JH, Nam SW, Kim HY, Kim CW, You CR, Choi SW, Cho SH, Han JY, Song DS, Chang UI, Yang JM, Lee HL, Lee SW, Han NI, Kim SH, Song MJ, Hwang S, Sung PS, Jang JW, Bae SH, Choi JY, Yoon SK. Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients. J Viral Hepat 2018;25:1189-96. [PMID: 29660199 DOI: 10.1111/jvh.12918] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
150 Mathur P, Kottilil S, Wilson E. Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. J Clin Transl Hepatol 2018;6:431-7. [PMID: 30637222 DOI: 10.14218/JCTH.2018.00007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
151 Abdel Malak CA, Abelhafez TH, Tabll AA, Mashaly MM, El Shenawy R, El-Abd YS, Shaker MH, El-Awady MK. Neutralizing activity and safety of human monoclonal antibodies against hepatitis C virus. Hum Antibodies 2017;26:127-34. [PMID: 29036810 DOI: 10.3233/HAB-170330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
152 Rahamathulla S, Ratnagiri BSVV, Manickam M, Sultana S, Mamatha DM, Magisetty O, Nagarapu R, Ponamgi SPD. Determination of Sustained Virological Response in Hepatitis C Virus Genotypes by the Number of Mutations in the E2 and NS5A-ISDR Regions: A Meta-Analysis. Russ J Genet 2018;54:1013-24. [DOI: 10.1134/s1022795418090119] [Reference Citation Analysis]
153 Hsieh YC, Jeng WJ, Huang CH, Teng W, Chen WT, Chen YC, Lin SM, Tai DI, Lin CY, Sheen IS. Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. PLoS One 2018;13:e0202777. [PMID: 30138456 DOI: 10.1371/journal.pone.0202777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
154 Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Marinho RT, Borrego P, Taveira N. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018;8:12266. [PMID: 30116054 DOI: 10.1038/s41598-018-30528-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
155 Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24:169-229. [PMID: 30092624 DOI: 10.3350/cmh.2018.1004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
156 Kao JH, Yu ML, Chen CY, Peng CY, Chen MY, Tang H, Chen Q, Wu JJ. Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study. J Gastroenterol Hepatol 2018;33:1507-10. [PMID: 29346834 DOI: 10.1111/jgh.14096] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
157 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018;69:461-511. [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026] [Cited by in Crossref: 1139] [Cited by in F6Publishing: 1162] [Article Influence: 227.8] [Reference Citation Analysis]
158 Wu J, Yin Z, Cao L, Xu X, Yan T, Liu C, Li D. Adjuvant pegylated interferon therapy improves the survival outcomes in patients with hepatitis-related hepatocellular carcinoma after curative treatment: A meta-analysis. Medicine (Baltimore). 2018;97:e11295. [PMID: 29995763 DOI: 10.1097/md.0000000000011295] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
159 Zitzmann C, Kaderali L. Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling. Front Microbiol 2018;9:1546. [PMID: 30050523 DOI: 10.3389/fmicb.2018.01546] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
160 Gupta V, Kumar A, Sharma P, Arora A. Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. Indian J Med Res 2017;146:23-33. [PMID: 29168457 DOI: 10.4103/ijmr.IJMR_679_15] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
161 Davoodi L, Masoum B, Moosazadeh M, Jafarpour H, Haghshenas MR, Mousavi T. Psychiatric side effects of pegylated interferon-α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta-analysis. Exp Ther Med 2018;16:971-8. [PMID: 30116347 DOI: 10.3892/etm.2018.6255] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
162 Aisyah DN, Shallcross L, Hully AJ, O'Brien A, Hayward A. Assessing hepatitis C spontaneous clearance and understanding associated factors-A systematic review and meta-analysis. J Viral Hepat 2018;25:680-98. [PMID: 29345844 DOI: 10.1111/jvh.12866] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
163 Hajarizadeh B, Grebely J, Matthews GV, Martinello M, Dore GJ. Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia. J Viral Hepat 2018;25:640-8. [PMID: 29274192 DOI: 10.1111/jvh.12852] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 10.8] [Reference Citation Analysis]
164 Vasanthakumar A, Davis JW, Abunimeh M, Söderholm J, Zha J, Dumas EO, Cohen DE, Waring JF, Lagging M. Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens. PLoS One 2018;13:e0198296. [PMID: 29851985 DOI: 10.1371/journal.pone.0198296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
165 Oh JY, Kim BS, Lee CH, Song JE, Lee HJ, Park JG, Hwang JS, Chung WJ, Jang BK, Kweon YO, Tak WY, Park SY, Jang SY, Suh JI, Kwak SG. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world. Korean J Intern Med 2019;34:794-801. [PMID: 29792020 DOI: 10.3904/kjim.2017.368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
166 de Souza SL, Vidal LL, Ramos J, Cardoso CC, Coelho HSM, Villela-Nogueira CA, Perez RM, Soares MA, Santos AF. Hepatitis C Virus-Infected Responders and Relapsers to Treatment Show Similar Genetic Profiles of IL28B and IL10 Single Nucleotide Polymorphisms. Biomed Res Int 2018;2018:2931486. [PMID: 29888255 DOI: 10.1155/2018/2931486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
167 Kuwashiro T, Iwane S, Jinghe X, Matsuhashi S, Eguchi Y, Anzai K, Fujimoto K, Mizuta T, Sakamoto N, Ikeda M, Kato N, Ozaki I. Regulation of interferon signaling and HCV‑RNA replication by extracellular matrix. Int J Mol Med 2018;42:957-65. [PMID: 29786754 DOI: 10.3892/ijmm.2018.3693] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
168 Hall EW, Rosenberg ES, Sullivan PS. Estimates of state-level chronic hepatitis C virus infection, stratified by race and sex, United States, 2010. BMC Infect Dis 2018;18:224. [PMID: 29769036 DOI: 10.1186/s12879-018-3133-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
169 Crisan D, Grigorescu MD, Radu C, Suciu A, Grigorescu M. Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response. Indian J Med Res 2017;145:543-50. [PMID: 28862188 DOI: 10.4103/ijmr.IJMR_1410_14] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
170 Hu CC, Weng CH, Chang LC, Lin CL, Chen YT, Hu CF, Hua MC, Chen LW, Chien RN. Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy. Ther Clin Risk Manag 2018;14:783-91. [PMID: 29750037 DOI: 10.2147/TCRM.S158424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
171 Yao Y, Yue M, Zang F, Liu M, Fan H, Zhuo L, Wu J, Xia X, Feng Y, Huang P, Yu R. Genetic variants in chemokine CC subfamily genes influence hepatitis C virus viral clearance. J Hum Genet 2018;63:831-9. [PMID: 29703961 DOI: 10.1038/s10038-018-0452-9] [Reference Citation Analysis]
172 Enciso-vargas M, Ruíz-madrigal B, Muñoz-valle JF, Morales-balderas OY, Hernández-nazara ZH, Martínez-lópez E, Dávalos-cobian C, Padilla-gutiérrez JR, Torres-baranda JR, Domínguez-rosales JA, Maldonado-gonzález M. Association of −319 C/T and +49 A/G polymorphisms of CTLA-4 gene in patients with hepatitis C virus infection. Medicina Clínica (English Edition) 2018;150:251-256. [DOI: 10.1016/j.medcle.2018.01.024] [Reference Citation Analysis]
173 Fabrizi F, Poordad FF, Martin P. Diagnostic Workup of Hepatitis C and the Patient on Maintenance Dialysis. Int J Artif Organs 2001;24:843-52. [DOI: 10.1177/039139880102401206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
174 Echeverría N, Chiodi D, López P, Sanchez Ciceron A, Angulo J, López-Lastra M, Silvera P, Canavesi A, Bianchi C, Colistro V, Cristina J, Hernandez N, Moreno P. IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients. Virol J 2018;15:40. [PMID: 29499724 DOI: 10.1186/s12985-018-0946-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
175 Bunchorntavakul C, Mitrani R, Reddy KR. Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road? J Clin Exp Hepatol 2018;8:81-94. [PMID: 29743799 DOI: 10.1016/j.jceh.2017.11.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
176 Papić N, Budimir J, Kurelac I, Dušek D, Jugović D, Krajcar N, Vince A. Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study. Acta Clin Croat 2018;57:61-70. [PMID: 30256012 DOI: 10.20471/acc.2018.57.01.07] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
177 Roulot D, Thibault V, Laforest C, Fontaine H, Bronowicki JP, Asselah T, Bourlière M, Canva V, Leroy V, Loustaud-Ratti V, Ouzan D, Zoulim F, Schischmanoff O, Rousseau C, Renault A, Petrov-Sanchez V, Diallo A, Bellissant E, Serfaty L; ANRS HC32 QUATTRO study group. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study. Eur J Gastroenterol Hepatol 2018;30:302-9. [PMID: 29271782 DOI: 10.1097/MEG.0000000000001035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
178 Khalid M, Dahal S, Gayam V, Mandal A, Hossain MR, Mukhtar O, Khalid M, Garlapati P, Mansour M. Assessment of Knowledge, Attitudes, and Practices Regarding Chronic Hepatitis C Treatment and Its Challenges: A Survey of Internal Medicine Residents in a Community Hospital. Gastroenterology Res 2018;11:31-5. [PMID: 29511403 DOI: 10.14740/gr963w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
179 Politi MC, George N, Li T, Korenblat KM, Fowler KJ, Ho C, Liapakis A, Roth D, Yee J. Project HELP: a study protocol to pilot test a shared decision-making tool about treatment options for patients with hepatitis C and chronic kidney disease. Pilot Feasibility Stud 2018;4:55. [PMID: 29484199 DOI: 10.1186/s40814-018-0251-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
180 Jardim ACG, Shimizu JF, Rahal P, Harris M. Plant-derived antivirals against hepatitis c virus infection. Virol J 2018;15:34. [PMID: 29439720 DOI: 10.1186/s12985-018-0945-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
181 Kichatova VS, Kyuregyan KK, Soboleva NV, Karlsen AA, Isaeva OV, Isaguliants MG, Mikhailov MI. Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context. J Immunol Res 2018;2018:7685371. [PMID: 29577052 DOI: 10.1155/2018/7685371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
182 Cheng CH, Lin CC, Chen HL, Lin IT, Wu CH, Lee YK, Bair MJ. Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection. PLoS One 2018;13:e0191799. [PMID: 29389957 DOI: 10.1371/journal.pone.0191799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
183 Kumada H, Mochida S, Nakamuta M, Suzuki F, Yagi T, Takasaki R, Okai M, Kamiya N, Okada Y, Hirota S, Orihashi M, Ochi M, Chayama K. Efficacy and safety of telaprevir with natural human interferon-β and ribavirin in Japanese chronic hepatitis C patients with depression. Hepatol Res 2018;48:184-92. [PMID: 28497489 DOI: 10.1111/hepr.12914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
184 Miarons M, Sánchez-Ulayar A, Sempere G, Marín S, Castellví JM. New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groups. Eur J Hosp Pharm 2019;26:135-9. [PMID: 31428320 DOI: 10.1136/ejhpharm-2017-001352] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
185 Kaneko R, Nakazaki N, Omori R, Yano Y, Ogawa M, Sato Y. Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience. World J Hepatol 2018; 10(1): 88-94 [PMID: 29399282 DOI: 10.4254/wjh.v10.i1.88] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
186 Papadopoulos N, Argiana V, Deutsch M. Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management. Ann Gastroenterol 2018;31:35-41. [PMID: 29333065 DOI: 10.20524/aog.2017.0204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
187 He CL, Liu M, Tan ZX, Hu YJ, Zhang QY, Kuang XM, Kong WL, Mao Q. Hepatitis C virus core protein-induced miR-93-5p up-regulation inhibits interferon signaling pathway by targeting IFNAR1. World J Gastroenterol 2018; 24(2): 226-236 [PMID: 29375208 DOI: 10.3748/wjg.v24.i2.226] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
188 Kawano A, Shigematsu H, Miki K, Ichiki Y, Morita C, Yanagita K, Takahashi K, Dohmen K, Nomura H, Ishibashi H, Shimoda S. Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study. Intern Med 2018;57:1533-42. [PMID: 29321441 DOI: 10.2169/internalmedicine.9857-17] [Reference Citation Analysis]
189 Hsu JW, Hiemenz JW, Wingard JR, Leather H. Viral Infections in Patients with Hematological Malignancies. Neoplastic Diseases of the Blood 2018. [DOI: 10.1007/978-3-319-64263-5_51] [Reference Citation Analysis]
190 Wang HC, Ren YP, Qiu Y, Zheng J, Li GL, Hu CP, Zhou TY, Lu W, Li L. Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C. Acta Pharmacol Sin 2018;39:140-53. [PMID: 28880015 DOI: 10.1038/aps.2017.84] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
191 Devarbhavi H, Bonkovsky HL, Russo M, Chalasani N. Drug-Induced Liver Injury. Zakim and Boyer's Hepatology 2018. [DOI: 10.1016/b978-0-323-37591-7.00056-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
192 Hicks JK, Dunnenberger HM. Genetic Contributions and Personalized Medicine. Chronic Illness Care 2018. [DOI: 10.1007/978-3-319-71812-5_1] [Reference Citation Analysis]
193 Simbiri KO, Robertson ES. Conjunctival Carcinoma. Encyclopedia of AIDS 2018. [DOI: 10.1007/978-1-4939-7101-5_27] [Reference Citation Analysis]
194 Hytiroglou P. Hepatitis C. Practical Hepatic Pathology: a Diagnostic Approach 2018. [DOI: 10.1016/b978-0-323-42873-6.00015-9] [Reference Citation Analysis]
195 Kpossou AR, Séhonou J, Adjigbé GMG, Vignon RK, Alassan KS, Kodjoh N. Treatment of Hepatitis C with Pegylated Interferon Alpha-2a and Ribavirin: Experience from Benin. OJGas 2018;08:275-283. [DOI: 10.4236/ojgas.2018.88030] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
196 Ozono Y, Nagata K, Hasuike S, Iwakiri H, Nakamura K, Tsuchimochi M, Yamada Y, Takaishi Y, Sueta M, Miike T, Tahara Y, Yamamoto S, Shide K, Hidaka T, Kubuki Y, Kusumoto K, Ochiai T, Kato J, Komada N, Hirono S, Kuroki K, Shigehira M, Shimoda K. Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1. World J Hepatol 2017; 9(36): 1340-1345 [PMID: 29359017 DOI: 10.4254/wjh.v9.i36.1340] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
197 Guardigni V, Badia L, Conti M, Rinaldi M, Mancini R, Viale P, Verucchi G. Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals. World J Hepatol 2017; 9(34): 1270-1277 [PMID: 29290908 DOI: 10.4254/wjh.v9.i34.1270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
198 Wattacheril J, Rose KL, Hill S, Lanciault C, Murray CR, Washington K, Williams B, English W, Spann M, Clements R, Abumrad N, Flynn CR. Non-alcoholic fatty liver disease phosphoproteomics: A functional piece of the precision puzzle. Hepatol Res 2017;47:1469-83. [PMID: 28258704 DOI: 10.1111/hepr.12885] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
199 Araújo LF, Dorna MS, Santos LAA, Lima TB, Ietsugu MV, Nunes HRC, Paiva SAR, Silva GF, Qi X, Romeiro FG. Anthropometric changes caused by hepatitis C treatment with interferon and ribavirin: which patients and which measures are affected? Nutrire 2017;42:21. [DOI: 10.1186/s41110-017-0049-7] [Reference Citation Analysis]
200 Mohamed MS, Hanafy AS, Bassiony MAA, Hussein S. Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2017;29:1368-72. [PMID: 28953002 DOI: 10.1097/MEG.0000000000000963] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
201 Cacoub P, Vautier M, Desbois AC, Lafuma A, Saadoun D. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era. Liver Int 2017;37:1805-13. [PMID: 28467688 DOI: 10.1111/liv.13465] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
202 Nagao Y, Nakasone K, Maeshiro T, Nishida N, Kimura K, Kawahigashi Y, Tanaka Y, Sata M. Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma. Case Rep Gastroenterol. 2017;11:701-710. [PMID: 29430221 DOI: 10.1159/000484132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
203 Iqbal S, Yousuf MH, Yousaf MI. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. World J Gastroenterol 2017; 23(44): 7899-7905 [PMID: 29209131 DOI: 10.3748/wjg.v23.i44.7899] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
204 de Leuw P, Stephan C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect Dis 2017;5:Doc08. [PMID: 30671330 DOI: 10.3205/id000034] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
205 Yek C, de la Flor C, Marshall J, Zoellner C, Thompson G, Quirk L, Mayorga C, Turner BJ, Singal AG, Jain MK. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study. BMC Med 2017;15:204. [PMID: 29151365 DOI: 10.1186/s12916-017-0969-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
206 Grando AV, Ferreira PRA, Pessôa MG, Mazo DFC, Brandão-Mello CE, Reuter T, Martinelli ALC, Gonzalez MP, Nastri ACS, Campos AF, Lopes MIBF, Brito JDU, Mendes-Corrêa MC. Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus. Rev Inst Med Trop Sao Paulo 2017;59:e67. [PMID: 29116287 DOI: 10.1590/S1678-9946201759067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
207 Qiao J, Li L. Analysis of competitive infectious diseases with multiple strains. Chaos, Solitons & Fractals 2017;104:215-221. [DOI: 10.1016/j.chaos.2017.08.017] [Reference Citation Analysis]
208 Hochstatter KR, Stockman LJ, Holzmacher R, Greer J, Seal DW, Taylor QA, Gill EK, Westergaard RP. The continuum of hepatitis C care for criminal justice involved adults in the DAA era: a retrospective cohort study demonstrating limited treatment uptake and inconsistent linkage to community-based care. Health Justice 2017;5:10. [PMID: 29086078 DOI: 10.1186/s40352-017-0055-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
209 Fried MW, Darling JM, Lemon SM. Hepatitis C. Schiff's Diseases of the Liver 2017. [DOI: 10.1002/9781119251316.ch25] [Reference Citation Analysis]
210 Ling YM, Chen JY, Guo L, Wang CY, Tan WT, Wen Q, Zhang SD, Deng GH, Lin Y, Kwok HF. β-defensin 1 expression in HCV infected liver/liver cancer: an important role in protecting HCV progression and liver cancer development. Sci Rep 2017;7:13404. [PMID: 29042578 DOI: 10.1038/s41598-017-13332-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
211 Callefi LA, Villela-Nogueira CA, de Barros Tenore S, Carnaúba-Júnior D, Coelho HSM, Pinto PTA, Nabuco LC, Pessoa MG, Ferraz MLCG, Ferreira PRA, de Lourdes Candolo Martinelli A, Chachá SGF, de Souza Paiva Ferreira A, de Macedo Bisio AP, Brandão-Mello CE, Álvares-Da-Silva MR, Reuter T, Ivantes CAP, de Mello Perez R, Mendes-Correa MCJ. Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study. Clinics (Sao Paulo) 2017;72:378-85. [PMID: 28658438 DOI: 10.6061/clinics/2017(06)08] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
212 Austria AM, Ninčević V, Wu GY. A Brief Update on the Treatment of Hepatitis C. Update on Hepatitis C 2017. [DOI: 10.5772/intechopen.70685] [Reference Citation Analysis]
213 Lee AS, van Driel ML, Crawford DH. The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia. Clinicoecon Outcomes Res 2017;9:595-607. [PMID: 29042803 DOI: 10.2147/CEOR.S146280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
214 He T, Lopez-Olivo MA, Hur C, Chhatwal J. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. Aliment Pharmacol Ther 2017;46:711-21. [PMID: 28836278 DOI: 10.1111/apt.14271] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
215 Honda M, Sugawara Y, Watanabe T, Tateyama M, Tanaka M, Uchida K, Kawabata S, Yoshii D, Miura K, Isono K, Hayashida S, Ohya Y, Yamamoto H, Sasaki Y, Inomata Y. Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation. Hepatol Res 2017;47:1147-54. [PMID: 28002876 DOI: 10.1111/hepr.12853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
216 Miotto N, Mendes LC, Zanaga LP, Goncales ESL, Lazarini MSK, Pedro MN, Gonçales FL Jr, Stucchi RSB, Vigani AG. Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort. Eur J Gastroenterol Hepatol 2017;29:1149-54. [PMID: 28800033 DOI: 10.1097/MEG.0000000000000944] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
217 Kang MG, Kang MJ, Ji E, Yoo BK. Meta-analysis of the Efficacy and Safety of Grazoprevir and Elbasvir for the Treatment of Hepatitis C Virus Infection. Korean J Clin Pharm 2017;27:150-160. [DOI: 10.24304/kjcp.2017.27.3.150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
218 Carrillo-Bustamante P, Nguyen THT, Oestereich L, Günther S, Guedj J, Graw F. Determining Ribavirin's mechanism of action against Lassa virus infection. Sci Rep 2017;7:11693. [PMID: 28916737 DOI: 10.1038/s41598-017-10198-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
219 Gomez-Moreno AZ, Pineda-Tenor D, Jimenez-Sousa MA, Sánchez-Ruano JJ, Artaza-Varasa T, Saura-Montalban J, Ryan P, Resino S. Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study. PLoS One 2017;12:e0184404. [PMID: 28880930 DOI: 10.1371/journal.pone.0184404] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
220 Bukhsh A, Goh B, Lee L, Khan TM. Effectiveness of conventional interferon and ribavirin combination therapy in chronic Hepatitis C patients in Pakistan. Journal of Infection and Public Health 2017;10:692-693. [DOI: 10.1016/j.jiph.2016.09.012] [Reference Citation Analysis]
221 Maya AAE, da Silveira Alves CF, Marangon CG, Frizon K, Gorziza RP, Lunge VR, Simon D. Influence of the IL6 − 147C/G polymorphism on clinical characteristics of chronic hepatitis C in Brazilian patients. Gene Reports 2017;8:75-78. [DOI: 10.1016/j.genrep.2017.05.009] [Reference Citation Analysis]
222 Mousa N, Abdel-Razik A, Farag R, Shabana W, Elgamal A, El-Wakeel N, Elzehery R, Elkashef W, Eldars W. Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response? Eur J Gastroenterol Hepatol 2017;29:1004-9. [PMID: 28749790 DOI: 10.1097/MEG.0000000000000929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
223 Oh IS, Won JW, Kim HJ, Lee HW. Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection. Korean J Intern Med 2017;32:1010-7. [PMID: 28797159 DOI: 10.3904/kjim.2016.405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
224 Chen X, Li W, Li Y, Xu L, Zhou S, Zhu J, Xu Z, Liu F, Lin D, Hu F, Liu Y, Jiang W, Cui L, Su C. Elevated serum antibody against Schistosoma japonicum HSP60 as a promising biomarker for liver pathology in schistosomiasis. Sci Rep 2017;7:7765. [PMID: 28798366 DOI: 10.1038/s41598-017-08283-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
225 Kozuka R, Hai H, Teranishi Y, Motoyama H, Kawamura E, Hagihara A, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N, Tamori A. Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy. J Gastroenterol Hepatol 2017;32:1495-502. [PMID: 28109022 DOI: 10.1111/jgh.13743] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
226 Kim S, Han KH, Ahn SH. Hepatitis C Virus and Antiviral Drug Resistance. Gut Liver 2016;10:890-5. [PMID: 27784846 DOI: 10.5009/gnl15573] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
227 Ahmed KT, Almashhrawi AA, Ibdah JA, Tahan V. Is the 25-year hepatitis C marathon coming to an end to declare victory? World J Hepatol 2017; 9(21): 921-929 [PMID: 28824743 DOI: 10.4254/wjh.v9.i21.921] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
228 Tauste R, Moreno-navarro F, Gallego R, Rubio-gámez MC. Analysis of the sensitivity of the impact resonance frequency test as a tool to determine the elastic properties of bituminous materials. Mater construcc 2017;7:131. [DOI: 10.3989/mc.2017.04916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
229 Mecci AJ, Cheung M. Treatment of Hepatitis C. eLS 2017. [DOI: 10.1002/9780470015902.a0024786] [Reference Citation Analysis]
230 Muñoz de Rueda P, Fuentes Rodríguez JM, Quiles Pérez R, Gila Medina A, Martín Álvarez AB, Casado Ruíz J, Ruíz Extremera A, Salmerón J. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment. World J Gastroenterol 2017; 23(25): 4538-4547 [PMID: 28740342 DOI: 10.3748/wjg.v23.i25.4538] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
231 Sherigar JM, Gayam V, Khan A, Mukhtar O, Arefiev Y, Khalid M, Siddiqui I, Rangaraju AM, Budhathoki N, Mansour M, Guss D, Mohanty SR. Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2017;29:767-76. [PMID: 28346233 DOI: 10.1097/MEG.0000000000000871] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
232 Maan R, Al Marzooqi SH, Klair JS, Karkada J, Cerocchi O, Kowgier M, Harrell SM, Rhodes KD, Janssen HLA, Feld JJ, Duarte-Rojo A. The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens. Aliment Pharmacol Ther 2017;46:46-55. [PMID: 28470850 DOI: 10.1111/apt.14117] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
233 Zhang R, Shao C, Huo N, Li M, Xu X. Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China. Gut Liver 2016;10:446-55. [PMID: 26470765 DOI: 10.5009/gnl15162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
234 Pillai AA, Maheshwari R, Vora R, Norvell JP, Ford R, Parekh S, Cheng N, Patel A, Young N, Spivey JR, Mgbemena O, Wedd JP. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Aliment Pharmacol Ther 2017;45:1427-32. [PMID: 28382751 DOI: 10.1111/apt.14059] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
235 Tamai H, Shingaki N, Mori Y, Moribata K, Kawashima A, Maeda Y, Niwa T, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M. Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus. Gut Liver 2016;10:617-23. [PMID: 26601828 DOI: 10.5009/gnl15193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
236 Grassi A, Ballardini G. Hepatitis C in injection drug users: It is time to treat. World J Gastroenterol 2017; 23(20): 3569-3571 [PMID: 28611509 DOI: 10.3748/wjg.v23.i20.3569] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
237 Miotto N, Mendes LC, Zanaga LP, Goncales ES, Lazarini MS, Pedro MN, Goncales FL Jr, Stucchi RS, Vigani AG. Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors. Braz J Med Biol Res 2016;49:S0100-879X2016000700702. [PMID: 27356107 DOI: 10.1590/1414-431X20165300] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
238 Cenderello G, Fanizza C, Marenco S, Nicolini LA, Artioli S, Baldissarro I, Dentone C, De Leo P, Di Biagio A. Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis. Clinicoecon Outcomes Res 2017;9:281-93. [PMID: 28579812 DOI: 10.2147/CEOR.S129859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
239 Vasudevan S, Kavimandan A, Kalra N, Nayak B, Thakur B, Das P, Gupta SD, Panda SK, Acharya SK; Shalimar. Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India. Indian J Med Res 2016;143:331-40. [PMID: 27241647 DOI: 10.4103/0971-5916.182624] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
240 Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. Expert Opin Drug Saf. 2017;16:651-672. [PMID: 28471314 DOI: 10.1080/14740338.2017.1325869] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
241 Gonzalez SA, Fierer DS, Talal AH. Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. Addict Disord Their Treat. 2017;16:S1-S23. [PMID: 28701904 DOI: 10.1097/adt.0000000000000104] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
242 Pashaei Zanjani A, Esmaeilpour N, Rasoolinejad M, Moradnejad P, Hedayat Yaghoobi M. Treatment of Hepatitis C Virus Infection in the HIV- Infected Patients by Pegylated Interferon and Ribavirin in Tehran, Iran. Avicenna J Clin Microbiol Infect 2017;4:43623-43623. [DOI: 10.5812/ajcmi.43623] [Reference Citation Analysis]
243 Zaily DG, Marlen CF, Santiago DC, Gillian MD, Carmen VS, Zurina CE, Enrique R AS, Liz AL, Lisset GF, Sacha LDV, Elena FB. Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C. Curr Ther Res Clin Exp 2017;85:20-8. [PMID: 29158855 DOI: 10.1016/j.curtheres.2017.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
244 Hajiabdolbaghi M, Shahsiah R, Motavaf M, Zavari T. The Impact of Interleukin-28B rs12979860 Polymorphism on Peginterferon-alpha and Ribavirin Combination Therapy in Iranian Patients with Hepatitis C Virus Genotype 1 Infection. J Human Gen Genom 2017;1. [DOI: 10.5812/jhgg.65255] [Reference Citation Analysis]
245 Cosson F, Faroux A, Baltaze JP, Farjon J, Guillot R, Uziel J, Lubin-Germain N. Synthesis of ribavirin 2'-Me-C-nucleoside analogues. Beilstein J Org Chem 2017;13:755-61. [PMID: 28503210 DOI: 10.3762/bjoc.13.74] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
246 Saeedi R, Mojebi-Mogharar A, Sandhu SK, Dubland JA, Ford JA, Yousefi M, Pudek M, Holmes DT, Erb SR, Peter Kwan W, Kendler DL, Yoshida EM. Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism. Ann Hepatol 2017;16:207-14. [PMID: 28233741 DOI: 10.5604/16652681.1231577] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
247 Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Tangkijvanich P, Treeprasertsuk S, Thaimai P, Wasitthankasem R, Poovorawan Y, Komolmit P. Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients. BMC Gastroenterol 2017;17:54. [PMID: 28415985 DOI: 10.1186/s12876-017-0613-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
248 Bauer L, Lyoo H, van der Schaar HM, Strating JR, van Kuppeveld FJ. Direct-acting antivirals and host-targeting strategies to combat enterovirus infections. Curr Opin Virol 2017;24:1-8. [PMID: 28411509 DOI: 10.1016/j.coviro.2017.03.009] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 8.0] [Reference Citation Analysis]
249 Arfin Qasmi S. Molecular Characterization of HCV and Introduction of Biorisk Management CWA 15793-2008 at DHQ Divisional Headquarters Teaching Hospital & MBBS Medical College, Chattar Parri, Mirpur District AJK. JMEN 2017;4. [DOI: 10.15406/jmen.2017.04.00121] [Reference Citation Analysis]
250 Huang CF, Huang CI, Yeh ML, Hou C, Hou NJ, Hsieh MY, Huang JF, Chen SC, Lin ZY, Dai CY, Chuang WL, Yu ML. Disease severity and erythropoiesis in chronic hepatitis C. J Gastroenterol Hepatol 2017;32:864-9. [PMID: 27637864 DOI: 10.1111/jgh.13600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
251 Sidhu SS, Malhi NS, Goyal O, Singh R, Dutta U, Grover R, Sidhu JS, Nanda V, Saluja H, Bansal A, Singh G, Sehgal A, Kishore H, Sidhu S. Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study. Hepatol Int 2017;11:277-85. [PMID: 28361300 DOI: 10.1007/s12072-017-9794-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
252 Alghamdi AS, Alghamdi M, Sanai FM, Alghamdi H, Aba-Alkhail F, Alswat K, Babatin M, Alqutub A, Altraif I, Alfaleh F. SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol 2016;22 Suppl:S25-57. [PMID: 27538727 DOI: 10.4103/1319-3767.188067] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
253 Mangia A, Foster GR, Berg CP, Curescu M, Ledinghen V, Habersetzer F, Manolakopoulos S, Negri E, Papatheodoridis G, Ahlers S, Castillo M, Bakalos G, Mauss S; PegBase Group Investigators. Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. Ann Gastroenterol 2017;30:327-43. [PMID: 28469364 DOI: 10.20524/aog.2017.0136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
254 Wu SY, Faire B, Gane E. Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction. Case Rep Med 2017;2017:4895736. [PMID: 28408931 DOI: 10.1155/2017/4895736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
255 Yang Y, Dang SS. Safety of direct antiviral agents for treatment of hepatitis C virus infection. Shijie Huaren Xiaohua Zazhi 2017; 25(8): 659-669 [DOI: 10.11569/wcjd.v25.i8.659] [Reference Citation Analysis]
256 Ke H, Yoo D. The viral innate immune antagonism and an alternative vaccine design for PRRS virus. Vet Microbiol 2017;209:75-89. [PMID: 28341332 DOI: 10.1016/j.vetmic.2017.03.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
257 Tong Y, Chi X, Yang W, Zhong J. Functional Analysis of Hepatitis C Virus (HCV) Envelope Protein E1 Using a trans-Complementation System Reveals a Dual Role of a Putative Fusion Peptide of E1 in both HCV Entry and Morphogenesis. J Virol 2017;91:e02468-16. [PMID: 28100619 DOI: 10.1128/JVI.02468-16] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
258 Ahmed K, Almashhrawi A, Ibdah JA, Tahan V. Is the 25-year hepatitis C marathon coming to an end to declare victory?. [DOI: 10.1101/115378] [Reference Citation Analysis]
259 Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, Rapaccini GL, Pompili M, Gasbarrini A. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol 2017; 9(7): 352-367 [PMID: 28321272 DOI: 10.4254/wjh.v9.i7.352] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
260 Toyota J, Karino Y, Suzuki F, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, Hu W, McPhee F, Linaberry M, Yin PD, Swenson ES, Kumada H. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J Gastroenterol 2017;52:385-95. [PMID: 27502287 DOI: 10.1007/s00535-016-1245-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
261 Liu Z, Wei X, Chen T, Huang C, Liu H, Wang Y. Characterization of fibrosis changes in chronic hepatitis C patients after virological cure: A systematic review with meta-analysis. J Gastroenterol Hepatol 2017;32:548-57. [PMID: 27503423 DOI: 10.1111/jgh.13500] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
262 Morio K, Imamura M, Kawakami Y, Morio R, Kobayashi T, Yokoyama S, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Makokha GN, Hayes CN, Aikata H, Miki D, Ochi H, Honda Y, Mori N, Takaki S, Tsuji K, Chayama K. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients. J Gastroenterol Hepatol 2017;32:645-50. [PMID: 27513614 DOI: 10.1111/jgh.13511] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
263 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. J Gastroenterol Hepatol 2017;32:687-94. [PMID: 27577675 DOI: 10.1111/jgh.13589] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
264 Abe K, Wada A, Oshima S, Kono S, Takahashi A, Kanno Y, Imaizumi H, Hayashi M, Okai K, Niwa SI, Yabe H, Ohira H. Reduced frontal activation during verbal fluency task in chronic hepatitis C patients with interferon-based therapy as measured by near-infrared spectroscopy. Hepatol Res 2017;47:E55-63. [PMID: 27062374 DOI: 10.1111/hepr.12721] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
265 Mir F, Kahveci AS, Ibdah JA, Tahan V. Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure. Drug Des Devel Ther. 2017;11:497-502. [PMID: 28260862 DOI: 10.2147/dddt.s130945] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
266 El-Fakharany EM, El-Baky NA, Linjawi MH, Aljaddawi AA, Saleem TH, Nassar AY, Osman A, Redwan EM. Influence of camel milk on the hepatitis C virus burden of infected patients. Exp Ther Med 2017;13:1313-20. [PMID: 28413471 DOI: 10.3892/etm.2017.4159] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
267 Cousien A, Leclerc P, Morissette C, Bruneau J, Roy É, Tran VC, Yazdanpanah Y, Cox J. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study. BMC Infect Dis 2017;17:162. [PMID: 28222681 DOI: 10.1186/s12879-017-2256-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
268 Lee SH, Jin YJ, Shin JY, Lee JW. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs. Medicine (Baltimore). 2017;96:e5321. [PMID: 28072684 DOI: 10.1097/md.0000000000005321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
269 Carmali S, Murata H, Cummings C, Matyjaszewski K, Russell AJ. Polymer-Based Protein Engineering: Synthesis and Characterization of Armored, High Graft Density Polymer-Protein Conjugates. Methods Enzymol 2017;590:347-80. [PMID: 28411645 DOI: 10.1016/bs.mie.2016.12.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
270 Duncan I, Curtis R, Reyes JC, Abadie R, Khan B, Dombrowski K. Hepatitis C serosorting among people who inject drugs in rural Puerto Rico. Prev Med Rep 2017;6:38-43. [PMID: 28271018 DOI: 10.1016/j.pmedr.2017.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
271 Wu P, Wang W, Duan W, Li Y, Hou X. Comprehensive Analysis of the CDPK-SnRK Superfamily Genes in Chinese Cabbage and Its Evolutionary Implications in Plants. Front Plant Sci 2017;8:162. [PMID: 28239387 DOI: 10.3389/fpls.2017.00162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
272 Ok KS, Jeong SH, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Bae SH, Lee HC. The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study. Medicine (Baltimore) 2016;95:e4594. [PMID: 27583874 DOI: 10.1097/MD.0000000000004594] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
273 Wong WW, Lee KM, Singh S, Wells G, Feld JJ, Krahn M. Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. CMAJ Open 2017;5:E97-E108. [PMID: 28401125 DOI: 10.9778/cmajo.20160161] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
274 Danilau D, Litvinchuk D, Solovey N, Krasko O, Karpov I. Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype. Clin Exp Hepatol 2017;3:16-22. [PMID: 28856285 DOI: 10.5114/ceh.2017.65279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
275 Pincus SH, Song K, Maresh GA, Frank A, Worthylake D, Chung HK, Polacino P, Hamer DH, Coyne CP, Rosenblum MG, Marks JW, Chen G, Weiss D, Ghetie V, Vitetta ES, Robinson JE, Hu SL. Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160. J Virol 2017;91:e01360-16. [PMID: 27795412 DOI: 10.1128/JVI.01360-16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
276 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017;66:153-94. [PMID: 27667367 DOI: 10.1016/j.jhep.2016.09.001] [Cited by in Crossref: 768] [Cited by in F6Publishing: 819] [Article Influence: 128.0] [Reference Citation Analysis]
277 Reeves JD, Parkin NT. Viral Phenotypic Resistance Assays. Antimicrobial Drug Resistance 2017. [DOI: 10.1007/978-3-319-47266-9_35] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
278 Llaneras J, Riveiro-Barciela M, Buti M, Esteban R. Hepatitis C virus genotype 4: Genotype 1's little brother. J Viral Hepat 2017;24:4-12. [PMID: 27905173 DOI: 10.1111/jvh.12620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
279 Vermehren J, Welsch C, Sarrazin C. Protease Inhibitor Resistance. Handbook of Antimicrobial Resistance 2017. [DOI: 10.1007/978-1-4939-0694-9_6] [Reference Citation Analysis]
280 Mirian M, Khanahmad H, Darzi L, Salehi M, Sadeghi-Aliabadi H. Oligonucleotide aptamers: potential novel molecules against viral hepatitis. Res Pharm Sci 2017;12:88-98. [PMID: 28515761 DOI: 10.4103/1735-5362.202447] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
281 Morad WS, El Said HH, El Shimi E, Obada M, El Fert A. Natural history of chronic hepatitis C development and progression as a consequence of iron and HFE or TfR1 mutations. Egyptian Liver Journal 2017;7:33-40. [DOI: 10.1097/01.elx.0000524701.59978] [Reference Citation Analysis]
282 Malespin M, Benyashvili T, Uprichard SL, Perelson AS, Dahari H, Cotler SJ. Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies. Therap Adv Gastroenterol 2017;10:68-73. [PMID: 28286560 DOI: 10.1177/1756283X16672392] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
283 Nordstrom EM, Keniston A, Baouchi F, Martinez-Camacho A. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety. Eur J Gastroenterol Hepatol 2017;29:10-6. [PMID: 27755117 DOI: 10.1097/MEG.0000000000000755] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
284 Venkatraman S. Discovery of Boceprevir and Narlaprevir: Ketoamide-Derived HCV NS3 Serine Protease Inhibitors for the Treatment of Chronic Hepatitis C. Comprehensive Medicinal Chemistry III 2017. [DOI: 10.1016/b978-0-12-409547-2.12452-7] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
285 Baloch K, Chen L, Memon AA, Dexter L, Irving W, Ilyas M, Thomson BJ. Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin. Antivir Chem Chemother 2017;25:2-10. [PMID: 28417642 DOI: 10.1177/2040206616686894] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
286 Hajarizadeh B, Grebely J, McManus H, Estes C, Razavi H, Gray RT, Alavi M, Amin J, McGregor S, Sievert W, Thompson A, Dore GJ. Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. J Gastroenterol Hepatol 2017;32:229-36. [PMID: 27197716 DOI: 10.1111/jgh.13453] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
287 Vaddi K. The Role of the JAK/STAT Signalling Pathway in Immunoregulation of Gastrointestinal Cancers. Immunotherapy for Gastrointestinal Cancer 2017. [DOI: 10.1007/978-3-319-43063-8_7] [Reference Citation Analysis]
288 Ding Y, Lou J, Chen H, Li X, Wu M, Li C, Liu J, Liu C, Li Q, Zhang H, Niu J. Tolerability, pharmacokinetics and antiviral activity of rHSA/IFNα2a for the treatment of chronic hepatitis B infection. Br J Clin Pharmacol 2017;83:1056-71. [PMID: 27862178 DOI: 10.1111/bcp.13184] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
289 Murira A, Lamarre A. Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection. Front Immunol 2016;7:609. [PMID: 28066419 DOI: 10.3389/fimmu.2016.00609] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 10.7] [Reference Citation Analysis]
290 Bokharaei-salim F, Salehi-vaziri M, Sadeghi F, Khanaliha K, Esghaei M, Monavari SH, Alavian SM, Fakhim S, Keyvani H. Genetic Variation in Interleukin-28B and Response to Peg-IFNα-2a/RBV Combination Therapy in Patients with Hepatitis C Virus Infection. Jundishapur J Microbiol 2016;10. [DOI: 10.5812/jjm.39178] [Reference Citation Analysis]
291 Scott JA, Chew KW. Treatment optimization for HIV/HCV co-infected patients. Ther Adv Infect Dis 2017;4:18-36. [PMID: 28357062 DOI: 10.1177/2049936116681279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
292 Wang X, Gao F, Yuan G, Shi K, Huang Y, Chen Y, Qiu R, Sun L, Liu J, Hu C, Zhou Y. Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy. J Viral Hepat 2016;23:971-6. [PMID: 27453300 DOI: 10.1111/jvh.12574] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
293 Wang LJ, Chen SW, Chen CK, Yen CL, Chang JJ, Lee TS, Liu CJ, Chen LW, Chien RN. Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C. BMC Psychiatry 2016;16:424. [PMID: 27884134 DOI: 10.1186/s12888-016-1135-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
294 Goyal G, Panag K, Garg R. Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy. Int J Appl Basic Med Res 2016;6:245-8. [PMID: 27857890 DOI: 10.4103/2229-516X.192587] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
295 Hesamizadeh K, Alavian SM, Najafi Tireh Shabankareh A, Sharafi H. Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review. Hepat Mon 2016;16:e42938. [PMID: 28123445 DOI: 10.5812/hepatmon.42938] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
296 Loftfield E, O'Brien TR, Pfeiffer RM, Howell CD, Horst R, Prokunina-Olsson L, Weinstein SJ, Albanes D, Morgan TR, Freedman ND. Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials. PLoS One 2016;11:e0166036. [PMID: 27832143 DOI: 10.1371/journal.pone.0166036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
297 Lewis H, Kunkel J, Axten D, Dalton J, Gardner H, Tippett A, Wynne S, Wilkinson M, Foster GR. Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment. Eur J Gastroenterol Hepatol 2016;28:1258-63. [PMID: 27487966 DOI: 10.1097/MEG.0000000000000711] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
298 Mancebo M, Real LM, Mira JA, Recio E, Pérez E, Monje-Agudo P, Merchante N, Macías J, Neukam K, Pineda JA. Changes in the response to treatment against chronic hepatitis C between 1999 and 2015: data from a prospective cohort. Eur J Gastroenterol Hepatol 2016;28:1253-7. [PMID: 27415157 DOI: 10.1097/MEG.0000000000000705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
299 Vidal LL, Soares MA, Santos AF. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects. J Viral Hepat 2016;23:840-9. [PMID: 26775769 DOI: 10.1111/jvh.12503] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
300 Fülöp B, Mihm U, Rohde P, Buggisch P, Schlosser B, Biermer M, Brodzinski A, Fischer J, Böhm S, van Bömmel F, Sarrazin C, Berg T. Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type. J Viral Hepat 2016;23:866-72. [PMID: 27346846 DOI: 10.1111/jvh.12562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
301 Misaka K, Kishimoto T, Kawahigashi Y, Sata M, Nagao Y. Use of Direct-Acting Antivirals for the Treatment of Hepatitis C Virus-Associated Oral Lichen Planus: A Case Report. Case Rep Gastroenterol 2016;10:617-22. [PMID: 27920651 DOI: 10.1159/000450679] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
302 Al-Judaibi B. The new era of hepatitis C virus therapy. Saudi J Gastroenterol 2015;21:345-54. [PMID: 26655128 DOI: 10.4103/1319-3767.170947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
303 Hirashima N, Iwase H, Shimada M, Ryuge N, Imamura J, Ikeda H, Tanaka Y, Matsumoto N, Okuse C, Itoh F, Yokomaku Y, Watanabe T. Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir. Clin J Gastroenterol 2017;10:41-6. [PMID: 27766544 DOI: 10.1007/s12328-016-0693-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
304 Keshvari M, Alavian SM, Behnava B, Pouryasin A, Craig JC, Sharafi H. Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C. J Clin Lab Anal 2017;31. [PMID: 27735085 DOI: 10.1002/jcla.22063] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
305 Sultana C, Oprişan G, Teleman MD, Dinu S, HepGen 88/2012 Project Team, Oprea C, Voiculescu M, Ruta S. Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C. World J Gastroenterol 2016; 22(37): 8406-8413 [PMID: 27729747 DOI: 10.3748/wjg.v22.i37.8406] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
306 Asselah T, Esmat G, Sanai FM, Goulis I, Messinger D, Bakalos G, Waked I. Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies. Adv Ther 2016;33:1797-813. [PMID: 27517563 DOI: 10.1007/s12325-016-0396-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
307 Hathorn E, Elsharkawy AM. Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterol 2016;3:e000112. [PMID: 27752338 DOI: 10.1136/bmjgast-2016-000112] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
308 Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol 2016; 22(35): 8050-8059 [PMID: 27672299 DOI: 10.3748/wjg.v22.i35.8050] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
309 Gill G, Bajwa H, Strouhal P, Buch HN. Interaction of interferon alpha therapy with thyroid function tests in the management of hepatitis C: a case report. J Med Case Rep 2016;10:253. [PMID: 27632981 DOI: 10.1186/s13256-016-1028-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
310 Sourimant J, Plemper RK. Organization, Function, and Therapeutic Targeting of the Morbillivirus RNA-Dependent RNA Polymerase Complex. Viruses 2016;8:E251. [PMID: 27626440 DOI: 10.3390/v8090251] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
311 Chen W, Liao B, Hu F, Nie J, Lan Y, Li H, Lu R, Gao Y, Song Y, Zhao Q, Zheng Y, Tang X, Cai W. Changing Epidemiology of Hepatitis C Virus Genotype among Patients with Human Immunodeficiency Virus/Hepatitis C Virus Co-Infection in China. PLoS One 2016;11:e0161844. [PMID: 27603929 DOI: 10.1371/journal.pone.0161844] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
312 Jahn M, Herzer K, Witzke O. Hepatitis C und Nierenerkrankungen. Nephrologe 2016;11:361-374. [DOI: 10.1007/s11560-016-0091-0] [Reference Citation Analysis]
313 Marascio N, Pavia G, Strazzulla A, Dierckx T, Cuypers L, Vrancken B, Barreca GS, Mirante T, Malanga D, Oliveira DM, Vandamme AM, Torti C, Liberto MC, Focà A; The SINERGIE-UMG Study Group. Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients. Int J Mol Sci 2016;17:E1416. [PMID: 27618896 DOI: 10.3390/ijms17091416] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
314 Yushchuk ND, Znoyko OO, Dudina KR, Kozina AN, Kalininа OV. [The efficiency of antiviral therapy in patients with chronic -hepatitis C infected with hepatitis C virus recombinants]. Ter Arkh 2016;88:101-5. [PMID: 27489903 DOI: 10.17116/terarkh2016886101-105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
315 Seifert LL, Heinzow H, Kabar I, Christensen S, Hüsing A, Schmidt HH. Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report. Am J Case Rep 2016;17:605-10. [PMID: 27554644 DOI: 10.12659/ajcr.895839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
316 Selvapatt N, Brown A. A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies. F1000Res 2016;5:2061. [PMID: 27746906 DOI: 10.12688/f1000research.9114.1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
317 Bastos JCS, Padilla MA, Caserta LC, Miotto N, Vigani AG, Arns CW. Hepatitis C virus: Promising discoveries and new treatments. World J Gastroenterol 2016; 22(28): 6393-6401 [PMID: 27605875 DOI: 10.3748/wjg.v22.i28.6393] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
318 Lee CM, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH, Yen YH. Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients. BMC Gastroenterol. 2016;16:73. [PMID: 27457659 DOI: 10.1186/s12876-016-0492-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
319 Janicko M, Drazilova S, Pella D, Fedacko J, Jarcuska P. Pleiotropic effects of statins in the diseases of the liver. World J Gastroenterol 2016; 22(27): 6201-6213 [PMID: 27468210 DOI: 10.3748/wjg.v22.i27.6201] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
320 Nagao Y, Kimura K, Kawahigashi Y, Sata M. Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals. Clin Transl Gastroenterol. 2016;7:e179. [PMID: 27388424 DOI: 10.1038/ctg.2016.37] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
321 Miyaki E, Imamura M, Hiraga N, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Aikata H, Hayes CN, Chayama K. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res 2016;46:758-64. [PMID: 26574180 DOI: 10.1111/hepr.12621] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 7.1] [Reference Citation Analysis]
322 Zayed N, Gamal Eldeen H, Elmakhzangy H, Seif M, El-Akel W, Awad T, Esmat G, Mabrouk M. Therapeutic outcome of 6198 interferon-naïve Egyptian patients with chronic hepatitis C: a real-life experience and lessons to be learned in DAAs' era. J Viral Hepat 2016;23:506-11. [PMID: 26936687 DOI: 10.1111/jvh.12514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
323 Fox DS, McCombs JS. Optimizing HCV treatment - Moving beyond the cost conundrum. J Hepatol 2016;65:222-5. [PMID: 26876940 DOI: 10.1016/j.jhep.2016.02.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
324 Chuang WL, Chien RN, Peng CY, Chang TT, Lo GH, Sheen IS, Wang HY, Chen JJ, Yang JC, Knox SJ, Gao B, Garrison KL, Mo H, Pang PS, Hsu YC, Hu TH, Chu CJ, Kao JH. Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. J Gastroenterol Hepatol 2016;31:1323-9. [PMID: 26841930 DOI: 10.1111/jgh.13305] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
325 Suzuki M, Tajiri H, Tanaka Y, Takano T, Miyoshi Y, Murakami J, Shimizu T, Brooks S. Peginterferon Therapy in Children With Chronic Hepatitis C: A Nationwide, Multicenter Study in Japan, 2004-2013. J Pediatr Gastroenterol Nutr 2016;63:88-93. [PMID: 26825765 DOI: 10.1097/MPG.0000000000001120] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
326 Basnayake SK, Easterbrook PJ. Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. J Viral Hepat 2016;23:545-59. [PMID: 27028545 DOI: 10.1111/jvh.12519] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
327 Suraweera D, Weeratunga AN, Saab S. Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C. Drug Des Devel Ther 2016;10:2119-27. [PMID: 27418810 DOI: 10.2147/DDDT.S90537] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
328 FakhriRavari A, Malakouti M, Brady R. Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. J Clin Transl Hepatol 2016;4:97-112. [PMID: 27350940 DOI: 10.14218/JCTH.2016.00007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
329 Palanisamy N, Lennerstrand J. Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach. Interdiscip Sci 2018;10:143-56. [PMID: 27311576 DOI: 10.1007/s12539-016-0177-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
330 Vernaz N, Girardin F, Goossens N, Brügger U, Riguzzi M, Perrier A, Negro F. Drug Pricing Evolution in Hepatitis C. PLoS One 2016;11:e0157098. [PMID: 27310294 DOI: 10.1371/journal.pone.0157098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
331 Cozen ML, Ryan JC, Shen H, Cheung R, Kaplan DE, Pocha C, Brau N, Aytaman A, Schmidt WN, Pedrosa M, Anand BS, Chang KM, Morgan T, Monto A. Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders. Dig Dis Sci 2016;61:1744-56. [PMID: 27059981 DOI: 10.1007/s10620-016-4122-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
332 Wang J, Xin S, Jin X, Cheng Y, Yan T, Qing S, Ding N, Zhao P. Meta-Analysis of Combination Therapy of Chinese Herbs Plus Interferon and Ribavirin in Patients with Chronic Hepatitis C. Med Sci Monit 2016;22:1817-26. [PMID: 27237628 DOI: 10.12659/msm.895647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
333 Helal GK, Gad MA, Abd-Ellah MF, Eid MS. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. J Med Virol 2016;88:2170-8. [PMID: 27183377 DOI: 10.1002/jmv.24575] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
334 Dresch KF, Mattos AA, Tovo CV, Onofrio FQ, Casagrande L, Feltrin AA, Barros IC, Almeida PR. IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS. Rev Inst Med Trop Sao Paulo 2016;58:37. [PMID: 27253739 DOI: 10.1590/S1678-9946201658037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
335 Ma X, Yang Y, Tu H, Gao J, Tan YT, Zheng JL, Bray F, Xiang YB. Risk prediction models for hepatocellular carcinoma in different populations. Chin J Cancer Res. 2016;28:150-160. [PMID: 27199512 DOI: 10.21147/j.issn.1000-9604.2016.02.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
336 Lim YS, Ahn SH, Lee KS, Paik SW, Lee YJ, Jeong SH, Kim JH, Yoon SK, Yim HJ, Tak WY, Han SY, Yang JC, Mo H, Garrison KL, Gao B, Knox SJ, Pang PS, Kim YJ, Byun KS, Kim YS, Heo J, Han KH. A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Hepatol Int 2016;10:947-55. [PMID: 27198664 DOI: 10.1007/s12072-016-9726-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
337 Ning G, Lin CS. History and future of antiviral therapy of chronic hepatitis C. Shijie Huaren Xiaohua Zazhi 2016; 24(14): 2117-2130 [DOI: 10.11569/wcjd.v24.i14.2117] [Reference Citation Analysis]
338 Hussaini T. Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review. Hepat Med. 2016;8:61-68. [PMID: 27274322 DOI: 10.2147/hmer.s72429] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
339 Kwo PY, Badshah MB. Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. Curr Gastroenterol Rep 2015;17:462. [PMID: 26342813 DOI: 10.1007/s11894-015-0462-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
340 Ahn SH, Lim YS, Lee KS, Paik SW, Lee YJ, Jeong SH, Kim JH, Yoon SK, Yim HJ, Tak WY, Han SY, Yang JC, Mo H, Mathias A, Han L, Knox SJ, Brainard DM, Kim YJ, Byun KS, Kim YS, Heo J, Han KH. A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. J Viral Hepat 2016;23:358-65. [PMID: 26864153 DOI: 10.1111/jvh.12499] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
341 Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DH, Kao JH, Yokosuka O, Lau GK, Sarin SK. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10:702-726. [PMID: 27130427 DOI: 10.1007/s12072-016-9717-6] [Cited by in Crossref: 157] [Cited by in F6Publishing: 153] [Article Influence: 22.4] [Reference Citation Analysis]
342 Shuldiner SR, Gong L, Muir AJ, Altman RB, Klein TE. PharmGKB summary: peginterferon-α pathway. Pharmacogenet Genomics 2015;25:465-74. [PMID: 26111151 DOI: 10.1097/FPC.0000000000000158] [Reference Citation Analysis]
343 Watanabe T, Joko K, Seike H, Michitaka K, Horiike N, Kisaka Y, Tanaka Y, Nakanishi S, Nakanishi K, Nonaka T, Yamauchi K, Onji M, Ohno Y, Tokumoto Y, Hirooka M, Abe M, Hiasa Y. Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients. Springerplus 2016;5:518. [PMID: 27186482 DOI: 10.1186/s40064-016-2190-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
344 Childs K, Taylor C, Dieterich D, Agarwal K. Directly acting antivirals for hepatitis C virus arrive in HIV/hepatitis C virus co-infected patients: from 'mind the gap' to 'where's the gap?'. AIDS 2016;30:975-89. [PMID: 26836785 DOI: 10.1097/QAD.0000000000001042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
345 Witteveldt J, Martin-Gans M, Simmonds P. Enhancement of the Replication of Hepatitis C Virus Replicons of Genotypes 1 to 4 by Manipulation of CpG and UpA Dinucleotide Frequencies and Use of Cell Lines Expressing SECL14L2 for Antiviral Resistance Testing. Antimicrob Agents Chemother 2016;60:2981-92. [PMID: 26953209 DOI: 10.1128/AAC.02932-15] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
346 Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepat Mon 2016;16:e37089. [PMID: 27275164 DOI: 10.5812/hepatmon.37089] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 7.9] [Reference Citation Analysis]
347 Lozano-Sepulveda SA, Bautista-Osorio E, Merino-Mascorro JA, Varela-Rey M, Muñoz-Espinosa LE, Cordero-Perez P, Martinez-Chantar ML, Rivas-Estilla AM. S-adenosyl-L-methionine modifies antioxidant-enzymes, glutathione-biosynthesis and methionine adenosyltransferases-1/2 in hepatitis C virus-expressing cells. World J Gastroenterol 2016; 22(14): 3746-3757 [PMID: 27076759 DOI: 10.3748/wjg.v22.i14.3746] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
348 Doyle T. The evolving role of interferons in viral eradication strategies. Journal of Virus Eradication 2016;2:121-3. [DOI: 10.1016/s2055-6640(20)30467-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
349 Scott N, Iser DM, Thompson AJ, Doyle JS, Hellard ME. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. J Gastroenterol Hepatol 2016;31:872-82. [PMID: 26514998 DOI: 10.1111/jgh.13223] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
350 Livingston SE, Townshend-Bulson LJ, Bruden DJ, Homan CE, Gove JE, Plotnik JN, Simons BC, Spradling PR, McMahon BJ. Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C. Int J Circumpolar Health 2016;75:30696. [PMID: 27029671 DOI: 10.3402/ijch.v75.30696] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
351 Taniguchi M, Tasaka-Fujita M, Nakagawa M, Watanabe T, Kawai-Kitahata F, Otani S, Goto F, Nagata H, Kaneko S, Nitta S, Murakawa M, Nishimura-Sakurai Y, Azuma S, Itsui Y, Mori K, Yagi S, Kakinuma S, Asahina Y, Watanabe M. Evaluation of Interferon Resistance in Newly Established Genotype 1b Hepatitis C Virus Cell Culture System. J Clin Transl Hepatol 2016;4:5-11. [PMID: 27047766 DOI: 10.14218/JCTH.2015.00047] [Reference Citation Analysis]
352 Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T; GUARD-C Study Group. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. PLoS One 2016;11:e0151703. [PMID: 27018988 DOI: 10.1371/journal.pone.0151703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
353 Wei K, Li Y, Chen H, Zhang Q. Genomic Surveillance Elucidates HCV 1a Phylodynamics and Molecular Evolution. Evol Biol 2016;43:380-91. [DOI: 10.1007/s11692-016-9379-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
354 Qian L, Wang N, Tian H, Jin H, Zhao H, Niu C, He H, Ge T, Han W, Hu J, Li D, Han F, Xu J, Ding X, Chen J, Li W, Cui J. Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients. J Immunol Res. 2016;2016:6837241. [PMID: 27069936 DOI: 10.1155/2016/6837241] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
355 Scherer ML, Sammons C, Nelson B, Hammer SM, Verna E. Anti-Hepatitis Virus Agents. Clinical Virology 2016. [DOI: 10.1128/9781555819439.ch13] [Reference Citation Analysis]
356 Koh C, Li Q, Liang J. Hepatitis C Virus. Clinical Virology 2016. [DOI: 10.1128/9781555819439.ch54] [Reference Citation Analysis]
357 Ha S, Totten S, Pogany L, Wu J, Gale-Rowe M. Hepatitis C in Canada and the importance of risk-based screening. Can Commun Dis Rep 2016;42:57-62. [PMID: 29770005 DOI: 10.14745/ccdr.v42i03a02] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
358 Yan S, Chang C, Chen C, Yeh Y, Tsai C. Reticulocyte production index as a predictor of clinically significant anemia in chronic hepatitis C patients receiving pegylated interferon combination therapy. Advances in Digestive Medicine 2016;3:18-23. [DOI: 10.1016/j.aidm.2014.10.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
359 Liu C. Simple predictor for anemia in chronic hepatitis C patients receiving peginterferon plus ribavirin. Advances in Digestive Medicine 2016;3:1-2. [DOI: 10.1016/j.aidm.2016.01.001] [Reference Citation Analysis]
360 Johansson S, Talloen W, Tuefferd M, Darling J, Fanning G, Fried MW, Aerssens J. High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity. Liver Int 2016;36:344-52. [PMID: 26344576 DOI: 10.1111/liv.12932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
361 Banerjee D, Reddy KR. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther 2016;43:674-96. [PMID: 26787287 DOI: 10.1111/apt.13514] [Cited by in Crossref: 111] [Cited by in F6Publishing: 91] [Article Influence: 15.9] [Reference Citation Analysis]
362 Pouryasin M, Keshvari M, Sharafi H, Alavian SM, Behnava B, Alavian SE, Pouryasin A. The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C. Hepat Mon 2016;16:e35278. [PMID: 27148387 DOI: 10.5812/hepatmon.35278] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
363 Shafran SD. The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing. Can J Gastroenterol Hepatol 2015;29:46-8. [PMID: 25706574 DOI: 10.1155/2015/216395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
364 Azer SA, Azer S. Bibliometric analysis of the top-cited gastroenterology and hepatology articles. BMJ Open 2016;6:e009889. [PMID: 26857105 DOI: 10.1136/bmjopen-2015-009889] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
365 Marotta P, Bailey R, Elkashab M, Farley J, Feinman SV, Peltekian K, Poliquin M, Witt-Sullivan H, Rampakakis E, Drolet M, Cooper C. Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies. Eur J Clin Microbiol Infect Dis 2016;35:597-609. [PMID: 26851949 DOI: 10.1007/s10096-016-2576-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
366 Zeremski M, Dimova RB, Zavala R, Kritz S, Lin M, Smith BD, Zibbell JE, Talal AH. Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance. J Addict Med. 2014;8:249-257. [PMID: 24820257 DOI: 10.1097/adm.0000000000000041] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
367 Chen ZW, Li H, Ren H, Hu P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep. 2016;6:20310. [PMID: 26842909 DOI: 10.1038/srep20310] [Cited by in Crossref: 68] [Cited by in F6Publishing: 76] [Article Influence: 9.7] [Reference Citation Analysis]
368 Vitor S, Marinho RT, Gíria J, Velosa J. An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal. BMC Res Notes 2016;9:62. [PMID: 26843372 DOI: 10.1186/s13104-016-1879-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
369 Wu LS, Jimmerson LC, MacBrayne CE, Kiser JJ, D'Argenio DZ. Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus. CPT Pharmacometrics Syst Pharmacol 2016;5:65-73. [PMID: 26933517 DOI: 10.1002/psp4.12058] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
370 Grebely J, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Phung N, Weltman MD, Day CA, Treloar C, Bath N, Haber PS, Dore GJ; ETHOS Study Group. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction 2016;111:311-9. [PMID: 26451534 DOI: 10.1111/add.13197] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 8.6] [Reference Citation Analysis]
371 Lens S, Torres F, Puigvehi M, Mariño Z, Londoño MC, Martinez SM, García-Juárez I, García-Criado Á, Gilabert R, Bru C, Solà R, Sanchez-Tapias JM, Carrión JA, Forns X. Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C. Aliment Pharmacol Ther 2016;43:364-74. [PMID: 26582599 DOI: 10.1111/apt.13472] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
372 Jindal N, Soin D, Grover P, Bansal R, Malhotra R, Singh S, Singh C. Hepatitis C Virus (HCV) Infection among Seronegative Patients undergoing Haemodialysis in a Remotely Located Tertiary Care Hospital of Northern India: Value of HCV-RNA and Genotypes. J Clin Diagn Res 2015;9:DC10-2. [PMID: 26816888 DOI: 10.7860/JCDR/2015/15310.6952] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
373 Loustaud-Ratti V, Debette-Gratien M, Jacques J, Alain S, Marquet P, Sautereau D, Rousseau A, Carrier P. Ribavirin: Past, present and future. World J Hepatol 2016; 8(2): 123-130 [PMID: 26807208 DOI: 10.4254/wjh.v8.i2.123] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
374 Louten J, Beach M, Palermino K, Weeks M, Holenstein G. MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations. Biomark Insights. 2015;10:25-52. [PMID: 26819546 DOI: 10.4137/bmi.s29512] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
375 Fu R, Gutfraind A, Brandeau ML. Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections. Math Biosci 2016;273:102-13. [PMID: 26775738 DOI: 10.1016/j.mbs.2016.01.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
376 Chen R, Kobewka M, Addison W, Lachance G, Tyrrell DL. Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice. PLoS One 2016;11:e0147007. [PMID: 26765841 DOI: 10.1371/journal.pone.0147007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
377 Gogela NA, Lin MV, Wisocky JL, Chung RT. Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep 2015;12:68-78. [PMID: 25761432 DOI: 10.1007/s11904-014-0243-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
378 Interferon alfa. Meyler's Side Effects of Drugs 2016. [DOI: 10.1016/b978-0-444-53717-1.00900-8] [Reference Citation Analysis]
379 Said A. 21. Chronic Liver Disease. CHRONIC DISEASE EPIDEMIOLOGY, PREVENTION, AND CONTROL, 4th edition 2016. [DOI: 10.2105/9780875532783ch21] [Reference Citation Analysis]
380 Saeed N, Gurakar A. Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies. Euroasian J Hepatogastroenterol 2016;6:35-42. [PMID: 29201722 DOI: 10.5005/jp-journals-10018-1163] [Reference Citation Analysis]
381 Dore GJ, Conway B, Luo Y, Janczewska E, Knysz B, Liu Y, Streinu-Cercel A, Caruntu FA, Curescu M, Skoien R, Ghesquiere W, Mazur W, Soza A, Fuster F, Greenbloom S, Motoc A, Arama V, Shaw D, Tornai I, Sasadeusz J, Dalgard O, Sullivan D, Liu X, Kapoor M, Campbell A, Podsadecki T. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. J Hepatol 2016;64:19-28. [PMID: 26321288 DOI: 10.1016/j.jhep.2015.08.015] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 7.6] [Reference Citation Analysis]
382 Tremblay N, Park AY, Lamarre D. HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies. Hepatitis C Virus II 2016. [DOI: 10.1007/978-4-431-56101-9_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
383 Maekawa S, Enomoto N. Viral Variation and Response to Therapy. Hepatitis C Virus II 2016. [DOI: 10.1007/978-4-431-56101-9_9] [Reference Citation Analysis]
384 Calvaruso V, Craxì A. Why do I treat my patients with mild hepatitis C? Liver Int 2016;36 Suppl 1:7-12. [PMID: 26725891 DOI: 10.1111/liv.13011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
385 Gürbüz Y, Tülek NE, Tütüncü EE, Koruk ST, Aygen B, Demirtürk N, Kınıklı S, Kaya A, Yıldırmak T, Süer K, Korkmaz F, Ural O, Akhan S, Günal Ö, Tuna N, Köse Ş, Gönen İ, Örmen B, Türker N, Saltoğlu N, Batırel A, Tuncer G, Bulut C, Sırmatel F, Ulçay A, Karagöz E, Tosun D, Şener A, Aynıoğlu A, Altunok ES. Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study. Balkan Med J 2016;33:18-26. [PMID: 26966614 DOI: 10.5152/balkanmedj.2015.15859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
386 Masuzaki R, Kanda T, Yoshida H, Kato N, Omata M. Hepatitis C and Hepatocellular Carcinoma. Hepatocellular Carcinoma 2016. [DOI: 10.1007/978-3-319-34214-6_17] [Reference Citation Analysis]
387 Houghton M. Towards the Control of Hepatitis C. Hepatitis C Virus I 2016. [DOI: 10.1007/978-4-431-56098-2_1] [Reference Citation Analysis]
388 Elashri M, Farag FM, El-malky N, Abd Elmaksood E, Elarman M. Serum level of interleukin-8 and interleukin-10 as predictors for response to interferon–ribavirin combined therapy. Egyptian Liver Journal 2016;6:7-15. [DOI: 10.1097/01.elx.0000481902.94221.61] [Reference Citation Analysis]
389 Nemr N, Kishk R, Mandour M. Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C. Indian J Gastroenterol 2016;35:7-13. [PMID: 26880169 DOI: 10.1007/s12664-016-0618-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
390 Li B, Ji YJ, Shao Q, Zhu Z, Ji D, Li F, Chen G. Comparative efficacy and cost effectiveness of splenectomy and thrombopoietin prior to peginterferon and ribavirin therapy with compensatory cirrhosis associated with hepatitis C and thrombocytopenia. Exp Ther Med 2015;10:2180-6. [PMID: 26668613 DOI: 10.3892/etm.2015.2830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
391 About F, Oudot-Mellakh T, Niay J, Rabiéga P, Pedergnana V, Duffy D, Sultanik P, Cagnot C, Carrat F, Marcellin P, Zoulim F, Larrey D, Hézode C, Fontaine H, Bronowicki JP, Pol S, Albert ML, Theodorou I, Cobat A, Abel L; ANRS CO20-CUPIC study group. Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. PLoS One 2015;10:e0145105. [PMID: 26670100 DOI: 10.1371/journal.pone.0145105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
392 Kumthip K, Maneekarn N. The role of HCV proteins on treatment outcomes. Virol J 2015;12:217. [PMID: 26666318 DOI: 10.1186/s12985-015-0450-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
393 Fujii H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Yokomizo C, Tanaka S, Ishikawa H, Nishioji K, Kimura H, Takami S, Nagao Y, Takeuchi T, Shima T, Sawa Y, Minami M, Yasui K, Itoh Y. Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. World J Hepatol 2015; 7(28): 2841-2848 [PMID: 26668696 DOI: 10.4254/wjh.v7.i28.2841] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
394 Jabłońska J, Pawłowski T, Laskus T, Zalewska M, Inglot M, Osowska S, Perlejewski K, Bukowska-Ośko I, Cortes KC, Pawełczyk A, Ząbek P, Radkowski M. The correlation between pretreatment cytokine expression patterns in peripheral blood mononuclear cells with chronic hepatitis C outcome. BMC Infect Dis 2015;15:556. [PMID: 26637466 DOI: 10.1186/s12879-015-1305-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
395 Southern WN, Norton B, Steinman M, DeLuca J, Drainoni ML, Smith BD, Litwin AH. A Birth-cohort testing intervention identified hepatitis c virus infection among patients with few identified risks: a cross-sectional study. BMC Infect Dis 2015;15:553. [PMID: 26626449 DOI: 10.1186/s12879-015-1283-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
396 Karchava M, Waldenström J, Parker M, Hallack R, Sharvadze L, Gatserelia L, Chkhartishvili N, Dvali N, Dzigua L, Dolmazashvili E, Norder H, Tsertsvadze T. High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment. Hepatol Res 2015;45:1292-8. [PMID: 25689487 DOI: 10.1111/hepr.12505] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
397 Choi G, Bahirwani R, Reddy KR. Hepatitis C Genotype 3: The Remaining Problem. Curr Hepatology Rep 2015;14:267-273. [DOI: 10.1007/s11901-015-0284-4] [Reference Citation Analysis]
398 Kaur D, Chhina RS, Goyal O, Goyal P. Treatment results and factors affecting sustained virological response in chronic hepatitis C patients in Northern India. Journal of Gastrointestinal Infections 2015;5:24-30. [DOI: 10.5005/jp-jogi-5-1-24] [Reference Citation Analysis]
399 Tai AW, Chung RT. Hepatitis C Virus Infection. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch96] [Reference Citation Analysis]
400 Ghany MG, Liang TJ. Acute Viral Hepatitis. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch94] [Reference Citation Analysis]
401 Hwang JJ, Lo CC, Lin CH, Cheng HS, Hung IW, Tsai WJ, Hung CH. Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy. Gut Liver 2015;9:214-23. [PMID: 25287171 DOI: 10.5009/gnl14095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
402 Hiramine S, Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Koyanagi T, Kotoh K, Shimoda S, Hayashi J. Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. World J Hepatol 2015; 7(26): 2688-2695 [PMID: 26609346 DOI: 10.4254/wjh.v7.i26.2688] [Reference Citation Analysis]
403 Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A global view. World J Hepatol 2015; 7(26): 2676-2680 [PMID: 26609344 DOI: 10.4254/wjh.v7.i26.2676] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 9.0] [Reference Citation Analysis]
404 Murdaca G, Contini P, Cagnati P, Marenco S, Pieri G, Lantieri F, Picciotto A, Puppo F. Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy. Clin Exp Med 2017;17:93-100. [PMID: 26567007 DOI: 10.1007/s10238-015-0399-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
405 Maier MM, Ross DB, Chartier M, Belperio PS, Backus LI. Cascade of Care for Hepatitis C Virus Infection Within the US Veterans Health Administration. Am J Public Health 2016;106:353-8. [PMID: 26562129 DOI: 10.2105/AJPH.2015.302927] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
406 Perales C, Quer J, Gregori J, Esteban JI, Domingo E. Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. Viruses. 2015;7:5746-5766. [PMID: 26561827 DOI: 10.3390/v7112902] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
407 Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med 2015;7:51-70. [PMID: 26586968 DOI: 10.2147/HMER.S55864] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 5.8] [Reference Citation Analysis]
408 Fung J. Era of direct acting antivirals in chronic hepatitis C: Who will benefit? World J Hepatol 2015; 7(24): 2543-2550 [PMID: 26523206 DOI: 10.4254/wjh.v7.i24.2543] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
409 Cai Q, Zhang X, Lin C, Shao X, Guan Y, Deng H, Wei M, Huang M, Ren Z, Lu L, Mei Y, Xu M, Zhu J, Shi H, Lin G, Liu Y, Hu F, Luo Q, Lan Y, Guo F, Zhao Z, Gao Z. 24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial. PLoS One 2015;10:e0140853. [PMID: 26509605 DOI: 10.1371/journal.pone.0140853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
410 Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, Silk R, Gross C, Akoth E, McManus M, Emmanuel B, Shrivastava S, Tang L, Nelson A, Teferi G, Chavez J, Lam B, Mo H, Osinusi A, Polis MA, Masur H, Kohli A, Kottilil S. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. Clin Infect Dis 2016;62:440-7. [PMID: 26503379 DOI: 10.1093/cid/civ897] [Cited by in Crossref: 7] [Cited by in F6Publishing: 22] [Article Influence: 0.9] [Reference Citation Analysis]
411 Salem ML, El-Badawy A. Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. World J Hepatol 2015; 7(23): 2449-2458 [PMID: 26483866 DOI: 10.4254/wjh.v7.i23.2449] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
412 Liu CH, Huang CF, Liu CJ, Dai CY, Huang JF, Lin JW, Liang CC, Yang SS, Lin CL, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Kao JH, Yu ML. Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. Sci Rep 2015;5:15255. [PMID: 26469083 DOI: 10.1038/srep15255] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
413 Righi E, Londero A, Carnelutti A, Baccarani U, Bassetti M. Impact of new treatment options for hepatitis C virus infection in liver transplantation. World J Gastroenterol 2015; 21(38): 10760-10775 [PMID: 26478668 DOI: 10.3748/wjg.v21.i38.10760] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
414 Farag MM, Sofy AR, Mousa AA, Ahmed MA, Alganzory MR. Molecular Assay and Genotyping of Hepatitis C Virus among Infected Egyptian and Saudi Arabian Patients. Virology (Auckl) 2015;6:1-10. [PMID: 26512201 DOI: 10.4137/VRT.S32016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
415 Adinolfi LE, Guerrera B. All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. World J Hepatol 2015; 7(22): 2363-2368 [PMID: 26464751 DOI: 10.4254/wjh.v7.i22.2363] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
416 Poonsapaya JM, Einodshofer M, Kirkham HS, Glover P, DuChane J. New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison. Cost Eff Resour Alloc 2015;13:17. [PMID: 26445564 DOI: 10.1186/s12962-015-0043-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
417 Hiramine S, Sugiyama M, Furusyo N, Uto H, Ido A, Tsubouchi H, Watanabe H, Ueno Y, Korenaga M, Murata K, Masaki N, Hayashi J, Thomas DL, Mizokami M. A thymine-adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus. J Gastroenterol 2015;50:1069-77. [PMID: 25735432 DOI: 10.1007/s00535-015-1056-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
418 Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV; ESSENTIAL II Study Group. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther 2015;42:829-44. [PMID: 26238707 DOI: 10.1111/apt.13342] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
419 Asal S, Sobhy O, Ismail O, Bedewy E. Study of the effect of combined interferon and ribavirin therapy on the hearing profile of hepatitis C virus patients. Egypt J Otolaryngol 2015;31:237-243. [DOI: 10.4103/1012-5574.168359] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
420 Falcão EM, Trope BM, Godinho MM, Carneiro LH, de Araujo-Neto JM, Nogueira CA, Ramos-E-Silva M. Cutaneous Eruption due to Telaprevir. Case Rep Dermatol 2015;7:253-62. [PMID: 26500538 DOI: 10.1159/000439264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
421 Rowan PJ, Bhulani N. Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments. World J Hepatol 2015; 7(19): 2209-2213 [PMID: 26380046 DOI: 10.4254/wjh.v7.i19.2209] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
422 Nakamoto S, Imazeki F, Arai M, Yasui S, Nakamura M, Haga Y, Sasaki R, Kanda T, Shirasawa H, Yokosuka O. Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy. Int J Mol Sci 2015;16:21177-90. [PMID: 26370958 DOI: 10.3390/ijms160921177] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
423 Pacou M, Basso F, Gore C, Hass B, Taieb V, Cognet M, Pol S. Patient and physician preferences for the treatment of chronic hepatitis C virus infections: does the perspective matter? Eur J Gastroenterol Hepatol 2015;27:1063-8. [PMID: 26049711 DOI: 10.1097/MEG.0000000000000410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
424 Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J; InC3 Study Group. Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study. J Viral Hepat 2015;22:708-17. [PMID: 25580520 DOI: 10.1111/jvh.12384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
425 Heim MH. Interferon signaling. Signaling Pathways in Liver Diseases 2015. [DOI: 10.1002/9781118663387.ch16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
426 Scott N, Hellard M, McBryde ES. Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges. Virulence 2016;7:201-8. [PMID: 26305706 DOI: 10.1080/21505594.2015.1085151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
427 Minami T, Tateishi R, Kondo M, Nakagomi R, Fujiwara N, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Moriya K, Shiina S, Koike K. Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients. Medicine (Baltimore) 2015;94:e901. [PMID: 26061310 DOI: 10.1097/MD.0000000000000901] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
428 Irudayam JI, Contreras D, Spurka L, Subramanian A, Allen J, Ren S, Kanagavel V, Nguyen Q, Ramaiah A, Ramamoorthy K, French SW, Klein AS, Funari V, Arumugaswami V. Characterization of type I interferon pathway during hepatic differentiation of human pluripotent stem cells and hepatitis C virus infection. Stem Cell Res 2015;15:354-64. [PMID: 26313525 DOI: 10.1016/j.scr.2015.08.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
429 Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez Ruano JJ, Serra M&, Gila A, Diago M, Romero-Gómez M, Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, Granados R, Fernández M, Martín AB, Muñoz de Rueda P, Quiles R, Alhambra Spanish Study Group. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. World J Gastroenterol 2015; 21(30): 9163-9174 [PMID: 26290644 DOI: 10.3748/wjg.v21.i30.9163] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
430 Balk JM, Haenen GR, Koc ÖM, Peters R, Bast A, van der Vijgh WJ, Koek GH. Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial. Pharmgenomics Pers Med 2015;8:137-44. [PMID: 26445557 DOI: 10.2147/PGPM.S82782] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
431 Nakayama M, Kobayashi H, Fukushima K, Ishido M, Komada Y, Yoshizawa K. Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin. Hepatol Int 2016;10:158-68. [PMID: 26264253 DOI: 10.1007/s12072-015-9654-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
432 Pouliot JJ, Thomson M, Xie M, Horton J, Johnson J, Krull D, Mathis A, Morikawa Y, Parks D, Peterson R, Shimada T, Thomas E, Vamathevan J, Van Horn S, Xiong Z, Hamatake R, Peat AJ. Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein. Antimicrob Agents Chemother 2015;59:6539-50. [PMID: 26259798 DOI: 10.1128/AAC.00813-15] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
433 Furuta A, Tsubuki M, Endoh M, Miyamoto T, Tanaka J, Salam KA, Akimitsu N, Tani H, Yamashita A, Moriishi K, Nakakoshi M, Sekiguchi Y, Tsuneda S, Noda N. Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase. Int J Mol Sci 2015;16:18439-53. [PMID: 26262613 DOI: 10.3390/ijms160818439] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
434 Haj-sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol 2015; 21(29): 8935-8942 [PMID: 26269684 DOI: 10.3748/wjg.v21.i29.8935] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
435 Hong W, Lang Y, Li T, Zeng Z, Song Y, Wu Y, Li W, Cao Z. A p7 Ion Channel-derived Peptide Inhibits Hepatitis C Virus Infection in Vitro. J Biol Chem 2015;290:23254-63. [PMID: 26251517 DOI: 10.1074/jbc.M115.662452] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
436 Antonelli A, Ferrari SM, Ruffilli I, Fallahi P. Cytokines and HCV-related autoimmune disorders. Immunol Res. 2014;60:311-319. [PMID: 25381483 DOI: 10.1007/s12026-014-8569-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
437 Scott J, Gilles L, Fu M, Brohan E, Panter C, Arbuckle R, Jessner W, Beumont M. Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 and PROMISE studies. J Viral Hepat 2015;22:639-50. [PMID: 25487355 DOI: 10.1111/jvh.12365] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
438 Suda G, Yamamoto Y, Nagasaka A, Furuya K, Kudo M, Chuganji Y, Tsukuda Y, Tsunematsu S, Sato F, Terasita K, Nakai M, Horimoto H, Sho T, Natsuizaka M, Ogawa K, Ohnishi S, Chuma M, Fujita Y, Abe R, Taniguchi M, Nakagawa M, Asahina Y, Sakamoto N; NORTE Study Group. Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. Hepatol Res 2015;45:837-45. [PMID: 25211174 DOI: 10.1111/hepr.12421] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
439 Hofmann WP, Mauss S, Lutz T, Schober A, Böker K, Moog G, Baumgarten A, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D, Wedemeyer H, Manns MP, Schott E. Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study. PLoS One 2015;10:e0134839. [PMID: 26230998 DOI: 10.1371/journal.pone.0134839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
440 Durante-Mangoni E, Parrella A, Iossa D, Andini R, Molaro R, Battimelli C, Sodano G, Utili R. Differential antiviral effects of pegylated interferon-α2a and pegylated interferon-α2b in chronic hepatitis C. Clin Drug Investig 2014;34:871-8. [PMID: 25349040 DOI: 10.1007/s40261-014-0241-y] [Reference Citation Analysis]
441 Khullar V, Firpi RJ. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol 2015; 7(14): 1843-1855 [PMID: 26207166 DOI: 10.4254/wjh.v7.i14.1843] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
442 Hinrichsen H. Hepatitis C. eCur Innere Med 2015. [DOI: 10.1007/s40531-015-0011-2] [Reference Citation Analysis]
443 Gundlapalli AV, Nelson RE, Haroldsen C, Carter ME, LaFleur J. Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009. PLoS One 2015;10:e0132056. [PMID: 26167690 DOI: 10.1371/journal.pone.0132056] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
444 Monje-Agudo P, Castro-Iglesias A, Rivero-Juárez A, Martínez-Marcos F, Ortega-González E, Real LM, Pernas B, Merchante N, Cid P, Macías J, Merino MD, Rivero A, Mena A, Neukam K, Pineda JA; Grupo de Estudio de Hepatitis Vírica, of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. Eur J Clin Microbiol Infect Dis 2015;34:1929-36. [PMID: 26155784 DOI: 10.1007/s10096-015-2434-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
445 Yee BE, Nguyen NH, Zhang B, Lin D, Vutien P, Wong CR, Lutchman GA, Nguyen MH. Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis. BMJ Open Gastroenterol. 2015;2:e000049. [PMID: 26462288 DOI: 10.1136/bmjgast-2015-000049] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
446 Amraoui N, Gallouj S, Oubelkacem N, Bono W, Mernissi F. Psoriasis induced by Interferon alfa-2a and ribavirin in a patient followed for hepatitis C. Journal of Dermatology & Dermatologic Surgery 2015;19:126-129. [DOI: 10.1016/j.jdds.2015.01.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
447 Aygen B, Yıldız O, Akhan S, Çelen MK, Ural O, Koruk ST, Köse Ş, Korkmaz F, Kuruüzüm Z, Tuna N, Taheri S, Sayan M, Demir NA, Sümer Ş, Altınok ES. Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey. Balkan Med J 2015;32:266-72. [PMID: 26185714 DOI: 10.5152/balkanmedj.2015.15366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
448 El Sherbini A, Mostafa S, Ali E. Systematic review with meta-analysis: comparison between therapeutic regimens for paediatric chronic hepatitis C. Aliment Pharmacol Ther 2015;42:12-9. [PMID: 25926269 DOI: 10.1111/apt.13221] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
449 Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, Fried M, Yang JC, Ding X, Pang PS, McHutchison JG, Pound D, Reddy KR, Marcellin P, Kowdley KV, Sulkowski M. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology 2015;62:25-30. [PMID: 25963890 DOI: 10.1002/hep.27890] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 9.0] [Reference Citation Analysis]
450 Badora-rybicka A, Waluga M, Musialik J, Boryczka G, Będkowska P, Hartleb M. Can laboratory parameters be predictive factors for treatment effectiveness of patients suffering from viral hepatitis C? Ann Acad Med Siles 2015;69:91-98. [DOI: 10.18794/aams/29127] [Reference Citation Analysis]
451 European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199-236. [PMID: 25911336 DOI: 10.1016/j.jhep.2015.03.025] [Cited by in Crossref: 874] [Cited by in F6Publishing: 915] [Article Influence: 109.3] [Reference Citation Analysis]
452 Buti M, Flisiak R, Kao JH, Chuang WL, Streinu-Cercel A, Tabak F, Calistru P, Goeser T, Rasenack J, Horban A, Davis GL, Alberti A, Mazzella G, Pol S, Orsenigo R, Brass C. Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial. J Viral Hepat 2015;22:596-606. [PMID: 25412795 DOI: 10.1111/jvh.12360] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
453 Meller S, Gerber PA, Kislat A, Hevezi P, Göbel T, Wiesner U, Kellermann S, Bünemann E, Zlotnik A, Häussinger D, Erhardt A, Homey B. Allergic sensitization to pegylated interferon-α results in drug eruptions. Allergy 2015;70:775-83. [PMID: 25831972 DOI: 10.1111/all.12618] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
454 Liu CH, Huang CF, Liu CJ, Dai CY, Huang JF, Lin JW, Liang CC, Yang SS, Lin CL, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Kao JH, Yu ML. Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. Sci Rep 2015;5:11710. [PMID: 26130141 DOI: 10.1038/srep11710] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
455 Vespasiani-Gentilucci U, Galati G, Gallo P, De Vincentis A, Riva E, Picardi A. Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World J Gastroenterol 2015; 21(24): 7412-7426 [PMID: 26139987 DOI: 10.3748/wjg.v21.i24.7412] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
456 Pipili C, Cholongitas E. Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol 2015; 7(12): 1606-1616 [PMID: 26140081 DOI: 10.4254/wjh.v7.i12.1606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
457 Brown JA, Thorpe IF. Dual Allosteric Inhibitors Jointly Modulate Protein Structure and Dynamics in the Hepatitis C Virus Polymerase. Biochemistry 2015;54:4131-41. [PMID: 26066778 DOI: 10.1021/acs.biochem.5b00411] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
458 Yang SY, Lee HW, Lee YJ, Park SJ, Yoo KY, Kim HJ. Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea. Clin Mol Hepatol 2015;21:125-30. [PMID: 26157749 DOI: 10.3350/cmh.2015.21.2.125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
459 Mechie NC, Goralzcyk AD, Reinhardt L, Mihm S, Amanzada A. Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study. BMC Res Notes 2015;8:260. [PMID: 26109044 DOI: 10.1186/s13104-015-1248-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
460 Zoller H, Jenal A, Staettermayer AF, Schroecksnadel S, Ferenci P, Fuchs D. Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism. Pharmaceuticals (Basel) 2015;8:337-50. [PMID: 26096654 DOI: 10.3390/ph8020337] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
461 Rehan HS, Manak S, Yadav M. Supervised conventional interferon α2a in combination with ribavirin therapy is the preferred alternative for treatment of chronic hepatitis C. Indian J Pharmacol 2014;46:490-2. [PMID: 25298576 DOI: 10.4103/0253-7613.140578] [Reference Citation Analysis]
462 Aissa Larousse J, Trimoulet P, Recordon Pinson P, Tauzin B, Azzouz MM, Ben Mami N, Cheikh I, Triki H, Fleury H. Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia. Virol J 2015;12:84. [PMID: 26047611 DOI: 10.1186/s12985-015-0318-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
463 Campos-Varela I, Lai JC, Verna EC, O'Leary JG, Todd Stravitz R, Forman LM, Trotter JF, Brown RS, Terrault NA; Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Hepatitis C genotype influences post-liver transplant outcomes. Transplantation 2015;99:835-40. [PMID: 25211520 DOI: 10.1097/TP.0000000000000413] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
464 Ho SH, Ng KP, Kaur H, Goh KL. Genotype 3 is the predominant hepatitis C genotype in a multi-ethnic Asian population in Malaysia. Hepatobiliary Pancreat Dis Int 2015;14:281-6. [PMID: 26063029 DOI: 10.1016/s1499-3872(15)60363-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
465 Nawaz A, Zaidi SF, Usmanghani K, Ahmad I. Concise review on the insight of hepatitis C. Journal of Taibah University Medical Sciences 2015;10:132-9. [DOI: 10.1016/j.jtumed.2014.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
466 Hodowanec AC, Thompson KD, Lurain NS. Antiviral Agents. Manual ofClinical Microbiology 2015. [DOI: 10.1128/9781555817381.ch110] [Reference Citation Analysis]
467 Nolte FS. Molecular Microbiology. Manual ofClinical Microbiology 2015. [DOI: 10.1128/9781555817381.ch6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
468 Wen Y, Zheng YX, Tan de M. A comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014. Hepat Mon 2015;15:e27181. [PMID: 26045707 DOI: 10.5812/hepatmon.15(5)2015.27181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
469 Nakamoto S, Kanda T, Shirasawa H, Yokosuka O. Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. World J Hepatol 2015; 7(8): 1133-1141 [PMID: 26052402 DOI: 10.4254/wjh.v7.i8.1133] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
470 Pfeil AM, Reich O, Guerra IM, Cure S, Negro F, Müllhaupt B, Lavanchy D, Schwenkglenks M. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PLoS One 2015;10:e0126984. [PMID: 25974722 DOI: 10.1371/journal.pone.0126984] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
471 Paul F, Pellegrini S, Uzé G. IFNA2: The prototypic human alpha interferon. Gene 2015;567:132-7. [PMID: 25982860 DOI: 10.1016/j.gene.2015.04.087] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
472 Thong VD, Wasitthankasem R, Tangkijvanich P, Vongpunsawad S, Poovorawan Y. Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection. PLoS One 2015;10:e0125400. [PMID: 25938236 DOI: 10.1371/journal.pone.0125400] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
473 Gidwani R, Barnett PG, Goldhaber-Fiebert JD, Asch SM, Lo J, Dally SK, Owens DK. Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans. J Viral Hepat 2015;22:489-95. [PMID: 25417805 DOI: 10.1111/jvh.12344] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
474 Kumada H, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. Hepatol Res 2015;45:501-13. [PMID: 24961662 DOI: 10.1111/hepr.12375] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
475 Morillas RM, Planas R. Tratamiento de la infección crónica por los virus de la hepatitis C y B. FMC - Formación Médica Continuada en Atención Primaria 2015;22:264-273. [DOI: 10.1016/j.fmc.2015.01.005] [Reference Citation Analysis]
476 Takayama K, Furusyo N, Ogawa E, Ikezaki H, Shimizu M, Murata M, Hayashi J. Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. World J Gastroenterol 2015; 21(15): 4696-4706 [PMID: 25914481 DOI: 10.3748/wjg.v21.i15.4696] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
477 Nguyen T, Guedj J. HCV Kinetic Models and Their Implications in Drug Development. CPT Pharmacometrics Syst Pharmacol 2015;4:231-42. [PMID: 26225247 DOI: 10.1002/psp4.28] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
478 Fortune BE, Martinez-Camacho A, Kreidler S, Gralla J, Everson GT. Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. Transpl Int. 2015;28:980-989. [PMID: 25818896 DOI: 10.1111/tri.12568] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
479 Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? Hepat Med 2015;7:11-20. [PMID: 25926761 DOI: 10.2147/HMER.S79584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
480 Ishiguro H, Abe H, Seki N, Sugita T, Aida Y, Itagaki M, Sutoh S, Shimada N, Furihata T, Tsubota A, Aizawa Y. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C. World J Gastroenterol 2015; 21(13): 3904-3911 [PMID: 25852275 DOI: 10.3748/wjg.v21.i13.3904] [Reference Citation Analysis]
481 Southern WN, Drainoni ML, Smith BD, Koppelman E, McKee MD, Christiansen CL, Gifford AL, Weinbaum CM, Litwin AH. Physician nonadherence with a hepatitis C screening program. Qual Manag Health Care 2014;23:1-9. [PMID: 24368717 DOI: 10.1097/QMH.0000000000000007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
482 Flamm SL, Muir AJ, Fried MW, Reddy KR, Nelson DR, Bzowej NH, Sullivan JC, Bengtsson L, DeMasi R, Wright CI, Kieffer TL, George S, Adda N, Dusheiko GM. Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. J Clin Gastroenterol 2015;49:336-44. [PMID: 24828357 DOI: 10.1097/MCG.0000000000000150] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
483 Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015;62:S87-99. [PMID: 25920094 DOI: 10.1016/j.jhep.2015.02.006] [Cited by in Crossref: 237] [Cited by in F6Publishing: 231] [Article Influence: 29.6] [Reference Citation Analysis]
484 Cunningham EB, Applegate TL, Lloyd AR, Dore GJ, Grebely J. Mixed HCV infection and reinfection in people who inject drugs--impact on therapy. Nat Rev Gastroenterol Hepatol 2015;12:218-30. [PMID: 25782091 DOI: 10.1038/nrgastro.2015.36] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 9.3] [Reference Citation Analysis]
485 Larrubia JR, Moreno-Cubero E, Miquel J, Sanz-de-Villalobos E. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastroenterol 2015; 21(12): 3480-3491 [PMID: 25834312 DOI: 10.3748/wjg.v21.i12.3480] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
486 Shaheen MA, Idrees M. Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol 2015; 7(3): 616-627 [PMID: 25848486 DOI: 10.4254/wjh.v7.i3.616] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
487 Hu CC, Lin CL, Chang LC, Chien CH, Chen LW, Liu CJ, Chien RN. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study. BMC Infect Dis 2015;15:156. [PMID: 25888020 DOI: 10.1186/s12879-015-0888-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
488 Choi JE, Kwon JH, Kim JH, Hur W, Sung PS, Choi SW, Yoon SK. Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication. PLoS One 2015;10:e0119172. [PMID: 25798824 DOI: 10.1371/journal.pone.0119172] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
489 Solbach P, Westhaus S, Deest M, Herrmann E, Berg T, Manns MP, Ciesek S, Sarrazin C, von Hahn T. Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. Cell Mol Gastroenterol Hepatol 2015;1:285-294.e1. [PMID: 28210681 DOI: 10.1016/j.jcmgh.2015.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
490 Ishikawa T, Abe S, Kojima Y, Sano T, Iwanaga A, Seki KI, Honma T, Yoshida T, Yamazaki M, Sakai T, Tasaki K, Suzuki Y. Prediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin. Exp Ther Med 2015;9:1646-50. [PMID: 26136872 DOI: 10.3892/etm.2015.2340] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
491 Yang N, Sun Q, Xu Z, Wang X, Zhao X, Cao Y, Chen L, Fan G. LC-ESI-MS/MS analysis and pharmacokinetics of GP205, an innovative potent macrocyclic inhibitor of hepatitis C virus NS3/4A protease in rats. Molecules 2015;20:4319-36. [PMID: 25756650 DOI: 10.3390/molecules20034319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
492 Grasso A, Malfatti F, Andraghetti G, Marenco S, Mazzucchelli C, Labanca S, Cordera R, Testa R, Picciotto A. HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients. Gastroenterol Res Pract 2015;2015:975695. [PMID: 25821463 DOI: 10.1155/2015/975695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
493 Werner CR, Franz C, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort. Virol J. 2015;12:37. [PMID: 25889921 DOI: 10.1186/s12985-015-0261-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
494 Sood A, Midha V, Goyal O. Optimal Duration of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 3 Patients who do not Achieve Rapid Virological Response. J Clin Exp Hepatol 2015;5:2-7. [PMID: 25941428 DOI: 10.1016/j.jceh.2015.02.003] [Reference Citation Analysis]
495 Markov PV, Gray RR, Iles J, Pybus OG. The evolutionary epidemiology of the hepatitis C virus. Parasite Diversity and Diversification 2015. [DOI: 10.1017/cbo9781139794749.030] [Reference Citation Analysis]
496 Al-Qahtani A, Al-Anazi M, Abdo AA, Sanai FM, Al-Hamoudi W, Alswat KA, Al-Ashgar HI, Khan MQ, Albenmousa A, Khalaf N, Viswan N, Al-Ahdal MN. Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection. J Immunol Res 2015;2015:768470. [PMID: 25811035 DOI: 10.1155/2015/768470] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
497 Wandtke T, Woźniak J, Kopiński P. Aptamers in diagnostics and treatment of viral infections. Viruses 2015;7:751-80. [PMID: 25690797 DOI: 10.3390/v7020751] [Cited by in Crossref: 88] [Cited by in F6Publishing: 90] [Article Influence: 11.0] [Reference Citation Analysis]
498 Harrod KS. Ebola: history, treatment, and lessons from a new emerging pathogen. Am J Physiol Lung Cell Mol Physiol 2015;308:L307-13. [PMID: 25502503 DOI: 10.1152/ajplung.00354.2014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
499 Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124-1135. [PMID: 25687730 DOI: 10.1016/s0140-6736(14)62401-6] [Cited by in Crossref: 364] [Cited by in F6Publishing: 306] [Article Influence: 45.5] [Reference Citation Analysis]
500 Shepherd SJ, Abdelrahman T, MacLean AR, Thomson EC, Aitken C, Gunson RN. Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. J Clin Virol 2015;65:50-3. [PMID: 25766988 DOI: 10.1016/j.jcv.2015.02.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
501 Clausen LN, Weis N, Ladelund S, Madsen L, Lunding S, Tarp B, Christensen PB, Krarup HB, Møller A, Gerstoft J, Clausen MR, Benfield T; DANHEP group. Genetic variants in the apoptosis gene BCL2L1 improve response to interferon-based treatment of hepatitis C virus genotype 3 infection. Int J Mol Sci 2015;16:3213-25. [PMID: 25648321 DOI: 10.3390/ijms16023213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
502 McDonald SA, Innes HA, Hayes PC, Dillon JF, Mills PR, Goldberg DJ, Barclay S, Allen S, Fox R, Fraser A, Kennedy N, Bhattacharyya D, Hutchinson SJ. What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C? J Hepatol 2015;62:262-8. [PMID: 25195556 DOI: 10.1016/j.jhep.2014.08.046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
503 Honda T, Ishigami M, Masuda H, Ishizu Y, Kuzuya T, Hayashi K, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Katano Y, Goto H. Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C. J Gastroenterol Hepatol 2015;30:321-8. [PMID: 25091027 DOI: 10.1111/jgh.12703] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
504 Dong ZX, Zhou HJ, Xiang XG, Guo SM, Zhuang Y, Zhao GD, Xie Q. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population. J Dig Dis 2015;16:90-7. [PMID: 25312023 DOI: 10.1111/1751-2980.12202] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
505 Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, Kim BK, Kim SU, Ahn SH, Han KH. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci 2015;60:573-81. [PMID: 25236421 DOI: 10.1007/s10620-014-3361-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
506 Tamaki K, Okubo A. Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: First case report. World J Gastroenterol 2015; 21(3): 1009-1013 [PMID: 25624738 DOI: 10.3748/wjg.v21.i3.1009] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
507 Holysz M, Bialas K, Migdalski P, Kmieciak D, Trzeciak WH. Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNα/RBV therapy. J Appl Genet 2015;56:403-9. [PMID: 25588648 DOI: 10.1007/s13353-014-0267-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
508 Wong WWL, Tu HA, Feld JJ, Wong T, Krahn M. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ 2015;187:E110-21. [PMID: 25583667 DOI: 10.1503/cmaj.140711] [Cited by in Crossref: 49] [Cited by in F6Publishing: 57] [Article Influence: 6.1] [Reference Citation Analysis]
509 Zhu Y. Two Types of Viral Hepatitis, Two Different Treats from Pharma -What’s After the Liver Meeting® 2014? JHVRV 2015;2. [DOI: 10.15406/jhvrv.2015.02.00029] [Reference Citation Analysis]
510 Ray SC, Thomas DL. Hepatitis C. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2015. [DOI: 10.1016/b978-1-4557-4801-3.00156-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
511 Kim J, Choi H, Kim T, Kim SI. A Study on the Anxiety of the Chronic Viral Hepatitis Patients Receiving Pegylated Interferon Therapy. J Korean Neuropsychiatr Assoc 2015;54:506. [DOI: 10.4306/jknpa.2015.54.4.506] [Reference Citation Analysis]
512 Spengler U. Chronische Hepatitis. Therapie-Handbuch Grundwerk inkl 6. Lfg. 2015. [DOI: 10.1016/b978-3-437-22107-1.50187-4] [Reference Citation Analysis]
513 Tahata Y, Hiramatsu N, Oze T, Urabe A, Morishita N, Yamada R, Yakushijin T, Saji Y, Oshita M, Mita E, Hagiwara H, Fukui H, Yamada Y, Ito T, Hijioka T, Inada M, Katayama K, Tamura S, Inoue A, Imai Y, Hikita H, Sakamori R, Yoshida Y, Tatsumi T, Hayashi N, Takehara T. Alanine aminotransferase elevations during triple therapy with simeprevir, pegylated interferon plus ribavirin. Acta hepatologica Japonica 2015;56:567-574. [DOI: 10.2957/kanzo.56.567] [Reference Citation Analysis]
514 Sharafi H, Alavian SM, Keshvari M. Efficacy of 24-week pegylated interferon alpha and ribavirin combination therapy in highly selected patients infected with hepatitis C virus genotype 1. Hepat Mon 2015;15:e24955. [PMID: 25741374 DOI: 10.5812/hepatmon.24955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
515 Shin HM, Lee J, Cho N. Role of Th17 and Treg during the Chronic Infection of Hepatitis C Virus. J Bacteriol Virol 2015;45:389. [DOI: 10.4167/jbv.2015.45.4.389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
516 Sassi AB, Nagarkar R, Hamblin P. Biobetter Biologics. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies 2015. [DOI: 10.1016/b978-0-12-416603-5.00009-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
517 Vermehren J, Welsch C, Sarrazin C. Protease Inhibitor Resistance. Handbook of Antimicrobial Resistance 2015. [DOI: 10.1007/978-1-4939-0667-3_6-1] [Reference Citation Analysis]
518 Dienstag JL. Antiviral Drugs against Hepatitis Viruses. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2015. [DOI: 10.1016/b978-1-4557-4801-3.00046-1] [Reference Citation Analysis]
519 Dolin R. Miscellaneous Antiviral Agents (Interferons, Imiquimod, Pleconaril). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2015. [DOI: 10.1016/b978-1-4557-4801-3.00047-3] [Reference Citation Analysis]
520 Morihara D, Watanabe H, Takata K, Iwashita H, Tsuchiya N, Kunimoto H, Kuno S, Fukunaga A, Yotsumoto K, Tanaka T, Sakurai K, Hirano G, Yokoyama K, Nishizawa S, Yoshikane M, Anan A, Takeyama Y, Kitamura Y, Iwata K, Irie M, Shakado S, Sohda T, Sakisaka S. Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate. Eur J Gastroenterol Hepatol 2015;27:55-64. [PMID: 25370853 DOI: 10.1097/MEG.0000000000000208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
521 Katsounas A, Frank AC, Lempicki RA, Polis MA, Asmuth DM, Kottilil S. Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo. J AIDS Clin Res 2015;6:1000410. [PMID: 26052470 DOI: 10.4172/2155-6113.1000410] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
522 Arbuthnot P. Gene Therapy for Hepatitis C Virus Infection. Gene Therapy for Viral Infections 2015. [DOI: 10.1016/b978-0-12-410518-8.00007-7] [Reference Citation Analysis]
523 Tachi Y, Hirai T, Miyata A, Ohara K, Iida T, Ishizu Y, Honda T, Kuzuya T, Hayashi K, Ishigami M, Goto H. Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatol Res 2015;45:238-46. [PMID: 24655233 DOI: 10.1111/hepr.12331] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
524 Dienstag JL, Delemos AS. Viral Hepatitis. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2015. [DOI: 10.1016/b978-1-4557-4801-3.00119-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
525 Gonzalez SA, Davis GL. Natural History of Hepatitis C. Transplantation of the Liver 2015. [DOI: 10.1016/b978-1-4557-0268-8.00010-5] [Reference Citation Analysis]
526 Arnold DL, Calabresi PA, Kieseier BC, Sheikh SI, Deykin A, Zhu Y, Liu S, You X, Sperling B, Hung S. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurol 2014;14:240. [PMID: 25551571 DOI: 10.1186/s12883-014-0240-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
527 Jardim AC, Igloi Z, Shimizu JF, Santos VA, Felippe LG, Mazzeu BF, Amako Y, Furlan M, Harris M, Rahal P. Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro. Antiviral Res. 2015;115:39-47. [PMID: 25557602 DOI: 10.1016/j.antiviral.2014.12.018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
528 Ishida YI, Takeshita M, Kataoka H. Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism. World J Hepatol 2014; 6(12): 870-879 [PMID: 25544874 DOI: 10.4254/wjh.v6.i12.870] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
529 Suzuki K, Tamano M, Katayama Y, Kuniyoshi T, Kagawa K, Takada H, Suzuki K. Study of pruritus in chronic hepatitis C patients. World J Gastroenterol 2014; 20(47): 17877-17882 [PMID: 25548485 DOI: 10.3748/wjg.v20.i47.17877] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
530 Takahashi M, Kikuchi M, Ebinuma H, Saito H. Nutritional Status and Body Composition Dynamics with Peginterferon Alpha and Ribavirin Combination Therapy in Chronic Hepatitis C Patients. International J of Virology 2014;11:12-19. [DOI: 10.3923/ijv.2015.12.19] [Reference Citation Analysis]
531 Chen T, Huang P, Show B, Wen C, Chen Y. Impact of interleukin-28B polymorphism on HCV-1 infected patients treated with response-guided therapy. Advances in Digestive Medicine 2015;2:25-32. [DOI: 10.1016/j.aidm.2014.11.001] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
532 Zou X, Chi X, Pan Y, Du D, Sun H, Matsuda A, Li W, Kuno A, Zhang X, Narimatsu H, Niu J, Zhang Y. LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients. Clin Proteomics 2014;11:44. [PMID: 25593566 DOI: 10.1186/1559-0275-11-44] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
533 Manickam C, Reeves RK. Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections. Front Microbiol. 2014;5:690. [PMID: 25538700 DOI: 10.3389/fmicb.2014.00690] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
534 de Kanter CT, Drenth JP, Arends JE, Reesink HW, van der Valk M, de Knegt RJ, Burger DM. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2014;53:409-27. [PMID: 24723109 DOI: 10.1007/s40262-014-0142-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
535 De Clercq E. Ebola virus (EBOV) infection: Therapeutic strategies. Biochem Pharmacol 2015;93:1-10. [PMID: 25481298 DOI: 10.1016/j.bcp.2014.11.008] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 5.8] [Reference Citation Analysis]
536 Kim DD, Hutton DW, Raouf AA, Salama M, Hablas A, Seifeldin IA, Soliman AS. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. Glob Public Health. 2015;10:296-317. [PMID: 25469976 DOI: 10.1080/17441692.2014.984742] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 5.2] [Reference Citation Analysis]
537 Kim S, Jin B, Choi SH, Han KH, Ahn SH. Casein kinase II inhibitor enhances production of infectious genotype 1a hepatitis C virus (H77S). PLoS One 2014;9:e113938. [PMID: 25464014 DOI: 10.1371/journal.pone.0113938] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
538 Farnik H, Ferreirós N, Labocha S, Geisslinger G, Zeuzem S, Sarrazin C, Vermehren J. Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection. Scand J Gastroenterol 2014;49:1473-9. [PMID: 25384840 DOI: 10.3109/00365521.2014.978363] [Reference Citation Analysis]
539 Gupta V, Kumar A, Sharma P, Tyagi P, Bansal N, Singla V, Arora A. Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India. J Clin Exp Hepatol 2014;4:287-92. [PMID: 25755575 DOI: 10.1016/j.jceh.2014.08.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
540 Kanwal S, Mahmood T. Hepatitis C virus resistance to interferon therapy: an alarming situation. Open Life Sciences 2014;9:1155-67. [DOI: 10.2478/s11535-014-0352-8] [Reference Citation Analysis]
541 Faisal N, Mumtaz K, Marquez M, Renner EL, Lilly LB. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation. Hepatol Int. 2015;9:76-83. [PMID: 25788382 DOI: 10.1007/s12072-014-9589-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
542 Jin YJ, Shim JH, Kim GA, Yu E, Kim KM, Lim YS, Lee HC. Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection. BMJ Open 2014;4:e006255. [PMID: 25431223 DOI: 10.1136/bmjopen-2014-006255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
543 Hajiaghamohammadi A, Samimi R, Miroliaee A, Kazemifar AM, Nazem M. Treatment outcome in chronic hepatitis C infection: a four years survey among Iranian patients. Glob J Health Sci 2014;7:75-81. [PMID: 25948447 DOI: 10.5539/gjhs.v7n3p75] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
544 Cashman SB, Marsden BD, Dustin LB. The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol. 2014;5:550. [PMID: 25426115 DOI: 10.3389/fimmu.2014.00550] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
545 Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle: an update. J Hepatol 2014;61:S3-S13. [PMID: 25443344 DOI: 10.1016/j.jhep.2014.06.031] [Cited by in Crossref: 127] [Cited by in F6Publishing: 126] [Article Influence: 14.1] [Reference Citation Analysis]
546 Pinter M, Hucke F, Zielonke N, Trauner M, Sieghart W, Peck-Radosavljevic M. Epidemiological trends of hepatocellular carcinoma in Austria. Dig Dis 2014;32:664-9. [PMID: 25376282 DOI: 10.1159/000367983] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
547 Kinagi S, Yasmeen SA, Kinagi A. STUDY OF SEROPOSITIVITY OF HBSAG AND ANTIHCV ANTIBODY IN HIV POSITIVE PATIENTS. jemds 2014;3:12881-12893. [DOI: 10.14260/jemds/2014/3711] [Reference Citation Analysis]
548 Mechie NC, Röver C, Cameron S, Amanzada A. Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. World J Hepatol 2014; 6(10): 759-765 [PMID: 25349647 DOI: 10.4254/wjh.v6.i10.759] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
549 Mangia A, Cenderello G, Orlandini A, Piazzolla V, Picciotto A, Zuin M, Ciancio A, Brancaccio G, Forte P, Carretta V. Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. PLoS One. 2014;9:e110284. [PMID: 25340799 DOI: 10.1371/journal.pone.0110284] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
550 Chen LZ, Sabo JP, Philip E, Rowland L, Mao Y, Latli B, Ramsden D, Mandarino DA, Sane RS. Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 2015;59:25-37. [PMID: 25313217 DOI: 10.1128/AAC.03861-14] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
551 Sulyok M, Makara M, Újhelyi E, Vályi-Nagy I. Non-Hodgkin lymphoma and hepatitis C: where we are and what next? Pathol Oncol Res. 2015;21:1-7. [PMID: 25273531 DOI: 10.1007/s12253-014-9845-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
552 Abe H, Hayes CN, Chayama K. New insight into the enhanced effect of pegylated interferon-α. Hepatology 2014;60:1435-7. [PMID: 24944103 DOI: 10.1002/hep.27269] [Reference Citation Analysis]
553 Rizzetto M, Grotzinger K, Theodore D, Demuth D, Irving WL, Manns M, Roughley A, Forssen UM. Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombocytopaenia: a retrospective chart review from five European countries. J Viral Hepat 2014;21:e129-34. [PMID: 24698004 DOI: 10.1111/jvh.12256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
554 Geri G, Maynard M, Rosenthal E, Fontaine H, Lacombe K, Slama L, Goujard C, Loustaud-Ratti V, Bergmann JF, Morlat P, Vittecoq D, Alric L, Cacoub P; GERMIVIC Group. Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010. Liver Int 2014;34:1349-57. [PMID: 25368876 DOI: 10.1111/liv.12388] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
555 Azzaroli F, Montagnani M, Porro A, Fiorillo D, Mazzella G. The future of dual therapy for hepatitis C virus. Future Virology 2014;9:905-12. [DOI: 10.2217/fvl.14.78] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
556 Lee A, Liu S, Wang T. Identification of novel human kinases that suppress hepatitis C virus infection. J Viral Hepat 2014;21:716-26. [PMID: 24205826 DOI: 10.1111/jvh.12203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
557 Chandra PK, Gunduz F, Hazari S, Kurt R, Panigrahi R, Poat B, Bruce D, Cohen AJ, Bohorquez HE, Carmody I, Loss G, Balart LA, Wu T, Dash S. Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. PLoS One. 2014;9:e108616. [PMID: 25265476 DOI: 10.1371/journal.pone.0108616] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
558 Arain A, Robaeys G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol 2014; 20(36): 12722-12733 [PMID: 25278674 DOI: 10.3748/wjg.v20.i36.12722] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
559 Bonnet D, Guivarch M, Bérard E, Combis JM, Remy AJ, Glibert A, Payen JL, Metivier S, Barange K, Desmorat H, Palacin A, Nicot F, Abravanel F, Alric L. Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. World J Hepatol 2014; 6(9): 660-669 [PMID: 25276282 DOI: 10.4254/wjh.v6.i9.660] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
560 Sapra S, Chang E, Broder MS, L'Italien G. Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. BMC Health Serv Res 2014;14:429. [PMID: 25249187 DOI: 10.1186/1472-6963-14-429] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
561 Pyrsopoulos N. Management of Hepatitis C in the Pre- and Post-Transplant Setting: Then and Now. GHOA 2014;1. [DOI: 10.15406/ghoa.2014.01.00019] [Reference Citation Analysis]
562 Yau AH, Yoshida EM. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol 2014;28:445-51. [PMID: 25229466 DOI: 10.1155/2014/549624] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 5.7] [Reference Citation Analysis]
563 Bock JA, Fairley KJ, Smith RE, Maeng DD, Pitcavage JM, Inverso NA, Williams MS. Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection. Public Health Genomics 2014;17:306-19. [PMID: 25247313 DOI: 10.1159/000365939] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
564 Amanzada A, Goralczyk AD, Reinhardt L, Moriconi F, Cameron S, Mihm S. Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy. BMC Infect Dis 2014;14:503. [PMID: 25227310 DOI: 10.1186/1471-2334-14-503] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
565 Strazzulla A, Costa C, Pisani V, De Maria V, Giancotti F, Di Salvo S, Parisi SG, Basso M, Franzetti MM, Marascio N, Liberto MC, Barreca GS, Lamberti AG, Zicca E, Postorino MC, Matera G, Focà A, Torti C. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals. BMC Infect Dis 2014;14 Suppl 5:S3. [PMID: 25236374 DOI: 10.1186/1471-2334-14-S5-S3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
566 Baker D, Alavi M, Erratt A, Hill S, Balcomb A, Hallinan R, Siriragavan S, Richmond D, Smart J, Keats J, Doong N, Marks P, Grebely J, Dore GJ. Delivery of treatment for hepatitis C virus infection in the primary care setting. Eur J Gastroenterol Hepatol 2014;26:1003-9. [PMID: 25051216 DOI: 10.1097/MEG.0000000000000150] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
567 Deborah Friedman N, Green JH, Weber HM, Stephen S, Lane SE, Ting AY, Watson JP. Hepatitis C virus treatment in the 'real-world': how well do 'real' patients respond? J Clin Exp Hepatol 2014;4:214-20. [PMID: 25755563 DOI: 10.1016/j.jceh.2014.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
568 Maan R, van der Meer AJ, Hansen BE, Feld JJ, Wedemeyer H, Dufour JF, Zangneh HF, Lammert F, Manns MP, Zeuzem S, Janssen HL, de Knegt RJ, Veldt BJ. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. J Hepatol 2014;61:482-91. [PMID: 24780302 DOI: 10.1016/j.jhep.2014.04.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
569 Ghanem HM, Ismaeel NN, Haseeb AF, Nabawy WM, Rehan M, Shreen H. Seminal parameters before and during combined antiviral (pegylated interferon α-2a and ribavirin) treatment in chronic hepatitis C virus patients in upper Egypt. Egypt J Intern Med 2014;26:104-109. [DOI: 10.4103/1110-7782.145302] [Reference Citation Analysis]
570 Rosina F, Tosti ME, Borghesio E, Masocco M, Mele A, Coppola C, Milella M, Borgia G, Andreone P, Koch M, Zignego AL, Romano M, Carrara M, Almasio PL, Azzola E, Nardone G, Benedetti A, Carosi G, Mazzotta F, Sagnelli E, Rizzetto M; AIFA Study Group, Italian Association for the Study of the Liver (AISF), Italian Society for Infectious and Tropical Diseases (SIMIT), Italian Association of Hospital Gastroenterologists (AIGO), Italian Society of Gastroenterology (SIGE), Italian Association for the Study of the Liver AISF, Italian Society for Infectious and Tropical Diseases SIMIT, Italian Association of Hospital Gastroenterologists AIGO, Italian Society of Gastroenterology SIGE. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency. Dig Liver Dis 2014;46:826-32. [PMID: 24986781 DOI: 10.1016/j.dld.2014.05.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
571 Scott J, Rosa K, Fu M, Cerri K, Peeters M, Beumont M, Zeuzem S, Evon DM, Gilles L. Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 2014;14:465. [PMID: 25164700 DOI: 10.1186/1471-2334-14-465] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
572 Dvory-Sobol H, Voitenleitner C, Mabery E, Skurnac T, Lawitz EJ, McHutchison J, Svarovskaia ES, Delaney W, Miller MD, Mo H. Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 2014;58:6599-606. [PMID: 25155588 DOI: 10.1128/AAC.02815-14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
573 Roeder C, Jordan S, Schulze zur Wiesch J, Pfeiffer-Vornkahl H, Hueppe D, Mauss S, Zehnter E, Stoll S, Alshuth U, Lohse AW, Lueth S. Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. World J Gastroenterol 2014; 20(31): 10984-10993 [PMID: 25152602 DOI: 10.3748/wjg.v20.i31.10984] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
574 Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H. Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients. Gastroenterol Res Pract. 2014;2014:549709. [PMID: 25197269 DOI: 10.1155/2014/549709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
575 Andriulli A, Morisco F, Ippolito AM, Di Marco V, Valvano MR, Angelico M, Fattovich G, Granata R, Smedile A, Milella M, Felder M, Gaeta GB, Gatti P, Fasano M, Mazzella G, Santantonio T. HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. Hepatol Int 2015;9:52-7. [PMID: 25788379 DOI: 10.1007/s12072-014-9556-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
576 Mi Y, Gao YT, Jiao XL, Guo H, Liu T, Jing L, Shi WX, Du Z. The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Hepat Mon 2014;14:e18793. [PMID: 25337144 DOI: 10.5812/hepatmon.18793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
577 Shier MK, El-Wetidy MS, Ali HH, Al-Qattan MM. Characterization of hepatitis C virus genotypes by direct sequencing of HCV 5'UTR region of isolates from Saudi Arabia. PLoS One 2014;9:e103160. [PMID: 25099694 DOI: 10.1371/journal.pone.0103160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
578 Rong X, Xu R, Xiong H, Wang M, Huang K, Chen Q, Li C, Liao Q, Huang J, Xia W, Luo G, Ye X, Zhang M, Fu Y. Increased prevalence of hepatitis C virus subtype 6a in China: a comparison between 2004-2007 and 2008-2011. Arch Virol 2014;159:3231-7. [PMID: 25085624 DOI: 10.1007/s00705-014-2185-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
579 Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, Horsmans Y, Weiland O, Reesink HW, Rodrigues L Jr, Hu YB, Podsadecki T, Bernstein B. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014;147:359-365.e1. [PMID: 24818763 DOI: 10.1053/j.gastro.2014.04.045] [Cited by in Crossref: 283] [Cited by in F6Publishing: 305] [Article Influence: 31.4] [Reference Citation Analysis]
580 Yu Y, Jing JF, Tong XK, He PL, Li YC, Hu YH, Tang W, Zuo JP. Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease. Acta Pharmacol Sin 2014;35:1074-81. [PMID: 25066323 DOI: 10.1038/aps.2014.55] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
581 Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology 2014;147:366-76.e6. [PMID: 24727022 DOI: 10.1053/j.gastro.2014.04.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
582 Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014;61:219-27. [PMID: 24727123 DOI: 10.1016/j.jhep.2014.04.004] [Cited by in Crossref: 124] [Cited by in F6Publishing: 132] [Article Influence: 13.8] [Reference Citation Analysis]
583 van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. J Viral Hepat 2014;21:568-77. [PMID: 24118177 DOI: 10.1111/jvh.12185] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
584 Lawitz EJ, Membreno FE. Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects. J Gastroenterol Hepatol 2014;29:1574-81. [PMID: 24852401 DOI: 10.1111/jgh.12632] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
585 European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014;61:373-95. [PMID: 24818984 DOI: 10.1016/j.jhep.2014.05.001] [Cited by in Crossref: 135] [Cited by in F6Publishing: 147] [Article Influence: 15.0] [Reference Citation Analysis]
586 Liu G, Holmberg SD, Kamili S, Xu F. Racial disparities in the proportion of current, unresolved hepatitis C virus infections in the United States, 2003-2010. Dig Dis Sci 2014;59:1950-7. [PMID: 24573716 DOI: 10.1007/s10620-014-3059-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
587 Eslam M, Leung R, Romero-Gomez M, Mangia A, Irving WL, Sheridan D, Spengler U, Mollison L, Cheng W, Bugianesi E, McLeod D, Zaitoun AM, Attino V, Goeltz D, Nattermann J, Douglas M, Booth DR, George J, Ahlenstiel G. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol 2014;61:235-41. [PMID: 24768758 DOI: 10.1016/j.jhep.2014.03.039] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
588 Donlin MJ, Lomonosova E, Kiss A, Cheng X, Cao F, Curto TM, Di Bisceglie A, Tavis JE. HCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma. PLoS One 2014;9:e103748. [PMID: 25079603 DOI: 10.1371/journal.pone.0103748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
589 Hetta HF, Mehta MJ, Shata MTM. Gut immune response in the presence of hepatitis C virus infection. World J Immunol 2014; 4(2): 52-62 [DOI: 10.5411/wji.v4.i2.52] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
590 Rao P, Koshy A, Philip J, Premaletha N, Varghese J, Narayanasamy K, Mohindra S, Pai NV, Agarwal MK, Konar A, Vora HB. Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C. World J Hepatol 2014; 6(7): 520-526 [PMID: 25068004 DOI: 10.4254/wjh.v6.i7.520] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
591 Lange CM, Jacobson IM, Rice CM, Zeuzem S. Emerging therapies for the treatment of hepatitis C. EMBO Mol Med. 2014;6:4-15. [PMID: 24106239 DOI: 10.1002/emmm.201303131] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 8.0] [Reference Citation Analysis]
592 Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;348:g3308. [PMID: 25002352 DOI: 10.1136/bmj.g3308] [Cited by in Crossref: 150] [Cited by in F6Publishing: 162] [Article Influence: 16.7] [Reference Citation Analysis]
593 Ortiz V, Wands JR. Chronic ethanol diet increases regulatory T-cell activity and inhibits hepatitis C virus core-specific cellular immune responses in mice. Hepatol Res 2014;44:788-97. [PMID: 23710581 DOI: 10.1111/hepr.12173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
594 Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. Liver Int 2014;34:890-5. [PMID: 24102823 DOI: 10.1111/liv.12321] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
595 Sood A, Midha V, Goyal O, Hissar S, Sharma SK, Khanna P. Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in treatment-naïve 'real-life' patients in India. Indian J Gastroenterol 2014;33:343-9. [PMID: 24619456 DOI: 10.1007/s12664-014-0451-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
596 Broering R, Lutterbeck M, Trippler M, Kleinehr K, Poggenpohl L, Paul A, Gerken G, Schlaak JF. Long-term stimulation of Toll-like receptor 3 in primary human hepatocytes leads to sensitization for antiviral responses induced by poly I:C treatment. J Viral Hepat 2014;21:480-90. [PMID: 24750363 DOI: 10.1111/jvh.12174] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
597 Beisel C, Heuer M, Otto B, Jochum J, Schmiedel S, Hertling S, Degen O, Lüth S, van Lunzen J, Schulze Zur Wiesch J. German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients. AIDS Res Ther 2014;11:16. [PMID: 25006340 DOI: 10.1186/1742-6405-11-16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
598 Cubero M, Gregori J, Esteban JI, García-Cehic D, Bes M, Perales C, Domingo E, Rodríguez-Frías F, Sauleda S, Casillas R, Sanchez A, Ortega I, Esteban R, Guardia J, Quer J. Identification of host and viral factors involved in a dissimilar resolution of a hepatitis C virus infection. Liver Int 2014;34:896-906. [PMID: 24134179 DOI: 10.1111/liv.12362] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
599 Iacobellis A, Cozzolongo R, Minerva N, Valvano MR, Niro GA, Fontana R, Palmieri O, Ippolito A, Andriulli A. Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia. Dig Liver Dis 2014;46:621-4. [PMID: 24675038 DOI: 10.1016/j.dld.2014.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
600 Jiang M, Zhang EZ, Ardzinski A, Tigges A, Davis A, Sullivan JC, Nelson M, Spanks J, Dorrian J, Nicolas O. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor. Antimicrob Agents Chemother. 2014;58:5456-5465. [PMID: 24982088 DOI: 10.1128/aac.03052-14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
601 Heo NY, Lim YS, Lee W, Oh M, An J, Lee D, Shim JH, Kim KM, Lee HC, Lee YS, Suh DJ. No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients. Clin Mol Hepatol 2014;20:177-84. [PMID: 25032184 DOI: 10.3350/cmh.2014.20.2.177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
602 El-Shamy A, Hotta H. Impact of hepatitis C virus heterogeneity on interferon sensitivity: An overview. World J Gastroenterol 2014; 20(24): 7555-7569 [PMID: 24976696 DOI: 10.3748/wjg.v20.i24.7555] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
603 Natasha A. V, Mcanenny C. Autoimmune hepatitis and viral hepatitis and nutrition. Advanced Nutrition and Dietetics in Gastroenterology 2014. [DOI: 10.1002/9781118872796.ch4.4] [Reference Citation Analysis]
604 Wang X, Liu F, Wei F, Ren H, Hu H. Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis. PLoS One 2014;9:e100128. [PMID: 24963667 DOI: 10.1371/journal.pone.0100128] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
605 Kamal SM. Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med. 2014;6:61-77. [PMID: 25114601 DOI: 10.2147/hmer.s41127] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
606 Adedeji AO, Sarafianos SG. Future treatment strategies for novel Middle East respiratory syndrome coronavirus infection. Future Med Chem 2013;5:2119-22. [PMID: 24261888 DOI: 10.4155/fmc.13.183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
607 Grebely J, Bilodeau M, Feld JJ, Bruneau J, Fischer B, Raven JF, Roberts E, Choucha N, Myers RP, Sagan SM, Wilson JA, Bialystok F, Tyrrell DL, Houghton M, Krajden M; National CIHR Research Training Program in Hepatitis C. The Second Canadian Symposium on hepatitis C virus: a call to action. Can J Gastroenterol 2013;27:627-32. [PMID: 24199209 DOI: 10.1155/2013/242405] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
608 Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L, Mehmedovic A, Junuzovic D, Bjelogrlic I, Sofic A, Djurovic A. Analysis of effect of antiviral therapy on regression of liver fibrosis in patient with HCV infection. Mater Sociomed. 2014;26:172-176. [PMID: 25126010 DOI: 10.5455/msm.2014.26.172-176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
609 Ishikane M, Watanabe K, Tsukada K, Nozaki Y, Yanase M, Igari T, Masaki N, Kikuchi Y, Oka S, Gatanaga H. Acute hepatitis C in HIV-1 infected Japanese Cohort: single center retrospective cohort study. PLoS One 2014;9:e100517. [PMID: 24945812 DOI: 10.1371/journal.pone.0100517] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
610 Chang SC, Yang SS, Chang CC, Lin CC, Chung YC, Li TC. Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ. Health Qual Life Outcomes. 2014;12:97. [PMID: 24941994 DOI: 10.1186/1477-7525-12-97] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
611 Hashmi AH, Ahmad N, Riaz S, Ali L, Siddiqi S, Khan KM, Shakoori AR, Mansoor A. Genotype CC of rs12979860 is providing protection against infection rather than assisting in treatment response for HCV genotype 3a infection. Genes Immun. 2014;15:430-432. [PMID: 24898388 DOI: 10.1038/gene.2014.31] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
612 Puri P, Anand AC, Saraswat VA, Acharya SK, Sarin SK, Dhiman RK, Aggarwal R, Singh SP, Amarapurkar D, Arora A, Chhabra M, Chetri K, Choudhuri G, Dixit VK, Duseja A, Jain AK, Kapoor D, Kar P, Koshy A, Kumar A, Madan K, Misra SP, Prasad MV, Nagral A, Puri AS, Jeyamani R, Saigal S, Shah S, Sharma PK, Sood A, Thareja S, Wadhawan M. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India. J Clin Exp Hepatol 2014;4:117-40. [PMID: 25755549 DOI: 10.1016/j.jceh.2014.06.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
613 Anand AC. Treatment of chronic hepatitis C: What is new? Apollo Medicine 2014;11:93-102. [DOI: 10.1016/j.apme.2014.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
614 Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology 2014;59:2403-12. [PMID: 24155107 DOI: 10.1002/hep.26905] [Cited by in Crossref: 102] [Cited by in F6Publishing: 91] [Article Influence: 11.3] [Reference Citation Analysis]
615 Wu JY, Shadbolt B, Teoh N, Blunn A, To C, Rodriguez-Morales I, Chitturi S, Kaye G, Rodrigo K, Farrell G. Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C. J Gastroenterol Hepatol 2014;29:1258-64. [PMID: 24955454 DOI: 10.1111/jgh.12515] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
616 Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol 2014;11:362-71. [PMID: 24535328 DOI: 10.1038/nrgastro.2014.17] [Cited by in Crossref: 120] [Cited by in F6Publishing: 121] [Article Influence: 13.3] [Reference Citation Analysis]
617 Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146:1669-79.e3. [PMID: 24602923 DOI: 10.1053/j.gastro.2014.02.051] [Cited by in Crossref: 210] [Cited by in F6Publishing: 215] [Article Influence: 23.3] [Reference Citation Analysis]
618 Dhiman RK. Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability? J Clin Exp Hepatol 2014;4:85-6. [PMID: 25755543 DOI: 10.1016/j.jceh.2014.06.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
619 Abd El-Kader SM, Al-Jiffri OH, Al-Shreef FM. Liver enzymes and psychological well-being response to aerobic exercise training in patients with chronic hepatitis C. Afr Health Sci 2014;14:414-9. [PMID: 25320592 DOI: 10.4314/ahs.v14i2.18] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
620 Larrey D, Ripault MP, Pageaux GP. Patient adherence issues in the treatment of hepatitis C. Patient Prefer Adherence 2014;8:763-73. [PMID: 24920888 DOI: 10.2147/PPA.S30339] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
621 Malaguarnera G, Pennisi M, Gagliano C, Vacante M, Malaguarnera M, Salomone S, Drago F, Bertino G, Caraci F, Nunnari G, Malaguarnera M. Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial. Hepat Mon 2014;14:e11608. [PMID: 24910702 DOI: 10.5812/hepatmon.11608] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
622 Zanini B, Benini F, Pigozzi MG, Furba P, Giacò E, Cinquegrana A, Fasoli M, Lanzini A. Addicts with chronic hepatitis C: difficult to reach, manage or treat? World J Gastroenterol. 2013;19:8011-8019. [PMID: 24307794 DOI: 10.3748/wjg.v19.i44.8011.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
623 Oramasionwu CU, Moore HN, Toliver JC. Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review. AIDS Patient Care STDS 2014;28:228-39. [PMID: 24738846 DOI: 10.1089/apc.2014.0033] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
624 Werner CR, Franz C, Egetemeyr DP, Janke-Maier P, Malek NP, Lauer UM, Berg CP. Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment. J Viral Hepat 2014;21:333-40. [PMID: 24716636 DOI: 10.1111/jvh.12145] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
625 Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014;49:941-53. [PMID: 24626851 DOI: 10.1007/s00535-014-0949-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 9.3] [Reference Citation Analysis]
626 Forde KA, Tanapanpanit O, Reddy KR. Hepatitis B and C in African Americans: current status and continued challenges. Clin Gastroenterol Hepatol 2014;12:738-48. [PMID: 23811241 DOI: 10.1016/j.cgh.2013.06.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
627 Karino T, Ozeki I, Hige S, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Sato T, Ohmura T, Toyota J. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat 2014;21:341-7. [PMID: 24001168 DOI: 10.1111/jvh.12162] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
628 Timm J, Roggendorf M. Plasticity of the Hepatitis C Virus Genome. Genome Plasticity and Infectious Diseases 2014. [DOI: 10.1128/9781555817213.ch11] [Reference Citation Analysis]
629 Bell BP. Hepatitis C Virus and Chronic Liver Disease. Emerging Infections 6 2014. [DOI: 10.1128/9781555816995.ch1] [Reference Citation Analysis]
630 Durantel D, Zoulim F. Clinical Aspects of Hepatitis C Virus Infection. Antiviral Research 2014. [DOI: 10.1128/9781555815493.ch14] [Reference Citation Analysis]
631 Sacchi P, Bruno R, Barbaro G, Barbarini G. Sequelae of Chronic Viral Hepatitis. Sequelae and Long-Term Consequences of Infectious Diseases 2014. [DOI: 10.1128/9781555815486.ch20] [Reference Citation Analysis]
632 Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine 2014;9:2051-67. [PMID: 24812506 DOI: 10.2147/IJN.S41822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
633 LaFleur J, Hoop R, Morgan T, DuVall SL, Pandya P, Korner E, Knippenberg K, Hayden C, Nelson RE. High rates of early treatment discontinuation in hepatitis C-infected US veterans. BMC Res Notes 2014;7:266. [PMID: 24758162 DOI: 10.1186/1756-0500-7-266] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
634 Ali L, Idrees M, Ali M, Hussain A, Ur Rehman I, Ali A, Iqbal SA, Kamel EH. Inhibitory effect of kaolin minerals compound against hepatitis C virus in Huh-7 cell lines. BMC Res Notes 2014;7:247. [PMID: 24742271 DOI: 10.1186/1756-0500-7-247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
635 Shehab H, Elbaz T, Deraz D, Hafez A, Elattar I. The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C. J Interferon Cytokine Res 2014;34:727-33. [PMID: 24730368 DOI: 10.1089/jir.2013.0127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
636 Dufner-Beattie J, O'Guin A, O'Guin S, Briley A, Wang B, Balsarotti J, Roth R, Starkey G, Slomczynska U, Noueiry A, Olivo PD, Rice CM. Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B. Antimicrob Agents Chemother 2014;58:3399-410. [PMID: 24709254 DOI: 10.1128/AAC.00113-14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
637 Cioe PA, Stein MD, Promrat K, Friedmann PD. A comparison of modified directly observed therapy to standard care for chronic hepatitis C. J Community Health 2013;38:679-84. [PMID: 23471655 DOI: 10.1007/s10900-013-9663-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
638 Helal SF, Gomaa HE, Thabet EH, Younan MA, Helmy NA. Impact of IL-10 (-1082) promoter-single nucleotide polymorphism on the outcome of hepatitis C virus genotype 4 infection. Clin Med Insights Gastroenterol 2014;7:19-24. [PMID: 24833945 DOI: 10.4137/CGast.S13658] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
639 Ampuero J, Romero-Gómez M, Reddy KR. Review article: HCV genotype 3 – the new treatment challenge. Aliment Pharmacol Ther 2014;39:686-98. [PMID: 24612116 DOI: 10.1111/apt.12646] [Cited by in Crossref: 89] [Cited by in F6Publishing: 80] [Article Influence: 9.9] [Reference Citation Analysis]
640 Larrea E, Riezu-Boj JI, Aldabe R, Guembe L, Echeverria I, Balasiddaiah A, Gastaminza P, Civeira MP, Sarobe P, Prieto J. Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes. Gut 2014;63:665-73. [PMID: 23787026 DOI: 10.1136/gutjnl-2012-304377] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
641 Gupta P, Cairns MJ, Saksena NK. Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma. Virol J. 2014;11:64. [PMID: 24690114 DOI: 10.1186/1743-422x-11-64] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
642 Lattimore S, Irving W, Collins S, Penman C, Ramsay M; Collaboration for the Sentinel Surveillance of Blood-Borne Virus Testing. Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection. Hepatology 2014;59:1343-50. [PMID: 24214920 DOI: 10.1002/hep.26926] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
643 Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K. IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. J Gastroenterol 2014;49:748-54. [PMID: 23689989 DOI: 10.1007/s00535-013-0826-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
644 Gatselis NK, Zachou K, Saitis A, Samara M, Dalekos GN. Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol 2014; 20(11): 2839-2853 [PMID: 24659876 DOI: 10.3748/wjg.v20.i11.2839] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
645 Upadya MH, Aweya JJ, Tan YJ. Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. World J Gastroenterol 2014; 20(11): 2913-2926 [PMID: 24659882 DOI: 10.3748/wjg.v20.i11.2913] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
646 Thong VD, Akkarathamrongsin S, Poovorawan K, Tangkijvanich P, Poovorawan Y. Hepatitis C virus genotype 6: Virology, epidemiology, genetic variation and clinical implication. World J Gastroenterol 2014; 20(11): 2927-2940 [PMID: 24659883 DOI: 10.3748/wjg.v20.i11.2927] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
647 Tovo CV, Mattos AA, Almeida PRL. Chronic hepatitis C genotype 1 virus: Who should wait for treatment? World J Gastroenterol 2014; 20(11): 2867-2875 [PMID: 24659878 DOI: 10.3748/wjg.v20.i11.2867] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
648 Sato M, Kondo M, Tateishi R, Fujiwara N, Kato N, Yoshida H, Taguri M, Koike K. Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. PLoS One 2014;9:e91822. [PMID: 24637774 DOI: 10.1371/journal.pone.0091822] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
649 Hayashi H, Beppu T, Shirabe K, Maehara Y, Baba H. Management of thrombocytopenia due to liver cirrhosis: A review. World J Gastroenterol 2014; 20(10): 2595-2605 [PMID: 24627595 DOI: 10.3748/wjg.v20.i10.2595] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
650 Brogan AJ, Talbird SE, Thompson JR, Miller JD, Rubin J, Deniz B. Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS One 2014;9:e90295. [PMID: 24603445 DOI: 10.1371/journal.pone.0090295] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
651 Backx M, Lewszuk A, White JR, Cole J, Sreedharan A, van Sanden S, Diels J, Lawson A, Neal KR, Wiselka MJ, Ito T, Irving WL. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. J Viral Hepat 2014;21:208-15. [PMID: 24438682 DOI: 10.1111/jvh.12132] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
652 Virlogeux V, Pradat P, Bailly F, Funingana G, Gonçalves F, Maynard M, Hartig-Lavie K, Amiri M, Zoulim F. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. J Viral Hepat 2014;21:e98-e107. [PMID: 24612466 DOI: 10.1111/jvh.12237] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
653 Dill MT, Makowska Z, Trincucci G, Gruber AJ, Vogt JE, Filipowicz M, Calabrese D, Krol I, Lau DT, Terracciano L, van Nimwegen E, Roth V, Heim MH. Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation. J Clin Invest 2014;124:1568-81. [PMID: 24569457 DOI: 10.1172/JCI70408] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
654 Rafique S, Idrees M, Ali A, Sahibzada KI, Iqbal M. Generation of infectious HCV pseudo typed particles and its utilization for studying the role of CD81 & SRBI receptors in HCV infection. Mol Biol Rep 2014;41:3813-9. [PMID: 24549717 DOI: 10.1007/s11033-014-3247-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
655 Yu M, Peng B, Chan K, Gong R, Yang H, Delaney W 4th, Cheng G. Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture. Antimicrob Agents Chemother 2014;58:2638-46. [PMID: 24550344 DOI: 10.1128/AAC.01780-13] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
656 Wadood A, Riaz M, Uddin R, Ul-Haq Z. In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening. PLoS One 2014;9:e89109. [PMID: 24551230 DOI: 10.1371/journal.pone.0089109] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
657 Chen LZ, Rose P, Mao Y, Yong CL, St George R, Huang F, Latli B, Mandarino D, Li Y. Mass balance and metabolite profiling of steady-state faldaprevir, a hepatitis C virus NS3/4 protease inhibitor, in healthy male subjects. Antimicrob Agents Chemother 2014;58:2369-76. [PMID: 24514093 DOI: 10.1128/AAC.02156-13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
658 Milwid JM, Elman JS, Li M, Shen K, Manrai A, Gabow A, Yarmush J, Jiao Y, Fletcher A, Lee J, Cima MJ, Yarmush ML, Parekkadan B. Enriched protein screening of human bone marrow mesenchymal stromal cell secretions reveals MFAP5 and PENK as novel IL-10 modulators. Mol Ther 2014;22:999-1007. [PMID: 24496384 DOI: 10.1038/mt.2014.17] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
659 Pol S, Vallet-Pichard A, Corouge M. Treatment of hepatitis C virus genotype 3-infection. Liver Int 2014;34 Suppl 1:18-23. [PMID: 24373074 DOI: 10.1111/liv.12405] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
660 Francioso S, Almerighi C, Forte P, Bandiera F, Nosotti L, Lionetti R, Taliani G, Piras MR, Ponti ML, Parruti G, Di Candilo F, Gentile S, Piccolo P, Salso A, Riccobelli F, Renzi S, Longo MA, Montalbano M, Zaru S, Biliotti E, Di Masi F, Santopaolo F, Angelico M. A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial. Dig Liver Dis 2014;46:164-9. [PMID: 24239044 DOI: 10.1016/j.dld.2013.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
661 Esmat G, El Kassas M, Hassany M, Gamil M, El Raziky M. Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues. Liver Int 2014;34 Suppl 1:24-8. [PMID: 24373075 DOI: 10.1111/liv.12397] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
662 Baran B, Gulluoglu M, Soyer OM, Ormeci AC, Gokturk S, Evirgen S, Yesil S, Akyuz F, Karaca C, Demir K, Kaymakoglu S, Besisik F. Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C. J Viral Hepat 2014;21:111-20. [PMID: 24383924 DOI: 10.1111/jvh.12127] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
663 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420. [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003] [Cited by in Crossref: 635] [Cited by in F6Publishing: 661] [Article Influence: 70.6] [Reference Citation Analysis]
664 Picchio G, De Meyer S, Dierynck I, Ghys A, Gritz L, Kieffer TL, Bartels DJ, Witek J, Bengtsson L, Luo D, Kauffman RS, Adda N, Sarrazin C. Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection. J Clin Virol 2014;59:148-55. [PMID: 24462470 DOI: 10.1016/j.jcv.2013.12.011] [Reference Citation Analysis]
665 Murakami E, Imamura M, Hayes CN, Abe H, Hiraga N, Honda Y, Ono A, Kosaka K, Kawaoka T, Tsuge M, Aikata H, Takahashi S, Miki D, Ochi H, Matsui H, Kanai A, Inaba T, McPhee F, Chayama K. Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin. Antimicrob Agents Chemother 2014;58:2105-12. [PMID: 24468783 DOI: 10.1128/AAC.02068-13] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
666 Marzio DLHD, Fenkel JM. Complementary and alternative medications in hepatitis C infection. World J Hepatol 2014; 6(1): 9-16 [PMID: 24653790 DOI: 10.4254/wjh.v6.i1.9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
667 Qiao J, Yu J, Yang H, Wei H. PCR-based in vitro synthesis of hepatitis C virus NS3 protease for rapid phenotypic resistance testing of protease inhibitors. J Clin Microbiol 2014;52:1139-45. [PMID: 24452171 DOI: 10.1128/JCM.03257-13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
668 Nishiya AS, de Almeida-Neto C, Ferreira SC, Alencar CS, Di-Lorenzo-Oliveira C, Levi JE, Salles NA, Mendrone A Jr, Sabino EC. HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, Brazil. PLoS One 2014;9:e86413. [PMID: 24466079 DOI: 10.1371/journal.pone.0086413] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
669 Eskander EF, Abd-Rabou AA, Yahya SM, El Sherbini A, Mohamed MS, Shaker OG. Correlation and multiple regression analyses of pituitary growth hormone and hepatic activities in hepatitis C infection and interferon response. Indian J Clin Biochem 2013;28:348-57. [PMID: 24426236 DOI: 10.1007/s12291-013-0309-0] [Reference Citation Analysis]
670 Rong L, Guedj J, Dahari H, Perelson AS. Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling. Antivir Ther. 2014;19:469-477. [PMID: 24434478 DOI: 10.3851/imp2725] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
671 Bhatt A, Everson GT. Virus de la hepatitis C: Terapia antiviral en pacientes en la lista de espera. Clin Liver Dis (Hoboken) 2013;2:73-7. [PMID: 31333829 DOI: 10.1002/cld.278] [Reference Citation Analysis]
672 Lowe RC. Interferons. Pocket Guide to Gastrointestinal Drugs 2014. [DOI: 10.1002/9781118481530.ch9] [Reference Citation Analysis]
673 Lambert PF, Sugden B. Viruses and Human Cancer. Abeloff's Clinical Oncology 2014. [DOI: 10.1016/b978-1-4557-2865-7.00011-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
674 Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2014;49:138-47. [PMID: 24005956 DOI: 10.1007/s00535-013-0875-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 7.2] [Reference Citation Analysis]
675 Aizawa N, Enomoto H, Takashima T, Sakai Y, Iwata K, Ikeda N, Tanaka H, Iwata Y, Saito M, Imanishi H, Iijima H, Nishiguchi S. Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2014;49:1253-63. [PMID: 24065124 DOI: 10.1007/s00535-013-0884-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
676 Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology 2014;59:71-7. [PMID: 23873583 DOI: 10.1002/hep.26624] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
677 Tsubota A, Shimada N, Atsukawa M, Abe H, Kato K, Ika M, Matsudaira H, Nagatsuma K, Matsuura T, Aizawa Y. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b. J Gastroenterol Hepatol 2014;29:144-50. [PMID: 24117654 DOI: 10.1111/jgh.12402] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
678 Chen MY, Liu CH, Chen TC, Su TH, Chen PJ, Chen DS, Kao JH, Liu CJ. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. J Gastroenterol Hepatol 2014;29:102-9. [PMID: 23829453 DOI: 10.1111/jgh.12329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
679 van der Meer AJ, Wedemeyer H, Feld JJ, Hansen BE, Manns MP, Zeuzem S, Janssen HL. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? J Hepatol 2014;60:191-6. [PMID: 23973931 DOI: 10.1016/j.jhep.2013.07.043] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
680 Murata K, Sugiyama M, Kimura T, Yoshio S, Kanto T, Kirikae I, Saito H, Aoki Y, Hiramine S, Matsui T, Ito K, Korenaga M, Imamura M, Masaki N, Mizokami M. Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients. J Gastroenterol 2014;49:126-37. [PMID: 23591768 DOI: 10.1007/s00535-013-0814-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
681 Shackelford RE, Mayhall G, Japa S, Nasir A, Malafa M, Coppola D. Molecular-Genetic Testing in Hepatocellular Carcinoma and Its Premalignant Conditions. Molecular Pathology and Diagnostics of Cancer 2014. [DOI: 10.1007/978-94-007-7192-5_7] [Reference Citation Analysis]
682 Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014;39:137-47. [PMID: 24251930 DOI: 10.1111/apt.12551] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
683 Londoño M, Forns X. Treatment of Hepatitis C Before Liver Transplantation. Hepatitis C Virus and Liver Transplantation 2014. [DOI: 10.1007/978-1-4614-8438-7_1] [Reference Citation Analysis]
684 Andriulli A, Di Marco V, Margaglione M, Ippolito AM, Fattovich G, Smedile A, Valvano MR, Calvaruso V, Gioffreda D, Milella M, Morisco F, Felder M, Brancaccio G, Fasano M, Gatti P, Tundo P, Barone M, Cozzolongo R, Angelico M, D'Andrea G, Andriulli N, Abate ML, Mazzella G, Gaeta GB, Craxi A, Santantonio T. Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. J Hepatol 2014;60:16-21. [PMID: 23973930 DOI: 10.1016/j.jhep.2013.07.040] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
685 Simbiri KO, Robertson ES. Conjunctival Carcinoma. Cancers in People with HIV and AIDS 2014. [DOI: 10.1007/978-1-4939-0859-2_25] [Reference Citation Analysis]
686 Takeda T, Sugiyama M, Kanto T, Korenaga M, Mizokami M, Watanabe S. Establishment of a Practical Workflow Using a Next Generation Sequencer to Search for Novel SNPs Associated with the Anti-HCV Treatment Response. Juntendo Medical Journal 2014;60:568-575. [DOI: 10.14789/jmj.60.568] [Reference Citation Analysis]
687 Nishiguchi S, Enomoto H, Aizawa N, Nishikawa H, Osaki Y, Tsuda Y, Higuchi K, Okazaki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, Kudo M. Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study. J Gastroenterol 2014;49:492-501. [PMID: 23543311 DOI: 10.1007/s00535-013-0785-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
688 Stasi C, Rosselli M, Zignego AL, Laffi G, Milani S. Serotonin and its implication in the side-effects of interferon-based treatment of patients with chronic viral hepatitis: Pharmacological interventions. Hepatol Res 2014;44:9-16. [PMID: 23607322 DOI: 10.1111/hepr.12116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
689 Lim EJ, Torresi J. Prevention of Hepatitis C Virus Infection and Liver Cancer. Viruses and Human Cancer 2014. [DOI: 10.1007/978-3-642-38965-8_7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
690 Mollison LC, Manning L, Miczkova S, Cheng W. Improved Sustained Virological Response Following Treatment with Pegylated-Interferon Alpha-2b Compared with Alpha-2a, Both with Ribavirin, for Chronic Hepatitis C Infection with Genotypes 2 and 3. IJCM 2014;05:111-117. [DOI: 10.4236/ijcm.2014.53019] [Reference Citation Analysis]
691 Fransen van de Putte DE, Makris M, Fischer K, Yee TT, Kirk L, van Erpecum KJ, Patch D, Posthouwer D, Mauser-Bunschoten EP. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. J Hepatol 2014;60:39-45. [PMID: 23978717 DOI: 10.1016/j.jhep.2013.08.010] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
692 Hai H, Tamori A, Enomoto M, Morikawa H, Uchida-Kobayashi S, Fujii H, Hagihara A, Kawamura E, Thuy le TT, Tanaka Y, Kawada N. Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin. J Gastroenterol Hepatol 2014;29:201-7. [PMID: 23980585 DOI: 10.1111/jgh.12376] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
693 Carcamo WC, Calise SJ, von Mühlen CA, Satoh M, Chan EK. Molecular cell biology and immunobiology of mammalian rod/ring structures. Int Rev Cell Mol Biol 2014;308:35-74. [PMID: 24411169 DOI: 10.1016/B978-0-12-800097-7.00002-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
694 Simeon RL, Chen Z. A screen for genetic suppressor elements of hepatitis C virus identifies a supercharged protein inhibitor of viral replication. PLoS One 2013;8:e84022. [PMID: 24391867 DOI: 10.1371/journal.pone.0084022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
695 Mathias S, Crosby RD, Bayliss MS, L'Italien G, Sapra S. Measurement properties of the flu-like symptom index from the hepatitis physical symptom severity diary. Qual Life Res 2014;23:1489-96. [PMID: 24379136 DOI: 10.1007/s11136-013-0609-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
696 Russell T, Westwood R. The Nutritional Management of Patients Living with HIV and Liver Disease. Nutrition and HIV 2013. [DOI: 10.1002/9781118786529.ch20] [Reference Citation Analysis]
697 Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Narahara Y, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C. Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepat Mon 2013;13:e14872. [PMID: 24403915 DOI: 10.5812/hepatmon.14872] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
698 Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World J Gastroenterol 2013; 19(47): 8940-8948 [PMID: 24379619 DOI: 10.3748/wjg.v19.i47.8940] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
699 Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, Bruno R, Baldanti F. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients. Virol J. 2013;10:355. [PMID: 24341898 DOI: 10.1186/1743-422x-10-355] [Cited by in Crossref: 66] [Cited by in F6Publishing: 73] [Article Influence: 6.6] [Reference Citation Analysis]
700 Abbas Z, Tayyab GN, Qureshi M, Memon MS, Subhan A, Shakir T, Jafri W, Hamid S. Consensus interferon plus ribavirin for hepatitis C genotype 3 patients previously treated with pegylated interferon plus ribavirin. Hepat Mon 2013;13:e14146. [PMID: 24358041 DOI: 10.5812/hepatmon.14146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
701 Kusano H, Akiba J, Ogasawara S, Sanada S, Yasumoto M, Nakayama M, Ueda K, Ueda K, Kurita T, Todoroki K, Umeno Y, Nakashima O, Yano H. Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo. PLoS One 2013;8:e83195. [PMID: 24349459 DOI: 10.1371/journal.pone.0083195] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
702 Raghavan R, Ferlic-Stark L, Clarke C, Rungta M, Goodgame R. The role of patient religiosity in the evaluation and treatment outcomes for chronic HCV infection. J Relig Health 2013;52:79-90. [PMID: 21246281 DOI: 10.1007/s10943-011-9455-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
703 O’Day R, Gillies MC, Ahlenstiel G. Ophthalmologic complications of antiviral therapy in hepatitis C treatment. World J Gastroenterol 2013; 19(45): 8227-8237 [PMID: 24363513 DOI: 10.3748/wjg.v19.i45.8227] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
704 Plemper RK, Hammond AL. Synergizing vaccinations with therapeutics for measles eradication. Expert Opin Drug Discov 2014;9:201-14. [PMID: 24303998 DOI: 10.1517/17460441.2014.867324] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
705 Gane EJ, Rouzier R, Wiercinska-Drapalo A, Larrey DG, Morcos PN, Brennan BJ, Le Pogam S, Nájera I, Petric R, Tran JQ, Kulkarni R, Zhang Y, Smith P, Yetzer ES, Shulman NS. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders. Antimicrob Agents Chemother 2014;58:1136-45. [PMID: 24295986 DOI: 10.1128/AAC.01515-13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
706 Nandakumar R, Finsterbusch K, Lipps C, Neumann B, Grashoff M, Nair S, Hochnadel I, Lienenklaus S, Wappler I, Steinmann E, Hauser H, Pietschmann T, Kröger A. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms. Gastroenterology 2013;145:1414-23.e1. [PMID: 23973921 DOI: 10.1053/j.gastro.2013.08.037] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
707 Wiśniewska-Ligier M, Pawłowska M, Pilarczyk M, Halota W, Woźniakowska-Gęsicka T. Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection. J Pediatr Gastroenterol Nutr 2013;57:694-9. [PMID: 23942001 DOI: 10.1097/MPG.0b013e3182a7d91e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
708 Hagan LM, Yang Z, Ehteshami M, Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat 2013;20:847-57. [PMID: 24304454 DOI: 10.1111/jvh.12111] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
709 Brjalin V, Salupere R, Tallo T, Kuznetsova T, Priimägi L, Tefanova V. Predictors of treatment response in patients with hepatitis C 1b genotype. Open Medicine 2013;8:822-9. [DOI: 10.2478/s11536-013-0221-2] [Reference Citation Analysis]
710 Everson GT, Bhatt A. Treatment of Hepatitis C in the Patient with Decompensated Cirrhosis. Curr Hepatitis Rep 2013;12:236-245. [DOI: 10.1007/s11901-013-0181-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
711 Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM. Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:713-28. [PMID: 24019151 DOI: 10.1038/nrgastro.2013.163] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
712 Kim GW, Jwa SW, Song M, Kim HS, Kim BS, Kim MB, Ko HC. Extensive psoriasis induced by pegylated interferon alfa-2a and ribavirin in the treatment of chronic hepatitis C. Ann Dermatol. 2013;25:479-482. [PMID: 24371397 DOI: 10.5021/ad.2013.25.4.479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
713 Zanini B, Benini F, Pigozzi MG, Furba P, Giacò E, Cinquegrana A, Fasoli M, Lanzini A. Addicts with chronic hepatitis C: Difficult to reach, manage or treat? World J Gastroenterol 2013; 19(44): 8011-8019 [PMID: 24307794 DOI: 10.3748/wjg.v19.i44.8011] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
714 Coats SJ, Garnier-Amblard EC, Amblard F, Ehteshami M, Amiralaei S, Zhang H, Zhou L, Boucle SR, Lu X, Bondada L, Shelton JR, Li H, Liu P, Li C, Cho JH, Chavre SN, Zhou S, Mathew J, Schinazi RF. Chutes and ladders in hepatitis C nucleoside drug development. Antiviral Res 2014;102:119-47. [PMID: 24275341 DOI: 10.1016/j.antiviral.2013.11.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
715 Rowan PJ. Does prophylactic antidepressant treatment boost interferon-alpha treatment completion in HCV? World J Virol. 2013;2:139-145. [PMID: 24255885 DOI: 10.5501/wjv.v2.i4.139.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
716 Hagan LM, Wolpe PR, Schinazi RF. Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol 2013;21:625-33. [PMID: 24238778 DOI: 10.1016/j.tim.2013.09.008] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 4.7] [Reference Citation Analysis]
717 Ydreborg M, Westin J, Rembeck K, Lindh M, Norrgren H, Holmberg A, Wejstål R, Norkrans G, Cardell K, Weiland O, Lagging M. Impact of Il28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection. PLoS One 2013;8:e80172. [PMID: 24244641 DOI: 10.1371/journal.pone.0080172] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
718 Striki A, Manolakopoulos S, Deutsch M, Mela M, Kalafateli M, Schini M, Anagnostou O, Triantos C, Andreadis I, Ketikoglou I, Papatheodoridis G, Pectasides D. Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin. J Viral Hepat 2014;21:624-32. [PMID: 24224747 DOI: 10.1111/jvh.12197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
719 Rowan PJ. Does prophylactic antidepressant treatment boost interferon-alpha treatment completion in HCV? World J Virol 2013; 2(4): 139-145 [PMID: 24255885 DOI: 10.5501/wjv.v2.i4.139] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
720 Chandra PK, Bao L, Song K, Aboulnasr FM, Baker DP, Shores N, Wimley WC, Liu S, Hagedorn CH, Fuchs SY, Wu T, Balart LA, Dash S. HCV infection selectively impairs type I but not type III IFN signaling. Am J Pathol 2014;184:214-29. [PMID: 24215913 DOI: 10.1016/j.ajpath.2013.10.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 5.1] [Reference Citation Analysis]
721 Grasso A, Malfatti F, Testa R. Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C? World J Gastroenterol 2013; 19(41): 6947-6956 [PMID: 24222938 DOI: 10.3748/wjg.v19.i41.6947] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
722 Akbarzadeh Baghban A, Pourhoseingholi A, Zayeri F, Jafari AA, Alavian SM. Application of zero-inflated poisson mixed models in prognostic factors of hepatitis C. Biomed Res Int 2013;2013:403151. [PMID: 24195069 DOI: 10.1155/2013/403151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
723 Zhou H, Luo H, Xiao S, Wang H, Gong G. Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis. Eur J Clin Microbiol Infect Dis. 2014;33:491-498. [PMID: 24193376 DOI: 10.1007/s10096-013-1992-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
724 Rolls DA, Sacks-Davis R, Jenkinson R, McBryde E, Pattison P, Robins G, Hellard M. Hepatitis C transmission and treatment in contact networks of people who inject drugs. PLoS One 2013;8:e78286. [PMID: 24223787 DOI: 10.1371/journal.pone.0078286] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
725 Liang CM, Hu TH, Lu SN, Hung CH, Huang CM, Wang JH, Yen YH, Chen CH, Chang KC, Tsai MC, Kuo YH, Lee CM. Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy. J Viral Hepat 2013;20:761-9. [PMID: 24168255 DOI: 10.1111/jvh.12097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
726 Ackefors M, Nyström J, Wernerson A, Gjertsen H, Sönnerborg A, Weiland O. Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment. J Viral Hepat 2013;20:770-8. [PMID: 24168256 DOI: 10.1111/jvh.12099] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
727 Han H, Noureddin M, Witthaus M, Park YJ, Hoofnagle JH, Liang TJ, Rotman Y. Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype. J Hepatol 2013;59:957-63. [PMID: 23850879 DOI: 10.1016/j.jhep.2013.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
728 Pol S. HCV, ribavirin, and anemia: a new dawn. Gastroenterology 2013;145:930-3. [PMID: 24060434 DOI: 10.1053/j.gastro.2013.09.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
729 Tsubota A, Furihata T, Matsumoto Y, Chiba K. Sustained and rapid virological responses in hepatitis C clinical trials. Clinical Investigation 2013;3:1083-1093. [DOI: 10.4155/cli.13.98] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
730 Scherzer TM, Stättermayer AF, Stauber R, Maieron A, Strasser M, Laferl H, Schwarzer R, Datz C, Rutter K, Beinhardt S, Steindl-Munda P, Hofer H, Ferenci P. Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients. J Hepatol 2013;59:964-71. [PMID: 23850877 DOI: 10.1016/j.jhep.2013.06.030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
731 Alwakeel HR, Zaghla HE, Omar NA, Alashinnawy HA, Rewisha EA, Matarese LE, Taha AA, Kandil HM. Spontaneous weight change during chronic hepatitis C treatment: association with virologic response rates. Int J Med Sci 2013;10:1830-6. [PMID: 24324359 DOI: 10.7150/ijms.6184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
732 Grandi T, da Silva CM, Amaral KM, Picon PD, Costi C, da Fré NN, Fiegenbaum M, Niel C, Rossetti ML. Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene. Mem Inst Oswaldo Cruz 2013;108:48-53. [PMID: 23440114 DOI: 10.1590/s0074-02762013000100008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
733 Hou XJ, Xu JH, Wang J, Yu YY. Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials? PLoS One 2013;8:e76799. [PMID: 24204676 DOI: 10.1371/journal.pone.0076799] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
734 Fischer J, Böhm S, Müller T, Witt H, Sarrazin C, Susser S, Migaud P, Schott E, Stewart G, Brodzinski A, Fülöp B, van Bömmel F, George J, Berg T. Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection. PLoS One 2013;8:e77530. [PMID: 24204859 DOI: 10.1371/journal.pone.0077530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
735 Bota S, Sporea I, Şirli R, Neghină AM, Popescu A, Străin M. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clin Drug Investig 2013;33:325-31. [PMID: 23532802 DOI: 10.1007/s40261-013-0074-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
736 CYTOKINES AND INTERFERONS. Biotechnology and Biopharmaceuticals 2013. [DOI: 10.1002/9781118660485.ch11] [Reference Citation Analysis]
737 Lin KH, Yu HC, Hsu PI, Tsai WL, Chen WC, Lin CK, Chan HH, Tsay FW, Lai KH. Baseline high viral load and unfavorable patterns of alanine aminotransferase change predict virological relapse in patients with chronic hepatitis C genotype 1 or 2 obtaining rapid virological response during antiviral therapy. Hepat Mon 2013;13:e11892. [PMID: 24348635 DOI: 10.5812/hepatmon.11892] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1]